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ABSTRACT 
Iron deficiency (ID) and malaria are co-existing and common causes of ill health in African 
children. In this thesis, I aimed to determine: 1) a more accurate estimate of the burden of ID 
in African children by adjusting for the influence of infections on iron biomarkers; 2) whether 
malaria causes ID; 3) whether iron status influences malaria risk; and 4) whether a mutation in 
the ferroportin coding gene, FPN Q248H, influences iron status, anaemia and risk of malaria. 
 
Among 4,853 children from community-based cohorts across Africa, the overall prevalence of 
ID was 52% using an inflammation and malaria regression-corrected estimate of ID, compared 
to a WHO-defined estimate of 34%. This WHO unidentified burden of ID increased with age 
and was highest in countries with high prevalence of inflammation and malaria, where up to a 
quarter of iron-deficient children were misclassified as iron replete. Transferrin saturation 
(TSAT) was least affected by inflammation and malaria and TSAT <11% most closely 
predicted the regression-corrected ID. 
 
In Mendelian randomisation analyses, sickle cell trait, a polymorphism conferring protection 
against malaria, was associated with a 30% reduction in ID in 7453 malaria-exposed African 
children but not in 3207 non-malaria exposed African-Americans. Genetically determined 
malaria risk was associated with a 2.5-fold increase in ID per unit increase in log-incidence 
rate of malaria. This suggests that an intervention that halves the risk of malaria episodes would 
reduce ID by 47% in African children. 
 
In 2683 Kenyan and Ugandan children, ID defined using either low ferritin or TSAT was 
associated with 33% and 21% reduction in malaria risk respectively. The FPN Q248H mutation 
which increases intracellular iron export, was associated with 23% and 25% protection from 
ii 
 
ID and anaemia, respectively, but there was little evidence of protection from malaria. This 
work demonstrates the complex relationship between iron and malaria. 
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CHAPTER ONE: LITERATURE REVIEW 
Both iron deficiency and malaria are important co-existing public health problems in African 
children. Their relationship is complex and may be bidirectional (Figure 1.1). Iron is a vital 
nutrient for the malaria parasite. Conversely, malaria may mediate blockade of intestinal iron 
absorption and macrophage iron recycling by up-regulating the iron-regulatory hormone, 
hepcidin. This complex relationship between iron deficiency and malaria may account for a 
large proportion of ill health in African children. Iron supplementation is recommended for 
children at risk of iron deficiency (World Health Organization, 2016). However, it is unclear 
whether improved body iron status causes increased risk of malaria infections. Conversely, 
little is known about whether malaria causes iron deficiency. In this chapter I review the 
literature on iron deficiency, malaria, putative causal relationships between iron deficiency and 
malaria, and Mendelian randomisation as an approach for understanding that complex 
relationship. 
 
Figure 1.1. Relationship between malaria and iron deficiency. 
Malaria may cause iron deficiency by up-regulating production of hepcidin by the liver 
blocking iron absorption. Conversely, the malaria parasite requires iron to grow and multiply, 
thus improving iron status may increase malaria risk. 
Iron deficiency
2. Does iron status 
influence malaria risk?
hep
cidi
n
1. Does malaria cause 
iron deficiency?
In 2018, Africa
- 213 million cases 
- 380,000 deaths
(WHO report, 2018)
- Commonest nutrient deficiency
- Main cause of anaemia
- Poor child development
- Leading cause of years lived with
disability
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1.1 Iron deficiency 
Iron deficiency is the most prevalent nutritional deficiency worldwide. It accounts for over 
60% of all anaemia cases and iron deficiency anaemia is estimated to affect over 1.2 billion 
people worldwide (Kassebaum and GBD 2013 Anemia Collaborators, 2016; GBD 2016 
Disease and Injury Incidence and Prevalence Collaborators, 2017). The global prevalence of 
iron deficiency in the absence of anaemia is unknown but is likely to be more frequent – at 
least double that of iron deficiency anaemia. Iron deficiency is associated with poor brain 
development and long-term impairment of behavioural and cognitive performance (Beard, 
2007; McCann and Ames, 2007; Lozoff, 2011; Doom and Georgieff, 2014). Importantly, iron 
deficiency is estimated to be a leading cause of years lived with disability (YLD) in children 
(GBD 2016 Disease and Injury Incidence and Prevalence Collaborators, 2017). In Africa, iron 
deficiency is estimated to be the leading cause of YLD in 30 out of the 46 sub-Saharan African 
countries (GBD 2016 Disease and Injury Incidence and Prevalence Collaborators, 2017). 
 
Iron deficiency is defined as insufficient body iron for maintaining normal physiological 
functions. It occurs in three stages: 1) depletion in body iron stores, 2) iron-deficient 
erythropoiesis or functional iron deficiency, and 3) iron deficiency anaemia (Camaschella, 
2015). Depletion in iron stores is reflected by reduced serum ferritin concentrations. Iron 
deficient erythropoiesis is characterised by low serum iron and reduced iron incorporation into 
red blood cells (RBCs). Iron deficiency is often confused for iron deficiency anaemia because 
most of the body iron needs are for production of RBCs and reduction in RBCs (or anaemia) 
is a more evident sign of iron deficiency. However, iron deficiency may occur long before 
anaemia becomes evident and is broad encompassing depleted iron even in other tissues such 
as muscle and brain. Common symptoms of iron deficiency include pallor (on skin, 
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conjunctivae and nail beds), weakness, difficult breathing, dizziness, headache, hair loss, 
dry/rough skin, pica, and restless leg syndrome (Powers and Buchanan, 2014). 
 
There are multiple causes of iron deficiency in children including low dietary iron intake, 
impaired iron absorption, excessive iron losses, increased iron need for growth, or genetic 
factors. The efficiency of intestinal iron absorption can be determined by the type of iron in 
foods (haem or non-haem), presence of iron absorption inhibitors or enhancers, infections, iron 
stores or iron requirements (these are discussed in the next Sub-section 1.1.1 on iron 
homeostasis). As children grow, iron requirements are increased due to rapid increase in 
erythroid and muscle mass (Ziegler, Nelson and Jeter, 2014). Meeting this iron need is also 
critical for proper development of the brain and other body organs. In developing countries 
chronic infections or malnutrition-associated inflammation are common and this may be an 
underlying cause of iron deficiency. 
 
Maternal iron status and newborn’s gestational age may also be a major determinant of a child’s 
iron status after birth. Higher maternal iron status or supplementation (especially when the 
mother is iron deficient) has been associated with reduced risks of infant iron deficiency, 
preterm births, and birthweight (Colomer et al., 1990; Scholl, 2005; Peña-Rosas et al., 2015; 
Mwangi, Prentice and Verhoef, 2017). Importantly, a fetus acquires most of its iron during the 
last trimester of pregnancy (Fisher and Nemeth, 2017). Preterm babies are therefore more likely 
to be born with low iron stores (Moreno-fernandez et al., 2019). Since high iron stores 
endowment at birth is necessary for rapid growth during infancy, preterm babies are more likely 
to develop iron deficiency (Moreno-fernandez et al., 2019). 
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1.1.1 Iron homeostasis 
Nearly all living organisms require iron for survival (Aisen, Enns and Wessling-Resnick, 
2001). In humans, iron is an essential element involved in key body functions such as oxygen 
and electron transport, deoxyribonucleic acid (DNA) synthesis, immune function, and also 
growth and development (Atamna, Walter and Ames, 2002; McCann and Ames, 2007). 
However, in excess or in its free state, iron is toxic to body tissues because it readily accepts 
or donates electrons forming highly reactive oxygen species (ROS). Moreover, excess body 
iron may be utilised by pathogens causing disease. Since there is no iron excretory means in 
mammals, the human body has developed mechanisms to tightly regulate iron. This iron 
regulation is either at systemic or cellular level. In this review, I will focus on systemic iron 
regulation. 
 
Systemic iron regulation involves mechanisms that regulate absorption of dietary iron and its 
distribution in the bloodstream. There are two types of absorbable dietary iron for humans: 
haem and non-haem iron. Haem iron (from meat, fish, and poultry) is more efficiently absorbed 
compared to iron sourced from plant foods (non-haem). In meat, 30-60% of iron is haem and 
15-35% of this iron is absorbed (Cook and Monsen, 1976; Monsen et al., 1978). In contrast, 
absorption of non-haem iron from plant-based foods is <10% (Monsen et al., 1978). Moreover, 
phytates and polyphenols (tannins) that are found in grains and tea inhibit iron absorption 
(Monsen et al., 1978). At the intestinal brush border, haem iron is absorbed through a haem 
transporter (possibly Haem Carrier Protein 1 (HCP1)) (Shayeghi et al., 2005) while non-haem 
iron passes through the divalent metal ion transporter 1 (DMT1) after conversion from ferric 
(Fe3+) form to ferrous (Fe2+) iron by duodenal cytochrome B (DCYTB), a ferrireductase  
(Gunshin et al., 1997; McKie et al., 2001) (Figure 1.2).  
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Once inside the enterocyte, iron is either stored as ferritin (and lost once the cell is exfoliated) 
or is transported across the basolateral membrane into the blood through ferroportin. In blood, 
ferrous iron is immediately oxidised by a ferroxidase to ferric iron and is transported to body 
tissue bound to transferrin and presented to cells through transferrin receptor 1 (TFR1). Iron is 
mainly transported to the bone marrow to produce RBCs (erythropoiesis). Once RBCs age or 
are haemolysed, they are taken up by splenic and liver macrophages and approximately 25mg 
of iron per day is recycled back into the circulation. Ferroportin is the sole known protein that 
exports intracellular iron mainly from enterocytes, macrophages and hepatocytes (Abboud and 
Haile, 2000; Donovan et al., 2000; McKie et al., 2000). Thus, ferroportin plays a major role in 
systemic iron homeostasis. 
 
Figure 1.2. Systemic iron homeostasis. 
Approximately 1mg of iron per day is absorbed through duodenal enterocytes and is exported 
into the circulation through ferroportin. In blood, iron is bound to transferrin and is 
transported to body tissues, mainly to the bone marrow to produce RBCs. When RBCs age, 
they are taken up by splenic or liver macrophages and approximately 25mg of iron per day is 
recycled back into the circulation. During iron overload or infection or inflammation, 
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production of hepcidin by the liver is up-regulated. Hepcidin degrades ferroportin on 
enterocytes and macrophages blocking absorption and recycling of iron. Conversely, during 
iron deficiency and expanded erythropoiesis, hepcidin production is suppressed to increase 
absorption and recycling of iron. Modified from (Spottiswoode and Fried, 2012). 
 
Systemic iron homeostasis is regulated by hepcidin, a hormone that is produced mainly by the 
liver. Since excess of iron is toxic to humans and is a nutrient to pathogens, production of 
hepcidin is up-regulated in iron overload or an inflammatory process or infection (Ganz, 2011). 
Hepcidin prevents iron absorption and recycling through occlusion and degradation of 
ferroportin on enterocytes and macrophages (Nemeth, Tuttle, et al., 2004; Aschemeyer et al., 
2018). Hepcidin also degrades and inhibits the transcription of DMT1, thus further blocking 
iron absorption through the duodenal enterocytes (Mena et al., 2008; Brasselagnel et al., 2011). 
Conversely, during iron deficiency, expanded erythropoiesis, or hypoxic conditions, hepcidin 
concentrations are down-regulated so that more iron can be absorbed and recycled (Ganz, 
2011). 
 
Since the discovery of hepcidin’s role in iron homeostasis in 2001 (Nicolas et al., 2001; Pigeon 
et al., 2001), evidence has been accumulating on the mechanisms of iron-regulation by 
hepcidin. Expression of hepcidin in the liver is mainly regulated by the BMP-SMAD (bone 
morphogenetic protein – sons of mothers against decapentaplegic) signaling pathway. During 
iron deficiency, transcription of BMP2 and BMP6 in liver sinusoidal endothelial cells is down-
regulated (recently reviewed in (Silvestri et al., 2019)). However, the mechanism through 
which liver sinusoidal endothelial cells sense iron concentrations remains unclear. Regulatory 
SMADs 1, 5, and 8 are phosphorylated by BMPs then form a complex with SMAD 4 (the 
common mediator) and are translocated to the nucleus to stimulate target gene expression 
(Silvestri et al., 2019).  
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Mutations in the haemojuvelin (HJV) gene and the haemochromatosis (HFE) and transferrin 
receptor 2 (TFR2) proteins are also important in the activation of the BMP-SMAD signaling 
pathway. During iron deficiency, the BMPs coreceptor HJV is cleaved from the surface of 
hepatocytes by transmembrane serine protease 6 (TMPRSS6) suppressing hepcidin production 
(Babitt et al., 2006; Silvestri et al., 2008; Lakhal et al., 2011). Moreover, in the absence of 
diferric transferrin, TFR2, a circulating iron sensor, is cleaved from the surface of hepatocytes 
and erythroid cells down-regulating hepcidin production (Pagani et al., 2015). Inactivation of 
BMP6 in TFR2 or HFE knock-out mice has been shown to suppress hepcidin production 
through unknown mechanisms (Latour et al., 2016). 
 
Similarly, hepcidin is suppressed during expanded erythropoiesis due to increased 
erythropoietin which stimulates production of erythroferrone to block hepcidin production 
(Kautz et al., 2014). Interestingly, the inhibitory effect of erythroferrone is attenuated in mice 
lacking SMAD 1 and 5 suggesting that erythroferrone requires SMAD proteins to block 
hepcidin production (Wang et al., 2017). However, the mechanism through which 
erythroferrone inhibits hepcidin production through the BMP pathway remains uncertain. 
Taken together, these mechanisms serve to explain how hepcidin concentrations are reduced 
during iron deficiency and expanded erythropoiesis to increase iron absorption and recycling 
(Figure 1.3). 
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Figure 1.3. Inhibition of hepcidin during iron deficiency and expanded erythropoiesis. 
Low iron concentrations lower the BMP-SMAD signaling pathway. Production of BMPs in the 
liver sinusoidal endothelial cells (LSECs) is decreased. Haemojuvelin (HJV) a coreceptor for 
BMPs is cleaved by the transmembrane serine protease 6 (TMPRSS6). Additionally, 
transferrin receptor 2 (TFR2) is removed from the cell surface in the absence of diferric 
transferrin (TF). Furthermore, histone deacetylase 3 (HDAC3) erases markers of hepcidin 
activation suppressing hepcidin production (Pasricha et al., 2017). Reduced hepcidin 
concentrations increase iron absorption by duodenal enterocytes and recycling by 
macrophages. In expanded erythropoiesis, erythropoietin (EPO) is increased and stimulates 
production of erythroferrone (ERFE) which blocks hepcidin production. BMPR, BMP 
receptor; CP, ceruloplasmin; DCYTB, duodenal cytochrome B; DMT1, divalent metal 
transporter 1; EPOR, EPO receptor; HEPH, hephaestin. Adapted from (Camaschella, 2019). 
 
During inflammation, hepcidin is up-regulated through a JAK2-STAT3 (Janus kinase 2 - signal 
transducer and activator of transcription 3) signaling pathway. Lipopolysaccharide (LPS), 
which is abundant on the outer membrane of Gram-negative bacteria induces production of 
inflammatory cytokines including interleukins, IL-6, IL-1α, and IL-1β, that up-regulate 
hepcidin production (Lee et al., 2005). LPS binds on Toll-like receptor 4 in macrophages 
mainly stimulating production of IL-6. IL-6 binds to its receptor, glycoprotein 130 in 
hepatocytes to activate the JAK2-STAT3 signaling pathway. Once STAT3 is phosphorylated, 
it translocates into the nucleus where it binds the STAT3 responsive element on the hepcidin 
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promoter activating expression of hepcidin (Verga-Falzacappa et al., 2007). LPS may also 
induce hepcidin expression through the BMP-SMAD pathway by stabilising SMAD4 (Layoun 
et al., 2018). 
 
1.1.2 Indicators of iron deficiency 
To combat iron deficiency, it is important to accurately measure iron status. The gold standard 
method for estimating body iron status is to stain bone marrow aspirate for iron (Phiri, Calis, 
Kachala, et al., 2009). However, this method is invasive and expensive and therefore 
impractical to perform during population surveys. A number of iron markers are used to 
indicate iron status but they all have limitations in estimating iron deficiency especially in areas 
of high infectious burden including sub-Saharan Africa (Aguilar et al., 2012). Conventional 
indicators of iron status include serum ferritin, soluble transferrin receptors (sTfR), transferrin 
saturation (TSAT), ferritin index, body iron stores, and zinc protoporphyrin (ZPP). Although 
haemoglobin defines anaemia, its usefulness in defining iron deficiency is limited due to its 
low sensitivity and specificity in determining iron status since it is influenced by multiple 
aetiological factors (Cook and Smith, 1976; Foote et al., 2013). Next, I will discuss each of the 
conventional iron biomarkers. 
 
1.1.2.1 Serum ferritin 
Ferritin is a hollow globular intracellular protein that stores body iron. Small amounts of ferritin 
are normally secreted into the serum. A measure of serum ferritin sensitively indicates body 
iron stores in the absence of an infection or inflammation. However, in the presence of 
infection, the concentration of ferritin may rise even when there are low iron stores since it is 
an acute phase reactant protein (Feelders et al., 1998). Therefore, ferritin may only be a reliable 
indicator of iron deficiency in the absence of infection (Ali, Luxton and Walker, 1978). Since 
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the detection of ferritin in serum in 1972 (Addison et al., 1972) and development of a sensitive 
immunoassay for ferritin in 1975 (Jacobs and Worwood, 1975), serum ferritin has been used 
to identify iron deficient individuals. 
 
Defining iron deficiency using serum ferritin in areas of high infectious disease burden is 
challenging. Based on clinical studies and in the absence of infection or inflammation, the 
World Health Organization (WHO) defines iron deficiency as serum ferritin < 12 µg/L in 
children < 5 years or < 15 µg/L in children ≥ 5 years (Table 1.1) (World Health Organization, 
2011b). In the presence of inflammation (defined as C-reactive protein (CRP) > 5 mg/L or α1-
antichymotrypsin (ACT) > 0.6 g/L or α-1-acid glycoprotein (AGP) > 1 g/L), the WHO defines 
iron deficiency as serum ferritin < 30 µg/L but only in children < 5 years (World Health 
Organization, 2011b). However, there is little consensus about this inflammation-adjustment. 
Recent evidence shows that an inflammatory process may influence serum ferritin levels long 
before an individual is considered clinically inflamed (at the above cut-offs) (Namaste, Rohner, 
et al., 2017). Another proposal for estimating the burden of iron deficiency in sites with high 
incidence of infection is to exclude individuals with inflammation (World Health Organization 
and Centers for Disease Control, 2007). However, this approach would reduce sample size, 
may not reflect population prevalence of iron deficiency, and uses an arbitrary cut-off to define 
inflammation. Thus, the current WHO definition of iron deficiency is likely to underestimate 
the ‘true’ burden of iron deficiency in sub-Saharan Africa. 
Table 1.1. Definition of iron deficiency using serum ferritin 
 Serum ferritin (µg/L) 
 Less than 5 years of age 5 years of age or older 
 Male Female Male Female 
Depleted iron stores < 12 < 12 < 15 < 15 
Depleted iron stores in the presence of infection < 30 < 30 - - 
Severe risk of iron overload (adults) - - > 200 > 150 
Table adapted from (World Health Organization, 2011b) 
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1.1.2.2 Soluble transferrin receptors 
Iron is normally presented to cells through transferrin receptors on the cell surface. Over 80% 
of transferrin receptors are found on erythroid cells (Huebers and Finch, 1987). The transferrin 
receptor binds transferrin-bound iron and is endocytosed to release iron into cell cytosol before 
being recycled back on the cell surface (Klausner et al., 1983). In 1987, sTfR was measured in 
human serum and the number of transferrin receptors were shown to reflect iron requirements 
for erythropoiesis (Kohgo et al., 1986, 1987). sTfR is a truncated form of tissue transferrin 
receptor (Shih et al., 1990). sTfR was proposed as an additional marker of iron deficiency 
especially in areas where inflammation is prevalent since it is only mildly increased during 
inflammation (Ferguson et al., 1992; Pettersson, Kivivuori and Siimes, 1994; Punnonen, Irjala 
and Rajamäki, 1994; Mast et al., 1998). However, the utility of sTfR as a measure of iron status 
may be complicated in African populations since it may be increased by malaria, even in 
asymptomatic infection, and by haemolytic conditions such as sickle cell disease, thalassaemia, 
and glucose-6-phosphate dehydrogenase (G6PD) deficiency (Menendez et al., 2001; Verhoef 
et al., 2001; Rohner et al., 2017). Moreover, there are no standardised sTfR reference assays 
or cut-offs to define iron deficiency. Computations of total body iron stores (BIS, calculated as 
–[log10((sTfR in mg/Lx1000)/ferritin in µg/L)-2.8229]/0.1207 (Cook, Flowers and Skikne, 
2003)) and ferritin index (calculated as sTfR in mg/L/log10(ferritin in µg/L) (Phiri, Calis, 
Siyasiya, et al., 2009)) have previously been proposed and suggested to improve the diagnostic 
utility of these two iron markers. However, since both ferritin and sTfR have the above 
discussed limitations, the utility of BIS and ferritin index in correctly defining iron deficiency 
in African populations may also be limited. 
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1.1.2.3 Transferrin saturation 
Iron is ferried in circulation mainly bound to transferrin, a protein that is mainly synthesised 
by the liver. TSAT is the ratio of serum iron to total iron-binding capacity (TIBC), which is the 
sum of all iron binding sites of transferrin (Yamanishi et al., 2003). Each mole of transferrin 
binds two moles of iron and it is estimated that a transferrin concentration of 1g/L would carry 
25.1 µmol/L of iron. Thus, TSAT (expressed as a percentage) can be calculated as (serum iron 
in µmol/L divided by transferrin in g/L) x 25.1 x 100) (Yamanishi et al., 2003). That is, the 
percentage of iron binding sites that are occupied by iron. Under normal circumstances only a 
third of transferrin sites bind iron. 
 
Since TSAT reflects the amount of circulating iron, it is thought to be a better marker of iron 
status compared to serum iron alone. However, TSAT is not without limitations since 
transferrin synthesis may be decreased during malnutrition (Agarwal et al., 1981), and serum 
iron is prone to diurnal fluctuations from dietary iron intake or recycled iron (World Health 
Organization and Centers for Disease Control, 2007). Nevertheless, TSAT is normally used as 
a marker of iron deficiency especially in adults where TSAT in the range of 20 - 50% is 
considered normal (World Health Organization and Centers for Disease Control, 2007). 
However, little is known about normal TSAT values in young children although values are 
likely to be lower compared to TSAT values in adults (Milman and Cohn, 1984; Higgins, Chan 
and Adeli, 2017). 
 
1.1.2.4 Zinc protoporphyrin 
During the last stage of haemoglobin formation, iron is incorporated into protoporphyrin (the 
immediate precursor of haem) by ferrochetalase. A lack of iron leads to incorporation of zinc 
in place of iron forming ZPP. Thus, increased concentration of ZPP is an indication of severe 
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iron deficiency, particularly iron-deficient erythropoiesis (Labbé and Dewanji, 2004). A ZPP 
>80 µmol/mol haem is considered to indicate iron deficiency (World Health Organization and 
Centers for Disease Control, 2007). However, high concentrations of ZPP may indicate lead 
poisoning rather than iron deficiency (Labbé and Dewanji, 2004). Moreover, ZPP may also be 
raised by the acute phase response to infections or inflammation or other causes that limit iron 
supply to erythroblasts thus limiting its utility in populations with a high burden of infections 
(Stoltzfus et al., 1997, 2000).  
 
1.1.3 Control and management of iron deficiency 
The long-term adverse effects of iron deficiency including impaired brain development 
(McCann and Ames, 2007) call for urgent need to treat and control iron deficiency. However, 
despite the many efforts to combat iron deficiency, there has been little success especially in 
areas with high infectious disease burden such as many parts of sub-Saharan Africa. This 
failure to control iron deficiency may partly be attributable to the fact that it is challenging to 
accurately estimate the burden of iron deficiency in populations where infections are prevalent 
(Aguilar et al., 2012). Moreover, low haemoglobin concentrations are normally used to monitor 
the need for and progress of nutritional iron interventions although iron deficiency without 
anaemia may be more common (World Health Organization, 2001) and there are multiple 
causes of anaemia (Foote et al., 2013).  
 
A number of approaches are applied to directly or indirectly control iron deficiency. At present, 
the WHO recommends daily oral iron supplementation (10 -12.5 mg of elemental iron) in 
children living in areas where the prevalence of anaemia is ≥ 40% (World Health Organization, 
2016). In malaria-endemic areas, the recommendation is that iron supplementation should be 
provided in conjunction with malaria control and treatment measures (World Health 
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Organization, 2016). This recommendation followed a Cochrane review that showed that iron 
supplements do not worsen malaria infection when malaria control and treatment measures are 
in place (Neuberger et al., 2016). However, questions arise on coverage or how effective 
malaria control and treatment services should be to warrant safe iron supplementation. I will 
discuss more of this conundrum in Section 1.3. Iron supplementation may also increase 
hepcidin concentrations leading to poor iron absorption (Moretti et al., 2015). 
 
Fortification of foods and use of iron-enriched multiple micronutrient powders (MNPs or 
“Sprinkles”) are other alternative strategies for managing and controlling iron deficiency. 
Fortification is performed on staple foods (such as maize flour, wheat and rice) and condiments 
using highly bioavailable iron compounds such as ferrous sulfate and fumarate (Allen et al., 
2006). In MNPs, iron is encapsulated in a lipid layer and supplied as single-dose sachets ready 
for use at home. In a Cochrane review home fortification with MNPs was associated with a 
51% decrease in iron deficiency among children < 2 years old (De-Regil et al., 2013), however, 
studies have shown that the iron content in MNPs or fortificants may disturb gut microbiota 
leading to gastrointestinal disorders (Zimmermann et al., 2010; Jaeggi et al., 2015; Tang et al., 
2017).  
 
There are other approaches that are used to control iron deficiency in children. Iron 
supplementation during pregnancy is thought to improve a child’s iron stores at birth and 
birthweight although a Cochrane review reported little benefit (Peña-Rosas et al., 2015). 
Periodic use of anthelmintic treatments, such as albendazole and praziquantel, was also thought 
to improve haemoglobin concentrations (Gulani et al., 2007), but a more recent Cochrane 
review reported insufficient evidence (Taylor-Robinson et al., 2015). In addition, delayed 
clamping of the umbilical cord improves iron stores at birth by allowing additional transfer of 
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placental iron to the newborn although this may increase risk of neonatal jaundice and 
polycythaemia (McDonald et al., 2014). Absorption of dietary non-haem iron can also be 
improved by the intake of enhancers such as ascorbic acid present in many fruits and by 
reducing intake of inhibitors such as phytates and polyphenols (Monsen et al., 1978). This 
review suggests that management of iron deficiency is difficult especially in populations where 
diets are poor and infections are prevalent. 
 
1.2 Malaria 
For millennia, malaria has remained a major public health burden particularly in sub-Saharan 
Africa. In 2018, the WHO estimated that there are 228 million cases of malaria (up from 219 
million cases in 2017) resulting in over 405,000 deaths globally (World Health Organization, 
2019). Of the total deaths, 94% occurred in sub-Saharan Africa and 67% were in children under 
the age of five years. Although the world has seen a substantial decline in malaria burden, 
especially since the year 2000, there has been no significant progress in reducing malaria cases 
since the year 2015 (World Health Organization, 2019). 
 
1.2.1 Malaria transmission 
The life cycle of the malaria parasite involves the mammalian host and a female Anopheles 
mosquito as a transmission vector. The infected mosquito injects sporozoites into the human 
host and the sporozoites are quickly transported to the liver where they invade hepatocytes, 
proliferate, and differentiate into merozoites that then burst out into the bloodstream and invade 
RBCs (Meibalan and Marti, 2017). Within RBCs, the parasite undergoes asexual multiplication 
(for a period of 48 hours for Plasmodium falciparum) from ring stage to trophozoites, which 
then form schizonts. The schizonts mature and burst out of the RBC as merozoites that then 
invade new RBCs and start the erythrocytic cycle again. Clinical symptoms of malaria, 
16 
 
especially fever, are associated with this burst of RBCs. Some schizonts sexually differentiate 
into male and female gametocytes that are then taken up by a feeding mosquito to begin the 
vector stage. Within the mosquito the male and female microgametes differentiate and fuse to 
form a zygote which then differentiates and matures into sporozoites ready for inoculation into 
another human host (Meibalan and Marti, 2017). 
 
Malaria in humans is caused by five species of Plasmodium, P. falciparum, P. vivax, P. 
malariae, P. ovale, and P. knowlesi.  P. falciparum accounts for the majority of infections and 
deaths in Africa. In 2018, P. falciparum accounted for 99.7% of all malaria infections in sub-
Saharan Africa (World Health Organization, 2019). P. vivax accounts for the highest number 
of cases of malaria outside Africa (>50%) and only <10% of cases in sub-Saharan Africa 
(Mendis et al., 2001). P. ovale and P. malariae may be more common in sub-Saharan Africa 
than previously estimated since they are often undetected by light microscopy although 
infection is less severe compared to P. falciparum (Doderer-Lang et al., 2014). P. knowlesi, 
whose natural host is non-human primates has emerged as infectious in humans, particularly 
in South East Asia, but this has not yet been reported in Africa (Moyes et al., 2014). Thus, this 
thesis focuses on P. falciparum malaria infection. 
 
1.2.2 Clinical symptoms of malaria 
P. falciparum malaria infection may present as either uncomplicated febrile malaria, severe 
malaria, or asymptomatic malaria depending on host susceptibility, immunity, and efficacy of 
antimalarial drugs. Uncomplicated P. falciparum malaria is characterised by symptoms that 
include fever, chills, fatigue, headache, malaise, back and limb pains, dizziness, and vomiting. 
When left untreated, uncomplicated P. falciparum malaria may progress to severe malaria and 
death. Severe malaria may mainly manifest as severe anaemia, cerebral malaria / impaired 
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consciousness, and/or respiratory distress (Marsh et al., 1995). Asymptomatic malaria presents 
as parasitaemia in the absence of fever or other clinical symptoms of malaria. In malaria 
endemic regions, such as most of sub-Saharan Africa, prolonged exposure to malaria infection 
results in development of partial immunity against the parasite (Bejon et al., 2009). This partial 
immunity to malaria may explain the existence of asymptomatic parasitaemia although the 
mechanisms of protection remain unclear. Although asymptomatic individuals carry parasites 
and maintain a reservoir for malaria transmission it remains controversial about whether they 
should be treated or not (Chen et al., 2016). Susceptibility to clinical P. falciparum malaria 
infection in individuals living in the same geographic area may be partially explained by 
acquired immunity or genetic predisposition. In Sub-section 1.2.4, I will focus on malaria 
susceptibility due to genetic variations.  
 
1.2.3 Malaria diagnoses, treatment and control 
In routine clinical practice, malaria parasitaemia can be confirmed using light microscopy or 
rapid diagnostic test (RDT). Treatment regimens for malaria depend on disease severity. 
Uncomplicated P. falciparum malaria is treated using a three-day regimen of artemisinin-based 
combination therapies (ACTs). Severe malaria is managed using intravenous or intramuscular 
artesunate for at least 24 hours followed by a three-day course of ACTs (Dondorp et al., 2010). 
There are reports of P. falciparum developing resistance to ACTs in South East Asia but none 
in Africa (Ashley et al., 2014). Despite the effectiveness of ACTs in treating malaria, only 20% 
of malaria-confirmed children less than five years of age in Africa had access to ACTs in 2015 
(Bennett et al., 2017). 
 
An integrated approach has historically been applied to control malaria. Approaches such as 
use of insecticide-treated bed nets (ITNs), indoor residual spraying (IRS) with 
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dichlorodiphenyltrichloroethane (DDT), larval habitat control, intermittent preventive 
treatment (IPT) during pregnancy and infancy, and seasonal malaria chemoprevention (SMC) 
are used in malaria control. Mass drug administration of antimalarials is another malaria control 
approach that has been shown to substantially reduce the initial risk of malaria infection 
especially in areas of low malaria transmission (Poirot et al., 2013; von Seidlein et al., 2019). 
A promising endeavor towards malaria control is the development of malaria vaccines. At 
present, only RTS,S has been approved for vaccination with an efficacy of approximately 30% 
in children (The RTSS Clinical Trials Partnership, 2012) and a waning efficacy over time (The 
RTSS Clinical Trials Partnership, 2014). Recently, ivermectin, an anti-parasitic drug, was 
reported to reduce residual malaria transmission and thus may have potential for use in 
integrated management and control of malaria (Foy et al., 2019). 
 
1.2.4 Genetics of malaria 
A number of genetic polymorphisms in the human genome have been evolutionarily selected 
due to malaria exposure. These can be classified into haemoglobinopathies, enzymatic 
deficiencies, blood groups, and RBC membrane defects among others. In this chapter, I will 
focus the review on the common polymorphisms that confer resistance to malaria in sub-
Saharan Africa. One common example of evolutionary selective pressure is sickle-cell trait 
(HbAS), the major haemoglobinopathy. HbAS results from inheriting one abnormal allele 
(substitution of glycine with valine at amino acid position 6) of beta-globin (HBB) gene (i.e. 
presence of one abnormal beta-chain in the haemoglobin). Inheritance of two abnormal alleles 
of HBB leads to sickle cell disease (HbSS). The prevalence of HbSS is normally low because 
of high early mortality in children born with this condition (Rees, Williams and Gladwin, 
2010). HbSS is associated with sickling of RBCs, which leads to adverse effects such as 
microvascular obstruction and haemolysis. 
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Unlike HbSS, HbAS is normally asymptomatic and has been associated with partial protection 
against both uncomplicated and severe malaria. For example, in a meta-analysis of longitudinal 
studies, HbAS was associated with 31% protection from uncomplicated malaria (Taylor, 
Parobek and Fairhurst, 2012). In a large multicentre genome-wide association study (GWAS), 
HbAS conferred 86% protection against severe malaria (Malaria Genomic Epidemiology 
Network, 2014). Thus, HbAS has risen to high frequencies in malaria-endemic regions as a 
strong selective advantage reaching a prevalence of over 40% in some parts of Africa 
(Mulumba and Wilson, 2015). The degree of protection conferred by HbAS on malaria exceeds 
any other malaria-associated polymorphisms (Malaria Genomic Epidemiology Network, 
2014). Indeed, only HbAS consistently protects from uncomplicated malaria (Taylor, Parobek 
and Fairhurst, 2012). Thus, this mutation has the potential to be utilised to proxy malaria 
exposure for both severe and uncomplicated malaria. 
 
Similar to HbAS, another haemoglobinopathy, the haemoglobin C (HbC) mutation results from 
a substitution of glutamine to lysine at amino acid position 6 of HBB. It is common in West 
African populations with prevalence reaching 15% (Piel et al., 2013; Malaria Genomic 
Epidemiology Network, 2014). A meta-analysis of case-control studies showed that individuals 
carrying the homozygous (HbCC) and heterozygous (HbAC) mutations are 73% and 17% 
protected against the risk of severe malaria respectively (Taylor, Parobek and Fairhurst, 2012). 
Similarly, each copy of the of the HbC allele was associated with 29% protection from severe 
malaria (Malaria Genomic Epidemiology Network, 2014). However, the evidence is mixed on 
whether HbCC or HbAC protects from uncomplicated malaria or asymptomatic parasitaemia 
(reviewed and meta-analysed in (Taylor, Parobek and Fairhurst, 2012). 
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Another group of commonly reported haemoglobinopathies is the thalassaemias. Alpha (α)-
thalassaemia results from mutations in alpha-globin (HBA1 and HBA2) genes while beta (β)-
thalassaemia results from mutations in the HBB gene. These mutations lead to a reduction or 
absence of one or more alpha- or beta- globin allele(s). For example, α-thalassemic individuals 
have a deletion of one or more α-globin allele(s): heterozygous (-α/αα), homozygous (-α/-α- 
or αα/--), Haemoglobin H disease (-α/--, a loss in three α-globin alleles), and hydrops fetalis 
(loss of all four α-globin alleles). β-thalassaemia results from impaired production of one β-
globin allele (called β-thalassaemia minor or trait) or two β-globin alleles (called β-
thalassaemia major) (Taylor, Cerami and Fairhurst, 2013).  
 
Alpha-thalassaemia is found predominantly in sub-Saharan Africa, the Middle East, Southeast 
Asia, and India at a prevalence of 10-20% while β-thalassaemia is mainly prevalent in the 
Mediterranean and a few parts of sub-Saharan Africa (Taylor, Cerami and Fairhurst, 2013). 
There are conflicting findings on whether heterozygotes or homozygotes are protected from 
uncomplicated malaria. Compared to normal individuals, the incidence of uncomplicated 
malaria in α-thalassaemia homozygotes and heterozygotes was higher in Vanuatu (Williams et 
al., 1996), but was lower in Kenya (Williams, Mwangi, Wambua, Peto, et al., 2005) and 
Tanzania (Enevold et al., 2008). However, α-thalassaemia homozygotes and heterozygotes are 
protected against severe malaria (Williams, Wambua, et al., 2005; Taylor, Parobek and 
Fairhurst, 2012). The mechanisms by which haemoglobinopathies may protect from P. 
falciparum malaria are not fully elucidated. Possible mechanisms involve attenuation of 
erythrocytic growth of the parasite, reduced parasite endothelial cytoadherence and rosetting, 
as well as enhancement of innate and adaptive immunity to the parasite (reviewed in (Taylor, 
Cerami and Fairhurst, 2013). 
 
21 
 
Lastly, an X-linked genetic mutation associated with a deficiency in the enzyme G6PD, which 
plays a role in reducing oxidative stress in RBCs, has been implicated in protection from P. 
falciparum malaria. Although findings have been controversial on which G6PD allele protects 
from malaria, a recent meta-analysis indicated that G6PD deficiency conferred 30% protection 
against uncomplicated malaria in heterozygous females (Mbanefo et al., 2017). Similarly, a 
well-powered study among Kenyan children showed that G6PD-deficient heterozygous girls 
were 18% protected against severe malaria but not against uncomplicated P. falciparum 
malaria or parasitaemia (Uyoga et al., 2015). 
 
1.3 Iron and malaria 
In this section, I will provide a background to the relationship between iron status and malaria. 
I will first discuss difficulties in estimating iron deficiency in malaria endemic regions. I will 
then discuss how malaria may be causing iron deficiency in African children and limitations 
of epidemiological approaches in testing that hypothesis. I will further discuss the effects of 
iron status on malaria risk by reviewing the literature on iron deficiency and supplementation 
on malaria risk. Finally, I will discuss the association between a ferroportin coding gene 
mutation, FPN Q248H, and iron status and malaria risk. 
 
1.3.1 Estimating the prevalence of iron deficiency in malaria-endemic areas 
Determining iron status in malaria endemic countries is challenging due to the effect of malaria 
on iron metabolism (Aguilar et al., 2012). Malaria causes a systemic maldistribution of iron 
into storage compartments. For example, through up-regulation of hepcidin, malaria causes 
blockade of iron recycling within the reticuloendothelial system as hepcidin degrades 
ferroportin (Howard et al., 2007; Ayoya et al., 2009; de Mast et al., 2009; Casals-Pascual et 
al., 2012; Atkinson et al., 2015). Perhaps more importantly, malaria directly or indirectly 
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influences conventional iron biomarkers (discussed in Section 1.1.2). Malaria infection is 
associated with elevated plasma ferritin concentrations (Das, Thurnham and Das, 1997; 
Odunukwe et al., 2000) and may also raise ferritin concentrations independently of malaria-
associated inflammation (Namaste, Rohner, et al., 2017). Thus, the use of ferritin 
concentrations to indicate iron deficiency in malaria endemic areas may underestimate the 
burden of iron deficiency.  
 
Other commonly used iron biomarkers are also affected by malaria. sTfR is recommended as 
an alternative indicator of iron status since it is only moderately influenced by inflammation 
(World Health Organization and Centers for Disease Control, 2007). However, sTfR 
concentrations can be markedly elevated during malaria infection (Menendez et al., 2001; 
Verhoef et al., 2001; Rohner et al., 2017) although some studies have found a reduction in 
sTfR during malaria infection (Williams et al., 1999; Beesley et al., 2000). ZPP concentrations 
are also elevated in malaria infection (Stoltzfus et al., 1997, 2000). Malaria infection was 
associated with increased ZPP independently of inflammation in Kenyan preschool children 
(Teshome et al., 2017) thus limiting its diagnostic utility in this population even among 
pregnant women (Mwangi et al., 2014). Malaria may also influence transferrin saturation since 
destruction of RBCs during malaria infection increases serum iron (Das, Thurnham and Das, 
1997). Thus, the use of conventional markers of iron status may be limited in malaria endemic 
areas. 
 
Despite the influence of malaria on iron biomarkers, the presence of malaria parasitaemia is 
often not adjusted for when defining iron deficiency. A study in Burkinabe children (48.5% 
with malaria parasitaemia) showed that adjustment for malaria parasitaemia, in addition to 
inflammation, led to a 15.9% further absolute increase in the prevalence of iron deficiency 
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(Wessells and Hess, 2014). Another multicentre study including children from Africa showed 
that malaria was independently associated with ferritin concentrations although adjustment for 
malaria, in addition to inflammatory markers, only slightly increased the prevalence of iron 
deficiency (Namaste, Rohner, et al., 2017). In that study, the prevalence of malaria ranged from 
19.7% to 32.5%. It is therefore possible that the independent effects of malaria on iron status 
may be higher in areas where malaria is more prevalent. 
 
Estimating iron status in malaria endemic areas is therefore difficult and a number of 
approaches have been proposed to account for the influences of inflammation and malaria. 
These include 1) regression-correction, 2) using adjustment factors, 3) using higher cutoffs, 
and 4) excluding individuals with inflammation (World Health Organization and Centers for 
Disease Control, 2007; Engle-stone et al., 2013; Thurnham, Northrop-clewes and Knowles, 
2015). Recently, the BRINDA (Biomarkers Reflecting Inflammation and Nutritional 
Determinants of Anaemia) project showed that the regression-correction approach performs 
better since it corrects for the linear effects of inflammation on iron biomarkers (Namaste, 
Aaron, et al., 2017; Namaste, Rohner, et al., 2017). In Chapter Three, I report predictors of 
iron biomarkers and use regression-correction to adjust for the effects of malaria and 
inflammation in estimating the ‘true’ burden of iron deficiency.  
 
1.3.2 Malaria as a possible cause of iron deficiency 
Few studies have investigated the effects of malaria infection on iron deficiency. A study in 
Kenyan and Gambian children observed that the prevalence of iron deficiency and iron 
deficiency anaemia were markedly higher at the end of a malaria season compared to the start 
(Atkinson et al., 2014). In another study in the Kenyan highlands, interruption of malaria 
transmission using antimalarials and indoor residual spraying reduced the prevalence of iron 
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deficiency from 36% to 25% (Frosch et al., 2014). However, the observational nature of these 
studies does not necessarily prove a causal relationship.  
 
Evidence from a few previous IPT trials also suggest that malaria may cause iron deficiency. 
IPT trials of malaria have reported a non-significant improvement in concentrations of ferritin 
(Verhoef, West, Nzyuko, et al., 2002; Glinz, Hurrell, Ouattara, et al., 2015) and a decrease in 
sTfR (Desai et al., 2003). Moreover, IPT of malaria was associated with a 29% reduction in 
the prevalence of anaemia in children following a meta-analysis of five trials (Meremikwu et 
al., 2012). However, anaemia may not be a good indicator of iron deficiency and the reported 
reduction in anaemia may also be malaria-related. Although it is well known that malaria 
causes anaemia by the destruction of infected and uninfected RBCs, the iron released from 
such cells is not lost from the body but is recycled and thus it is not clear whether malaria may 
be causing iron deficiency. 
 
The iron hormone hepcidin may link malaria with iron deficiency. Both clinical and 
asymptomatic malaria infections increase hepcidin concentrations. Clinical episodes of P. 
falciparum malaria are associated with increased hepcidin concentrations in African children 
(Howard et al., 2007; Ayoya et al., 2009; de Mast et al., 2009; Casals-Pascual et al., 2012; 
Atkinson et al., 2015). Similarly, asymptomatic P. falciparum is associated with a doubling of 
hepcidin concentrations (de Mast et al., 2010; Atkinson et al., 2015). In Ivorian children and 
Beninese women, treatment of asymptomatic malaria substantially reduced hepcidin 
concentrations, increased iron absorption and reduced iron deficiency (Cercamondi et al., 
2010; Glinz, Hurrell, Righetti, et al., 2015). Furthermore, the up-regulatory effects of malaria 
on hepcidin concentrations appear to occur both in the presence and absence of inflammation 
suggesting that malaria may further increase hepcidin independently of inflammation 
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(Atkinson et al., 2015). Increased hepcidin concentrations due to frequent and chronic malaria 
parasitaemia in children with iron-poor diets may lead to iron deficiency since hepcidin 
prevents iron absorption and recycling by inhibiting the activity of ferroportin (Nemeth, Tuttle, 
et al., 2004). However, the mechanisms through which malaria up-regulates hepcidin 
production are not fully elucidated, but may involve the BMP-SMAD signaling pathway 
(Spottiswoode et al., 2017). 
 
Malaria may also cause iron deficiency through increasing inflammatory cytokines such as 
tumor necrosis factor-α (TNF-α). Uncomplicated and asymptomatic malaria significantly raise 
TNF-α concentrations (Kwiatkowski et al., 1990; Kurtzhals et al., 1999). TNF-α blocks iron 
recycling from macrophages and inhibits erythropoiesis (Roodman et al., 1987; Alvarez-
Hernández et al., 1989). In addition, TNF-α, independently of hepcidin, blocks intestinal iron 
absorption by reducing DMT1 expression (Johnson et al., 2004), increasing deposition of iron 
into ferritin and degrading ferroportin (Laftah et al., 2006). In a cohort of Gambian children, 
the TNF-308 AA genotype (which is associated with higher TNF-α transcription compared with 
TNF-308 AG and TNF-308 GG genotypes (Kroeger, Carville and Abraham, 1997; Wilson et al., 
1997)) was strongly associated with increased risk of iron deficiency and iron deficiency 
anaemia (Atkinson et al., 2008). Interestingly, this effect was observed at the end of a malaria 
season when the prevalence of clinical malaria was highest (Atkinson et al., 2008). 
Furthermore, ZPP concentrations were significantly raised in the TNF-308 AA genotype 
indicating dyserythropoiesis (Atkinson et al., 2008). Figure 1.4 illustrates how malaria-induced 
hepcidin / TNF might contribute to iron deficiency. In the next section, I will discuss 
epidemiological approaches for investigating whether malaria causes iron deficiency. 
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Figure 1.4. The malaria - iron deficiency hypothesis. 
(A) In healthy children without malaria (A1), concentrations of hepcidin and TNF-α are low (A2) leading to increased absorption of iron through 
enterocytes (A3), reduced haemolysis of RBCs and increased recycling of iron recovered from senescent RBCs by macrophages (A4). More iron 
is thus available for the production of new RBCs (A5). (B) On the other hand, during malaria infection, blood-stage malaria parasites (B1) elicit 
increased production of hepcidin and TNF-α (B2), which in turn block absorption of iron through DMT1 and ferroportin (FPN) on enterocytes 
(B3). Hepcidin also degrades ferroportin on both infected and uninfected RBCs leading to accumulation of intracellular iron, oxidative stress, 
and consequently haemolysis. Haemolysed RBCs are taken up by the macrophage (B4). Hepcidin and TNF-α inhibit recycling of iron recovered 
from haemolysed RBCs back into the circulation leading to deficiency of the amount of biologically available iron. Consequently, little iron is 
available to produce new RBCs by the bone marrow leading to iron deficiency anaemia (B5). Tf, transferrin. I drew this diagram and it is 
reproduced from (Muriuki and Atkinson, 2018). 
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1.3.2.1 Epidemiological approaches to investigate whether malaria causes iron deficiency 
It is challenging to investigate whether malaria causes iron deficiency due to potential 
confounders and the possibility of reverse causality. Longitudinal cohort studies following up 
malaria exposed and unexposed children for iron status might be one approach to investigate 
whether malaria causes iron deficiency. However, since individuals in malaria endemic areas 
are likely to be exposed to malaria repeatedly and in varying degrees over time (Snow et al., 
2017), it would be difficult to group them as exposed or unexposed with certainty. Individuals 
who are continuously exposed to malaria develop partial immunity to malaria and may be 
misclassified as unexposed (Bejon et al., 2009). Moreover, it is difficult to specifically 
determine the degree of malaria exposure (Langhorne et al., 2008; Olotu et al., 2012). Another 
challenge is the fact that host iron status may also influence malaria risk making reverse 
causality a possibility (Nyakeriga et al., 2004; Gwamaka et al., 2012; Jonker et al., 2012; 
Barffour et al., 2017; Moya-Alvarez et al., 2017). Pragmatic cohort studies would involve 
comparing iron deficiency during the course of malaria seasons although many other factors 
may influence iron status during that period (Atkinson et al., 2014). For example, the 
nutritional status of children may improve during harvest seasons, which may coincide with 
rainy seasons (or peak malaria transmission) thereby confounding a possible effect of malaria 
on iron status. 
 
Another approach would be to spatially and temporally map-out the distribution of malaria and 
iron deficiency. If malaria causes iron deficiency, then areas or periods of high malaria 
transmission would also be associated with higher prevalence of iron deficiency. Carefully 
gathered and mapped epidemiological data of malaria in Africa, both in space and time, are 
available (Noor et al., 2014; Snow et al., 2017). Likewise, a number of iron deficiency studies 
have been conducted in African children over the years although not mapped. However, this 
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approach is limited by the fact that levels of ferritin and other iron biomarkers are raised by 
malaria infection (discussed in Section 1.3.1). Thus, malaria may obscure the true picture of 
iron deficiency so that children in malaria regions may appear more iron replete. Social 
economic status may further confound the geographical distribution of malaria and iron 
deficiency since both are more likely to occur in the poorest communities. 
 
Randomised controlled trials remain the gold standard study designs for investigating a causal 
relationship. Individuals could be randomised to receive interventions known to be effective 
against malaria such as antimalarials and insecticide-treated bed nets and then iron status could 
be assessed after a period of time. For example, children could be randomised to receive IPT 
of malaria followed by assessment of iron status. In a few previous trials, IPT of malaria was 
associated with non-significant improvement in ferritin concentrations and a decrease in sTfR 
suggesting modest improved iron status (Verhoef, West, Nzyuko, et al., 2002; Desai et al., 
2003; Glinz, Hurrell, Ouattara, et al., 2015). However, both ferritin and sTfR are raised during 
malaria infection (Das, Thurnham and Das, 1997; Phiri, Calis, Siyasiya, et al., 2009; Aguilar 
et al., 2012) making interpretation of iron status difficult and thus they may not be the best 
indicators of the effect of IPT on iron status. Transferrin saturation may be a good indicator of 
improved iron absorption while reduced ZPP concentrations may indicate improved 
erythrocyte iron incorporation. However, it may be expensive and difficult to justify large trials 
randomising children to IPT of malaria or none. Thus, in Section 1.4, I will review an approach 
(Mendelian randomisation) that can be utilised to study whether malaria causes iron deficiency 
and then test the hypothesis in Chapter Four. 
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1.3.3 Iron status and malaria risk 
Malaria parasites require iron to grow and multiply. For example, iron restriction inhibits 
development of both the liver and blood stage of Plasmodium (Matsuzaki-moriya et al., 2011; 
Portugal et al., 2011). In a seminal study by (Murray, Murray and Murray, 1975), feeding 
patients after admission during famine increased malaria episodes and parasitaemia and this 
was associated with increased serum iron and transferrin saturation. However, the exact source 
of iron for parasite growth and how it acquires iron remains unclear. In this section, I will 
discuss possible mechanisms through which the malaria parasite acquires iron and then provide 
evidence of associations between iron status and supplementation on malaria risk. 
 
1.3.3.1 Iron acquisition by malaria parasite 
The metabolism of iron in the malaria parasite is complex. Just like in humans, the parasite 
must regulate iron to meet its iron need and avoid toxicity from iron. Possible sources of iron 
for the parasite include haemoglobin, intracellular ferritin, traces of iron within RBCs, 
transferrin bound iron and non-transferrin bound iron (NTBI) (illustrated in Figure 1.5). It is 
thought that the parasite consumes copious amounts of haemoglobin although that is not clear. 
The parasite metabolises haemoglobin to acquire amino acids and release toxic haem. The 
parasite sequesters the toxic haem into haemozoin thus avoiding its toxicity although some 
trace free haem remains and gets oxidised to generate free ROS (Chugh et al., 2013). The mode 
of action of ACTs may involve inhibition of the parasite’s ability to detoxify ROS (Chugh et 
al., 2013). 
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Figure 1.5. Relation between iron and P. falciparum stages in human. 
After a bite of a malaria-infected female Anopheles mosquito, Plasmodium sporozoites infect 
liver cells then differentiate into merozoites before infecting red blood cells (RBCs). A) 
Presence of iron stores within hepatocytes is thought to fuel differentiation and multiplication 
of liver stages of Plasmodium. B) Within RBCs, the merozoites undergo a rapid intra-
erythrocytic proliferation possibly fueled by the high amount of haem or stored iron within 
RBCs. Intracellular labile iron may also play a role in the growth of the parasite. The parasite 
also metabolises haem and sequesters it into haemozoin to avoid its toxicity. Once RBCs 
haemolyse, merozoites are released into circulation to infect new RBCs. The merozoites may 
also utilise non-transferrin bound iron. I drew this diagram. 
 
Evidence suggests that the malaria parasite may utilise intracellular iron in RBCs. In a recent 
study, knock-out of the FPN gene in mice injected with Plasmodium yoelii YM caused an 
increase in parasite density and deaths compared to wild type mice (Zhang et al., 2018). These 
results suggest that FPN gene knock-out may increase the labile iron pool within RBCs and 
promote growth of the parasite. However, it is also possible that FPN knock-out may have 
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caused iron to accumulate within RBCs leading to increased oxidative stress, haemolysis and 
spread of the parasite to other uninfected RBCs (Zhang et al., 2018). 
 
It is also not clear whether the malaria parasite utilises serum iron. In vitro parasitised RBCs 
have been shown to take up iron bound to transferrin (Pollack and Fleming, 1984; Clark et al., 
2013). However, in other studies the malaria parasite does not seem to directly utilise serum 
iron (Peto and Thompson, 1986; Pollack and Schnelle, 1988). Thus, it is not clear whether any 
perturbations to host iron (either by iron deficiency or improved iron status through 
supplementation) may influence the risk of malaria infection. 
 
1.3.3.2 Iron status and malaria risk in observational studies 
Previous observational studies have all shown that iron deficiency is associated with a reduced 
risk of clinical and severe P. falciparum malaria in African children (Nyakeriga et al., 2004; 
Gwamaka et al., 2012; Jonker et al., 2012; Barffour et al., 2017; Moya-Alvarez et al., 2017). 
(Nyakeriga et al., 2004) reported a 30% reduction in clinical malaria during a six-month 
follow-up of 240 Kenyan children aged 8 months to 8 years.  Similarly, studies in Malawi (727 
children aged 6 - 60 months with one year of follow-up) (Jonker et al., 2012) and Tanzania 
(785 children followed-up from birth to 3 years) (Gwamaka et al., 2012) reported reduced 
malaria risk of 45% and 23% respectively. Other more recent studies in 745 Zambian children 
aged 4 - 8 years followed-up for six months, and in 400 Beninese infants followed-up from 
birth to 1 year of age, reported an increased risk of malaria in children with high ferritin 
concentrations (Barffour et al., 2017; Moya-Alvarez et al., 2017). However, despite the wide 
range of iron biomarkers, these studies largely reported iron deficiency defined using ferritin 
only. As discussed in Sub-section 1.3.1, ferritin is substantially increased by malaria thus, the 
protection observed may indicate an acute phase response from malaria infection. Moreover, it 
32 
 
is difficult to control for reverse causality in observational studies. Thus, there is a need for 
more pragmatic or innovative study designs to infer causality. 
 
1.3.3.3 Iron status and malaria risk in clinical trials 
In contrast, randomised controlled trials have reported inconsistent findings for the effects of 
iron on malaria. Some have reported that iron supplementation does not influence risk of 
malaria (Menendez et al., 1997), others that iron supplementation reduces malaria risk (Zlotkin 
et al., 2013), while others that iron supplementation increases malaria risk (Sazawal et al., 
2006; Veenemans et al., 2011; Esan et al., 2013). In a large trial (24,076 children) that was 
conducted in Pemba, Tanzania in 2006, iron supplementation increased the risk of malaria-
related events by 16% compared to the placebo group (Sazawal et al., 2006). However, in a 
subgroup with iron measurements, this study reported a 44% reduced risk of malaria-related 
adverse events following iron supplementation among iron-deficient children at baseline. 
Contrary to the Pemba study, supplementation with iron in another large trial in Ghana in 2013 
resulted in a 13% reduction in malaria incidence and a lack of evidence of increased malaria 
risk and hospital admissions among iron replete children at baseline (Zlotkin et al., 2013). 
However, multi-nutrient (including iron) supplementation of children in a Tanzanian trial in 
2011 increased malaria risk by 41% among children that were iron deficient at baseline but not 
among iron replete children (Veenemans et al., 2011). 
 
There are a number of possible explanations for the controversy of whether improving iron 
status through iron supplementation influences malaria risk. First, is the baseline randomisation 
of participants based on iron status. In the Pemba sub-study conflicting results were observed 
against the main study when they considered individuals with and without baseline iron 
deficiency (Sazawal et al., 2006). Moreover, baseline iron status in the Pemba study was 
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indicated by ZPP (Sazawal et al., 2006) while ferritin was used to indicate iron status in the 
2011 Tanzanian (Veenemans et al., 2011) and 2013 Ghanaian (Zlotkin et al., 2013) studies. 
Second, is the provision of malaria interventions during the study. It is possible that the 
reduction in the incidence of malaria following iron supplementation in Ghana may be 
attributable to malaria interventions (such as ITNs and antimalarials) that were provided during 
the study (Zlotkin et al., 2013). Third, is the administration of iron alone or in combination 
with other micronutrients which varied across the studies. Other factors include differences in 
study populations, intensity of malaria transmission, and factors relating to participants such 
as immunity to malaria and genetic predisposition. It is possible that immunity to malaria and 
carriage of haemoglobinopathies or G6PD deficiency, which protect from malaria, may 
confound possible causal effects of iron status on malaria risk. These conflicting findings have 
therefore left long-standing concerns among clinicians and policy makers regarding the safety 
of iron supplementation to correct iron deficiency in malaria-endemic regions such as sub-
Saharan Africa (Suchdev et al., 2010). In Chapter Five, I report analyses from longitudinal 
studies on whether a child’s iron status influences their subsequent risk of malaria infection. 
 
1.3.4 The ferroportin gene, iron deficiency and risk of malaria 
Ferroportin which is encoded by the SLC40A1 or FPN gene is the only known mammalian iron 
exporter (Donovan et al., 2000). Ferroportin is highly expressed in duodenal enterocytes and 
macrophages where it plays a crucial role in iron absorption and recycling, respectively  
(Donovan et al., 2005; Drakesmith, Nemeth and Ganz, 2015). A recent study showed that 
ferroportin is also abundant in RBCs and plays a role in reducing intracellular iron 
accumulation and haemolysis (Zhang et al., 2018). To optimize iron homeostasis, hepcidin 
occludes and degrades ferroportion during iron overload (Nemeth, Tuttle, et al., 2004; 
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Aschemeyer et al., 2018). Hepcidin also degrades ferroportin during infections to deny 
pathogens of iron. 
 
A number of polymorphisms in the SLC40A1 gene have been implicated in iron overloading 
(Mayr et al., 2010). One such polymorphism is the Q248H (glutamine to histidine at position 
248) mutation which occurs primarily in African populations (Beutler et al., 2003; Gordeuk et 
al., 2003). The FPN Q248H mutation may increase cellular iron export by rendering ferroportin 
partially resistant to degradation by hepcidin resulting in a 60% decrease in intracellular iron 
in Q248H cells (Nekhai et al., 2013). Thus, in enterocytes and macrophages the mutation might 
increase absorption and recycling of iron. However, Q248H has also been shown to impair 
cellular iron export (McGregor et al., 2005) or have no functional effect (Drakesmith et al., 
2005; Schimanski et al., 2005). Moreover, previous studies with limited sample sizes, have 
found conflicting associations between Q248H and haemoglobin concentrations (Beutler et al., 
2003; Gordeuk et al., 2003; McNamara, Gordeuk and MacPhail, 2005; Masaisa et al., 2012; 
Zhang et al., 2018) or with iron deficiency (Beutler et al., 2003; Gordeuk et al., 2003; Kasvosve 
et al., 2005, 2010, 2015; Rivers et al., 2007; Nekhai et al., 2013; Cikomola et al., 2017). 
 
Since the FPN Q248H mutation occurs mainly in African populations, it has been hypothesised 
that it is positively selected to protect from malaria risk (Zhang et al., 2018). A recent study 
showed that the Q248H mutation is associated with protection from malaria risk in Zambian 
children and primiparous Ghanaian women (Zhang et al., 2018). In the study, children carrying 
Q248H had lower P. falciparum asexual parasites in peripheral blood compared to children 
with the wild type allele. Similarly, the proportion of placental P. falciparum was lower in 
Q248H carriers compared to women with wild type allele. However, the study was of very 
limited size: 13 Q248H children with uncomplicated malaria and 11 Q248H women with 
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placental malaria. Furthermore, (Zhang et al., 2018) included only cases and no controls for 
their study of uncomplicated malaria among Zambian children and thus were unable to assess 
risk of malaria. They also reported contrasting results since geometric mean parasite densities 
in both peripheral and placental blood were higher in Q248H carriers compared to wild-type 
and no difference was observed in microscopy positive peripheral or placental blood (Zhang et 
al., 2018). In Chapter Six, I report large scale genomic datasets determining whether the 
Q248H mutation protects from iron deficiency, anaemia and malaria risk. 
 
1.4 Mendelian randomisation 
In Section 1.3.2.1, I discussed some limitations of epidemiological approaches for determining 
whether malaria causes iron deficiency. In this section, I will discuss Mendelian randomisation 
as an approach to test the hypothesis that malaria causes iron deficiency. Mendelian 
randomisation utilises genetic variants as proxies for modifiable environmental exposures (or 
instrumental variables) to infer a causal relationship between an exposure and an outcome 
(Davey Smith and Ebrahim, 2003). This study design provides an alternative to randomised 
controlled trials since genetic variants are unlikely to be confounded by environmental factors 
and reverse causality is eliminated as genetic variants are allocated at conception (Evans and 
Davey Smith, 2015) (Figure 1.5). Mendelian randomisation also reflects a life-time of 
exposure, which is important since age is a critical determinant of infectious risk. This approach 
has been successfully employed in other disease processes and has helped to explain previous 
controversies (Elliott et al., 2009; Voight et al., 2012; Afzal et al., 2014). 
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Figure 1.6. Comparison of a randomised controlled trial and Mendelian randomisation. 
Adapted from (Davey Smith, Timpson and Ebrahim, 2008) 
 
Similarly, Mendelian randomisation can be utilised to study whether malaria causes iron 
deficiency. There are known genetic polymorphisms that are associated with resistance to 
malaria such as sickle cell trait (HbAS), α-thalassaemia, and G6PD (discussed in Section 1.2.4) 
among others (Malaria Genomic Epidemiology Network, 2014). If malaria causes iron 
deficiency, then polymorphisms that protect from malaria should also be associated with 
reduced risk of iron deficiency. However, the polymorphisms should only influence iron status 
through malaria, thus the effect of the polymorphism(s) on iron status should only be observed 
in populations at risk of malaria, but not in malaria-free populations (i.e. there should be no 
pleiotropy or independent effect of the polymorphisms on iron deficiency). Additionally, each 
of the protective polymorphisms should influence iron deficiency in the same direction 
(Burgess, Butterworth and Thompson, 2013; Bowden, Davey Smith and Burgess, 2015). 
Figure 1.6 illustrates the conceptual Mendelian randomisation causal diagram for malaria and 
iron deficiency. 
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Figure 1.7. Conceptual Mendelian randomisation causal inference framework. 
(i) Genetic variants reliably associated with malaria are required, for example, sickle cell trait. 
(ii) The genetic variant should not be associated with any measured potential confounders. (iii) 
The genetic variant should influence iron deficiency only through malaria exposure, i.e. the 
effects should not be observed in populations that are not exposed to malaria. Adapted from 
Sheehan et al (Sheehan et al., 2008). 
 
There is little and conflicting information on how carriage of haemoglobinopathies influence 
iron status. HbAS (n = 75) was associated with reduced frequency of iron deficiency anaemia 
among inhabitants of a Lebanese village in an early study (Hershko et al., 1982). However, 
more recent small studies have reported mixed findings on the effect of sickle cell trait on iron 
status. For example, (Nyakeriga et al., 2005) did not find a difference in iron status between 
Kenyan children carrying HbAS (n = 39) and normal haemoglobin (HbAA) while (Engle-stone 
et al., 2017) found that HbAS (n = 40) was associated with increased iron stores among 
Cameroonian children. In children from Vanuatu, alpha-thalassaemic heterozygotes (n = 68) 
and homozygotes (n = 46) had increased sTfRs concentrations compared to normal controls, 
but there was no difference in ferritin levels (Rees et al., 1998). It is possible that, in a large 
study, these polymorphisms may protect from iron deficiency by reducing malaria risk. 
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1.5 Research questions raised during this literature review 
This literature review raises a number of research questions that I will address in this thesis. 
These include: 
1. How can we more accurately estimate the burden of iron deficiency in African children? 
The challenge is that conventional markers of iron status are influenced by 
inflammation and malaria thereby obscuring the true picture of iron deficiency in this 
population. In Chapter Three, I apply adjustments for the effects of inflammation and 
malaria on iron biomarkers to estimate the ‘true’ burden of iron deficiency. I also test 
the diagnostic utility of various iron biomarkers in predicting the burden of iron 
deficiency. 
 
2. Does malaria cause iron deficiency? It is difficult to answer this question in 
observational studies since malaria up-regulates iron markers and iron status may also 
influence malaria risk (i.e. reverse causality). In Chapter Four, I apply a Mendelian 
randomisation approach using genetic proxies for malaria to answer this question. 
 
3. Does iron status influence malaria risk? Previously, observational studies of limited 
size have only looked at the effect of ferritin-defined iron deficiency on malaria. How 
about other markers of iron status? In Chapter Five, I investigate whether a child’s iron 
status influences their subsequent risk of malaria infection using a wide range of iron 
biomarkers in two large cohorts of children. 
 
4. Can genetics help us determine whether iron status influences malaria risk? Since the 
FPN Q248H preserves ferroportin thereby increasing intracellular iron export, how 
does that influence iron status and malaria risk? In Chapter Six, I report analyses of 
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large datasets to determine the associations between FPN Q248H mutation and iron 
status, anaemia, and malaria. An important future question (which will not be addressed 
in this thesis) is to identify genetic variants that reliably alter iron status in African 
children, through a genome-wide association study, and use the identified variants to 
determine whether they are also associated with malaria risk in Mendelian 
randomisation analyses. 
 
1.6 Aim and objectives of the study 
Following the above questions, the general aim of this thesis is therefore to determine the causal 
relationship between iron deficiency and malaria. Specifically, the thesis objectives include: 
1. To determine the predictors of iron biomarkers and estimate the ‘true’ burden of iron 
deficiency in African children, 
2. To determine whether malaria is causally associated with iron deficiency, 
3. To determine whether iron status is associated with malaria infection, and 
4. To determine whether a mutation in the ferroportin gene (Q248H) is associated with 
iron status, anaemia and malaria risk. 
The next chapter details the general methods used to answer the above questions. Thereafter, 
chapters are organised based on the above objectives. Finally, I present a general discussion 
detailing conclusions and future research. 
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CHAPTER TWO: GENERAL METHODS 
In this chapter, I describe the main study populations included in this thesis, laboratory methods 
for measurement of iron and inflammatory biomarkers, as well as measurements for malaria 
parasitaemia and anthropometry. I finally highlight the definitions of key outcomes reported in 
Chapters Three to Six. Chapter-specific methods are described within the respective Chapters. 
 
2.1 Study populations 
Analyses in this thesis included data from 12 community-based studies, one hospital-based 
study, and the MalariaGEN consortium severe malaria datasets (Malaria Genomic 
Epidemiology Network, 2014). The community-based studies included nine from the malaria-
endemic regions of sub-Saharan Africa (in Kenya, Uganda, Burkina Faso, The Gambia, 
Malawi, Ghana, Democratic Republic of Congo (DRC), Tanzania, and Cameroon), and two 
studies in non-malaria exposed cohorts of South African children and African-Americans from 
the Jackson Heart Study (JHS) in Mississippi, USA. The hospital-based study was conducted 
in Kilifi County Hospital, Kilifi, Kenya. Figure 2.1 shows the African study sites mapped 
against a map of the prevalence of P. falciparum between 2010 and 2015 as previously 
published by (Snow et al., 2017). 
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Figure 2.1. African study sites. 
Studies are ordered based on the study prevalence of malaria parasitaemia. Highest in Malawi. 
Note, historically, there is no malaria in South Africa. 
 
These studies can further be divided into my role in data generation and curation. I was actively 
involved in data generation in four community-based studies: Kilifi, Kenya; Banfora, Burkina 
Faso; Entebbe, Uganda; and Soweto, South Africa. In Kilifi, Kenya, I also selected, retrieved 
and aliquoted plasma/serum samples. In these four studies, measurements of iron and 
inflammatory markers were performed at the Department of Clinical Biochemistry, University 
of Oxford by Ms Wandia Kimita (Dr Sarah Atkinson’s master’s student at the KEMRI-
Wellcome Trust Research Programme) and under the supervision of Dr Alireza Morovat, 
Consultant Clinical Biochemist (Oxford University Hospitals). I merged all the generated raw 
data files and checked for inconsistencies (such as samples with values below the detection 
limit and expected range of values from the assay manuals). In this thesis, I will refer to these 
four studies as the iron_vaccgene studies since the studies were designed in collaboration with 
Dr. Alexander Mentzer (University of Oxford) whose interest was in the genetics of vaccine 
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responses. I obtained data for the remaining study sites through collaborations with other 
investigators who had already measured markers of iron status and inflammation, tested for 
malaria, and conducted anthropometry and genotyping (Table 2.1). I then cleaned and analysed 
all datasets. Below, I describe the five main studies included in this thesis: the iron_vaccgene 
studies and The Gambia study. The rest of the studies (Malawi; Ghana; Western, Kenya; Sud-
Kivu and Congo central, DRC; Muheza, Tanzania; Yaoundé and Douala, Cameroon; and 
Jackson Heart Study, USA) had permission through collaboration for the analyses of whether 
malaria causes iron deficiency and are described in Chapter Four. I also analysed the effect of 
FPN Q248H on severe malaria using data from the MalariaGEN consortium (Malaria Genomic 
Epidemiology Network, 2014) with the help of Dr Gavin Band (University of Oxford). I 
analysed the Kenyan MalariaGEN dataset while Dr Gavin Band analysed MalariaGEN datasets 
for The Gambia, Malawi and Ghana. 
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Table 2.1. Data from individual study sites through collaboration 
Study site Collaborator(s) Total sample 
size 
Age 
(years) 
Data 
Kilifi, Kenya Prof Bejon 
Dr Ndungu 
Prof Williams 
1484 0 – 8 Age, sex, iron and inflammatory 
markers, malaria parasitaemia (including 
longitudinal data), anthropometry, sickle, 
α-thalassaemia, G6PD, and Q248H 
Banfora, 
Burkina Faso 
Prof Hill 
Dr Mentzer 
Dr Sodiomon 
348 0 – 2 Age, sex, iron and inflammatory 
markers, malaria parasitaemia, 
anthropometry, sickle, α-thalassaemia, 
G6PD, and Q248H 
Entebbe, 
Uganda 
Prof Elliott 1374 0 – 5 Age, sex, iron and inflammatory 
markers, malaria parasitaemia (including 
longitudinal), anthropometry, sickle, α-
thalassaemia, G6PD, and Q248H 
Soweto, South 
Africa 
Prof Madhi 894 0 – 2 Age, sex, iron and inflammatory 
markers, sickle, α-thalassaemia, G6PD, 
and Q248H 
West Kiang, The 
Gambia 
Prof Prentice 
Dr Atkinson 
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2 – 6 Age, sex, iron and inflammatory 
markers, malaria parasitaemia, 
anthropometry, sickle, G6PD, and 
Q248H 
Malawi Prof Suchdev 1233 0 – 5 Age, sex, iron and inflammatory 
markers, malaria parasitaemia, 
anthropometry, sickle, α-thalassaemia, 
and G6PD 
Ghana Dr Wegmüller 
Dr Wirth 
1159 0 – 5 Age, sex, iron and inflammatory 
markers, malaria parasitaemia, 
anthropometry, sickle, and α-
thalassaemia 
Western Kenya Prof Stewart 488 1 - 2 Age, sex, iron and inflammatory 
markers, malaria parasitaemia, 
anthropometry, sickle, and α-
thalassaemia 
Sud-Kivu and 
Congo central, 
DRC 
Prof Karakochuk 
Prof Green 
748 0 - 5 Age, sex, iron and inflammatory 
markers, malaria parasitaemia, 
anthropometry, sickle, α-thalassaemia, 
and G6PD 
Muheza, 
Tanzania 
Prof Duffy 680 0 - 3 Age, sex, iron and inflammatory 
markers, anthropometry, sickle, α-
thalassaemia, and G6PD 
Yaoundé and 
Douala, 
Cameroon 
Prof Engle-Stone 304 1 - 5 Age, sex, iron and inflammatory 
markers, malaria parasitaemia, 
anthropometry, sickle, and α-
thalassaemia 
Jackson Heart 
Study, USA 
Dr Raffield 
Dr Musani 
3457 21 - 95 Age, sex, iron and inflammatory 
markers, anthropometry, sickle, α-
thalassaemia, and G6PD 
MalariaGEN Prof 
Kwiatkowski 
11,982 0 - 8 Age, sex, malaria parasitaemia, 
haemoglobin, haematocrit, Blantyre 
coma test, and Q248H 
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Kilifi, Kenya: This included an ongoing rolling cohort evaluating malaria immunity in children 
in Kilifi, along the coast of Kenya (Bejon et al., 2010). Within this cohort, children were 
followed-up for malaria episodes up to 8 years of age with weekly follow-ups and annual cross-
sectional surveys during which anthropometry measurements, auxiliary temperature, and blood 
samples were taken. Malaria parasitaemia (Giemsa stained thick and thin blood films) and iron 
and inflammatory markers were measured from blood samples collected at a single cross-
sectional survey based on the availability of plasma samples archived at -800C. Genotyping of 
sickle cell (rs334), α-thalassaemia, and G6PD (rs1050828) was conducted by polymerase chain 
reaction (PCR) (Chong et al., 2000; Waterfall and Cobb, 2001) using DNA extracted by Qiagen 
DNA Blood Mini Kit (Qiagen, West Sussex, United Kingdom). Q248H (rs11568350) was 
directly typed using Agena Bioscience SEQUENOM® Matrix-Assisted Laser Desorption-
Ionization Time-of-Flight (MALDI-TOF) mass spectrometry on the iPLEX platform (Ross et 
al., 1998). 
 
Banfora, Burkina Faso: This was the VAC050 ME-TRAP Malaria Vaccine Trial that recruited 
infants between the ages of 6 and 18 months living in the Banfora region of Burkina Faso to 
participate in a Phase 1/2b clinical trial of the safety, immunogenicity and efficacy of a viral-
vectored prime-boost liver-stage malaria vaccine (Bliss et al., 2017). Samples from a total of 
350 infants were then selected into the iron_vaccgene study based on suitability of samples for 
DNA extraction. Plasma samples were available from the infants at multiple time-points 
following receipt of the experimental vaccine. Samples from individuals taken at time points 
as close to the 12-month age as possible were prioritised for the iron_vaccgene study. 
Anthropometry and malaria parasitaemia (Giemsa stained thick and thin blood films) were also 
measured (Bliss et al., 2017). 
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Entebbe, Uganda: This is the Entebbe Mother and Baby Study (EMaBS) which is a prospective 
birth cohort that was originally designed as a randomised controlled trial to test whether 
anthelminthic treatment during pregnancy and early childhood was associated with differential 
response to vaccination or incidence of infections including malaria (http://emabs.lshtm.ac.uk/) 
(Webb et al., 2011). A total of 2507 pregnant women from Entebbe and in their second or third 
trimester of pregnancy were initially enrolled at Entebbe Hospital antenatal clinic. A total of 
2345 livebirths from these mothers were enrolled into the EMaBS study. Blood samples were 
collected in vacutainer tubes containing ethylenediaminetetraacetic acid (EDTA) at birth and 
at subsequent birthdays up to five years of age. Anthropometry and iron / inflammatory 
biomarkers were measured from a single annual visit based on the availability of stored 
samples. The study included longitudinal active surveillance of malaria (Giemsa stained thick 
and thin blood films) during fortnightly home visits and quarterly clinic visits.  
 
South Africa: The Soweto Vaccine Response Study: Infants born in Chris Hani Baragwanath 
Hospital living in the Soweto region of Johannesburg, South Africa were recruited from 
vaccine trials (Nunes et al., 2016) that are coordinated by the Respiratory and Meningeal 
Pathogens Unit (http://www.rmpru.com/). Mothers of the infants were approached if the infants 
had received all of their EPI vaccines up to six months of age. The infants were sampled 
prospectively at six months of age and at 12 months after receipt of measles vaccine at nine 
months. Single whole blood samples were collected in EDTA vacutainer tubes for 
measurement of iron and inflammatory markers and DNA extraction. 
 
The Gambia: West Kiang study: All children aged two to six years (except those with chronic 
illness) were recruited from 10 rural villages in the West Kiang region of The Gambia during 
the start of a malaria season to initially investigate seasonal genetic effects of iron status and 
46 
 
haemoglobin concentrations between July and August 2001 (Atkinson et al., 2006). All 
children had a clinical examination, anthropometric measurements, and a three-day course of 
mebendazole for potential hookworm infection. A blood sample was collected for complete 
blood count, malaria slide, DNA extraction and measurement of iron / inflammatory markers. 
Single nucleotide polymorphisms (SNPs) for sickle cell (rs334), G6PD (rs1050828), and 
Q248H (rs11568350) were directly typed using Agena Bioscience SEQUENOM® MALDI-
TOF mass spectrometry on the iPLEX platform (Ross et al., 1998). 
 
2.2 Assays for iron and inflammatory markers 
The assayed biomarkers of iron (ferritin, soluble transferrin receptors (sTfR), hepcidin, serum 
iron, transferrin, unsaturated iron binding capacity (UIBC), zinc protoporphyrin (ZPP), and 
haemoglobin) and inflammation (C-reactive protein (CRP) and α1-antichymotrypsin (ACT) are 
shown in Table 2.2. The Gambian hepcidin values were harmonised with the rest of the cohorts’ 
hepcidin values (measured using high sensitive DRG kit) by converting to the old DRG 
hepcidin assay values and then to the new high sensitive DRG hepcidin assay values (Wray et 
al., 2017).  In Uganda, haemoglobin concentrations were adjusted for an altitude of >1000m 
above sea level (by subtracting 0.2g/dL) (World Health Organization, 2011a).
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Table 2.2. Laboratory assays for iron and inflammatory biomarkers by site 
Site Ferritin Soluble 
transferrin 
receptor 
Hepcidin Serum iron Transferrin Unsaturated 
iron binding 
capacity 
Zinc 
protoporphyrin 
Haemoglobin/ 
MCV/MCHC 
CRP ACT 
Kilfi, 
Kenya 
Microparticle 
Enzyme 
Immunoassay 
(Abbott 
Architect, 
USA) 
Human sTfR 
ELISA 
(BioVendor, 
Czech 
Republic) 
DRG Hepcidin 
25 [bioactive] 
high sensitive 
ELISA (DRG 
International, 
USA) 
MULTIGENT 
iron 
calorimetric 
assay, Abbott 
Architect, USA 
Chemiluminescent 
Microparticle 
Immunoassay 
(Abbott Architect, 
USA) 
Not measured Not measured Coulter analyser 
(ACT5Diff, Beckman 
Coulter, USA) 
MULTIGENT 
CRP Vario 
assay, (Abbott 
Architect, 
USA) 
Not measured 
Banfora, 
Burkina Faso 
Microparticle 
Enzyme 
Immunoassay 
(Abbott 
Architect, 
USA) 
Human sTfR 
ELISA 
(BioVendor, 
Czech 
Republic) 
DRG Hepcidin 
25 [bioactive] 
high sensitive 
ELISA (DRG 
International, 
USA) 
MULTIGENT 
iron 
calorimetric 
assay, Abbott 
Architect, USA 
Chemiluminescent 
Microparticle 
Immunoassay 
(Abbott Architect, 
USA) 
Not measured Not measured Coulter analyser 
(Beckman Coulter, 
USA) 
MULTIGENT 
CRP Vario 
assay, (Abbott 
Architect, 
USA) 
Not measured 
Entebbe, 
Uganda 
Microparticle 
Enzyme 
Immunoassay 
(Abbott 
Architect, 
USA) 
Human sTfR 
ELISA 
(BioVendor, 
Czech 
Republic) 
DRG Hepcidin 
25 [bioactive] 
high sensitive 
ELISA (DRG 
International, 
USA) 
Not measured Chemiluminescent 
Microparticle 
Immunoassay 
(Abbott Architect, 
USA) 
Not measured Not measured Coulter analyser 
(Beckman Coulter, 
Nyon, Switzerland) 
MULTIGENT 
CRP Vario 
assay, (Abbott 
Architect, 
USA) 
Not measured 
Soweto, 
South Africa 
Microparticle 
Enzyme 
Immunoassay 
(Abbott 
Architect, 
USA) 
Human sTfR 
ELISA 
(BioVendor, 
Czech 
Republic) 
DRG Hepcidin 
25 [bioactive] 
high sensitive 
ELISA (DRG 
International, 
USA) 
Not measured Chemiluminescent 
Microparticle 
Immunoassay 
(Abbott Architect, 
USA) 
Not measured Not measured Not measured MULTIGENT 
CRP Vario 
assay, (Abbott 
Architect, 
USA) 
Not measured 
West Kiang, 
The Gambia 
Microparticle 
Enzyme 
Immunoassay 
(Abbott 
Architect, 
USA) 
Quantikine 
sTfR ELISA 
kit, (R&D 
Systems, 
USA) 
Hepcidin-25 
[human] 
Enzyme 
Immunoassay 
Kit (Bachem, 
Switzerland) 
Ferrozine-
based 
photometry and 
colorimetry 
analyser 
(Hitachi 911, 
Hitachi, Tokyo, 
Japan) 
Not measured Ferrozine-
based 
photometry 
and 
colorimetry 
analyser 
(Hitachi 911, 
Hitachi, 
Tokyo, Japan) 
Aviv Biomedical 
Hematoflurometer 
(within 24 hours of 
collection) 
Medonic CA 530 
Oden 16 
Haemoglobinometer 
Not measured Immunoturbidimetry, 
Cobas Mira Plus Bio-
analyser, Roche 
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2.3 Genotyping in the iron_vaccgene studies 
This section describes genotyping of sickle cell (rs334), the FPN Q248H mutation 
(rs11568350) and G6PD (rs1050828) in the iron_vaccgene studies except Kilifi, Kenya where 
typing was directly performed using PCR or Agena Bioscience SEQUENOM® MALDI-TOF 
mass spectrometry. I extracted the genetic variants for Ugandan, Burkinabe, and South African 
children from whole-genome typed data. Genotyping was performed using the Illumina 
HumanOmni 2.5M-8 (‘octo’) BeadChip array version 1.1 (Illumina Inc., San Diego, USA), at 
the Genotyping Core facilities at the Wellcome Trust Sanger Institute. Genotypes were called 
from intensities using Illuminus and GenCall clustering algorithms in GenomeStudio (Illumina 
Inc., San Diego, USA) incorporating data from pre-determined genotypes. 
 
I received genotype files in binary PLINK format from Dr Alexander Mentzer. I performed 
quality control for samples and single nucleotide polymorphisms (SNPs) separately for each 
cohort (using identical steps) and using SNPs mapped to Human Genome Build 37. Dr Alex 
Mentzer provided files generated by the Dr Will Rayner pipeline that ensures that Illumina 
SNPs correctly map on human Build 37. Using the strand files 
(http://www.well.ox.ac.uk/~wrayner/strand/), I removed low quality variants (those that 
mapped to multiple regions within the human genome or did not map to any region) and 
duplicate SNPs.  
 
I then performed quality control (Anderson et al., 2010). I used PLINK (version 1.9) 
(http://zzz.bwh.harvard.edu/plink/) to calculate and filter samples with a call rate of <97% and 
heterozygosity outside three-standard deviations around the mean. I compared reported and 
genotyped sex using PLINK and removed samples with discordance using default F values of 
<0.2 for males and >0.8 for females. I then removed SNPs with a call rate of <97%, those in 
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high (r2>0.2) linkage disequilibrium (LD, calculated using a sliding window size of 50 SNPs 
sliding 5 SNPs sequentially) and those with minor allele frequency < 1%. I calculated identity-
by-descent (IBD) to identify duplicate or related individuals and removed samples with IBD 
>0.9. I finally used PLINK to calculate scores for deviation from Hardy-Weinberg equilibrium 
(HWE) using individuals with IBD <0.05 and excluded SNPs with HWE P value <10-8.  
 
To impute missing genotypes, I uploaded the quality controlled genotypes on Haplotype 
Reference Consortium (HRC) reference panel (http://www.haplotype-reference-
consortium.org/data-access) (Haplotype-Reference-Consortium, 2016). This reference panel is 
hosted in the Sanger Institute or University of Michigan servers and is not publicly available 
as some of the cohorts do not have consent for public release. Thus, imputation is performed 
remotely. The HRC reference panel consists of a number of screened cohorts including the 
1000 genomes (http://www.haplotype-reference-consortium.org/participating-cohorts). Using 
the imputed data, I finally extracted the variants coding sickle cell trait (rs334), the FPN Q248H 
mutation (rs11568350) and G6PD (rs1050828) for each of the three iron_vaccgene studies. 
 
2.4 Definitions 
Inflammation was defined as CRP >5mg/L or ACT >0.6g/L or AGP >1g/L (World Health 
Organization and Centers for Disease Control, 2007). Iron deficiency was defined as plasma 
ferritin <12µg/L or <30µg/L in the presence of inflammation in children <5 years or < 15µg/L 
in children ≥5 years (World Health Organization, 2011b). Anaemia was defined as 
haemoglobin <11 g/dL in children aged <5 years, or haemoglobin <11.5 g/dL in children ≥5 
years (World Health Organization, 2001). Iron deficiency anaemia was defined as presence of 
iron deficiency and anaemia (World Health Organization, 2001). Transferrin saturation was 
calculated as (serum iron (µmol/L)/transferrin (g/L) x 25.1) x 100 or as (serum iron/ UIBC + 
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serum iron) x 100 (Yamanishi et al., 2003). Malaria parasitaemia was defined as asexual P. 
falciparum parasite positive. Stunting was defined as height-for-age z-scores <-2, underweight 
as weight-for-age z-score <-2, and wasting as height-for-weight z-score <-2 (World Health 
Organization, 2006). 
 
2.5 Ethical Approvals 
For the iron_vaccgene studies and The Gambia, individual study site ethical approvals were 
obtained. For Kilifi, Kenya (by the Scientific Ethics Review Unit of the Kenya Medical 
Research Institute (KEMRI/SERU/CGMR-C/046/3257/2983)); Entebbe, Uganda (locally by 
the Uganda Virus Research Institute (GC/127/12/07/32) and Uganda National Council for 
Science and Technology (MV625), and in the UK by the London School of Hygiene and 
Tropical Medicine (A340) and Oxford Tropical Research (OTR) (39-12, 42-14 and 37-15) 
Ethics Committees); Banfora, Burkina Faso (by Ministere de la Recherche Scientifique et de 
l’Innovation in Burkina Faso (2014-12-151) and the OTR Ethics Committees (41-12)); Soweto, 
South Africa (by the University of Witwatersrand Human Research (M130714) and the OTR 
Ethics Committees (1042-13 and 42-14)); and West Kiang, The Gambia (by the Gambian 
Government / Medical Research Council Ethics Committee (874/830)). For the other seven 
study sites, individual study data transfer agreements were signed with the responsible 
study/institution’s principal investigator (PI) and the KEMRI-Wellcome Trust Research 
Programme study PI, Dr Sarah Atkinson. These other studies had ethical approval to share data 
for further secondary analyses presented in this thesis. 
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CHAPTER THREE: EPIDEMIOLOGY OF IRON DEFICIENCY IN AFRICAN 
CHILDREN 
The material in this chapter forms the basis of a published manuscript in BMC Medicine entitled 
“Estimating the burden of iron deficiency in African children”, in which I was the first author. 
 
3.1 Abstract 
Background: For effective nutritional iron interventions, accurate prevalence estimates of iron 
deficiency are important. However, iron deficiency may be commonly underestimated in 
Africa since most measures of iron status are altered by inflammation and infections such as 
malaria. I therefore aimed to describe predictors of iron biomarkers and estimate the burden of 
iron deficiency in African children. 
Methods: I used data on iron and inflammatory biomarkers in 4,853 children aged 0–8 years 
from community-based cohorts in the iron_vaccgene studies and The Gambia. I described iron 
status and its relationship with age, sex, malaria parasitaemia, inflammation, stunting, 
underweight, and wasting. I used regression modelling, correcting ferritin for inflammation 
and malaria, to estimate the prevalence of iron deficiency and compared with the WHO-defined 
prevalence. I further investigated the utility of other iron biomarkers in predicting the 
regression-corrected iron deficiency.  
Results: The prevalence of iron deficiency was highest at one year of age and in male children. 
Stunting and underweight were associated with anaemia and iron deficient erythropoiesis. 
Inflammation and malaria parasitaemia were associated with all iron biomarkers, although 
transferrin saturation (TSAT) was least affected. Overall prevalence of ID was 52% using an 
inflammation and malaria regression-corrected estimate of ID, compared to a WHO-defined 
estimate of 34%. This WHO unidentified burden of iron deficiency increased with age and was 
highest in countries with high prevalence of inflammation and malaria, where up to a quarter 
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of iron-deficient children were misclassified as iron replete. TSAT < 11% most closely 
predicted the prevalence of iron deficiency according to the regression-correction. 
Conclusions: The prevalence of iron deficiency is underestimated in African children when 
defined using WHO guidelines, especially in malaria-endemic populations and the use of 
TSAT may provide a more accurate approach. Further research is needed to identify the most 
accurate measures for determining the prevalence of iron deficiency in sub-Saharan Africa. 
 
3.2 Introduction 
Despite the detrimental effects of iron deficiency on child development (McCann and Ames, 
2007), the true burden of iron deficiency in African children remains largely unknown because 
inflammation and infections such as malaria influence biomarkers of iron deficiency (reviewed 
in Chapter One). To enable planning, monitoring and targeting of effective nutritional iron 
interventions, reliable and accurate estimates of the prevalence of iron deficiency are necessary. 
However, staining of bone marrow aspirate for iron which is the gold standard method for 
estimating iron status, is invasive and therefore impractical in population surveys. In areas with 
high burden of infectious diseases, the World Health Organization (WHO) defines iron 
deficiency using low ferritin concentrations (<12µg/L in children <5 years or <15µg/L in 
children ≥5 years), with an arbitrarily higher cut-off of ferritin (<30µg/L) in children <5 years 
with inflammation (World Health Organization and Centers for Disease Control, 2007; World 
Health Organization, 2011b). Ferritin is a sensitive marker of body iron stores and has 
standardised laboratory assays and established cut-offs. However, both inflammation and 
malaria independently influence synthesis of ferritin (Feelders et al., 1998; Namaste, Rohner, 
et al., 2017). I therefore hypothesised that the WHO definition of iron deficiency may 
underestimate the prevalence of iron deficiency in African children that are exposed to high 
burdens of inflammation and malaria. 
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Alternative markers of iron status also have limitations. Soluble transferrin receptor (sTfR) is 
only mildly increased during the inflammatory response (Mast et al., 1998), but its utility is 
complicated in African populations since it is upregulated by malaria, even in asymptomatic 
infection (Menendez et al., 2001; Verhoef et al., 2001; Rohner et al., 2017). Moreover, there 
are no standardised sTfR reference assays. Other iron biomarkers may also be confounded by 
the effects of inflammation or malaria (World Health Organization and Centers for Disease 
Control, 2007). Estimating iron status in African children is therefore challenging, although a 
number of approaches have been proposed to account for the effects of inflammation and 
malaria including using higher ferritin cut-offs, or excluding, individuals with raised 
inflammatory markers (Suchdev et al., 2017). A regression-correction approach, which 
accounts for the linear effects of inflammatory markers and / or malaria on iron biomarkers, as 
proposed by the Biomarkers Reflecting Inflammation and Nutritional Determinants of 
Anaemia (BRINDA) project, appears to reflect iron status more accurately (Namaste, Aaron, 
et al., 2017; Namaste, Rohner, et al., 2017).  
 
In this chapter, I describe the relationship between markers of iron status and age, sex, 
inflammation, malaria parasitaemia, stunting, underweight and wasting. I then utilised the 
regression-correction approach proposed by BRINDA (Namaste, Aaron, et al., 2017; Namaste, 
Rohner, et al., 2017) to predict what the ferritin level would have been in the absence of 
inflammation and malaria, and then used these predicted values to estimate the prevalence of 
iron deficiency in African children. I then compared the regression-corrected prevalence of 
iron deficiency to the prevalence of WHO-defined iron deficiency. Finally, I assessed the 
diagnostic utility of various iron markers in predicting the regression-corrected iron deficiency 
as a gold standard.  
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3.3 Methods 
3.3.1 Study population 
To determine the burden of iron deficiency, I included children from the iron_vaccgene (Kilifi, 
Kenya; Entebbe, Uganda; Banfora, Burkina Faso; and Soweto, South Africa) and the West 
Kiang, The Gambia community-based cohorts which are described in Chapter Two Section 
2.1. In these studies, measures of iron and inflammatory markers and anthropometric indices 
were available as described in Chapter Two Section 2.1. 
 
3.3.2 Statistical analysis 
I conducted all analyses using STATA 13.0 (StataCorp., College Station, TX). I natural (Ln)-
transformed biomarkers (except transferrin and haemoglobin) to normalise their distributions. 
I used two-tailed Student’s t-tests for differences in biomarker means between age groups. I 
fitted both univariable and multivariable linear regression models to determine the associations 
between iron biomarkers and age, sex, inflammation, malaria and nutritional status (indicated 
by stunting, underweight and wasting). I excluded Gambian sTfR, transferrin saturation 
(TSAT), body iron stores (BIS) and ferritin index in pooled analyses since different assays 
were used in this population meaning that values were not directly comparable with those from 
the other cohorts (Table 2.2 in Chapter Two). All p-values reflect two-tailed tests and a p-value 
of <0.05 was considered significant.  
 
3.3.2.1 Regression-correction 
Following analyses of predictors of iron status, I then estimated the prevalence of iron 
deficiency by adjusting for the effects of inflammation and malaria on ferritin levels using a 
regression-correction approach as developed by BRINDA (Namaste, Aaron, et al., 2017; 
Namaste, Rohner, et al., 2017). I used these estimates as the gold standard. The regression-
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correction approach followed a three-step process. In the first step, I defined internal reference 
values for inflammatory markers (CRP or ACT) as the 10th percentile. To avoid overcorrection 
for very low levels of inflammatory markers only participants with CRP or ACT values above 
the 10th percentile (0.2mg/L and 0.3g/L for unlogged CRP and ACT respectively) had their 
ferritin values subtracted from observed values in equations (1) to (3) below (Namaste, Rohner, 
et al., 2017). In the second step, I applied univariable linear regression models to the full 
dataset, with ferritin as the dependent variable, to estimate regression coefficients for the crude 
association between inflammatory marker level and ferritin (!1), and for the crude association 
between malaria and ferritin (!2), and applied multivariable linear regression to estimate 
adjusted regression coefficients for associations between inflammatory marker level and 
ferritin (!3) and between malaria parasitaemia and ferritin (!4). In the third step, I used the 
regression coefficients estimated in step 2 to calculate adjusted ferritin values using equation 
(1), (2) or (3). For the purposes of comparison, I applied equation (1) to adjust for the 
inflammatory marker only, equation (2) for malaria parasitaemia only, and equation (3) for 
both inflammatory marker and malaria parasitaemia. I ln-transformed ferritin and 
inflammatory markers before applying them in the equations. 
 "#$$%&%'()*+,-.)/ = 	"#$$%&%'+2()*+,-.) − !/(567	8$	95:;<, − 567	8$	95:=.>) (1) "#$$%&%'()*+,-.)@ = 	"#$$%&%'+2()*+,-.) − !@ABCB$%B (2) "#$$%&%'()*+,-.)D = 	"#$$%&%'+2()*+,-.) − !DE567	8$	95:;<, − 567	8$	95:=.>F − !GABCB$%B	 (3) 
where ‘obs’ is the observed value and ‘ref’ is the reference value. 
 
I then defined iron deficiency using the regression-corrected unlogged ferritin (i.e. adjusted for 
the effects of inflammation and malaria) using the same thresholds that were applied to the 
uncorrected ferritin levels in the WHO recommendations (i.e. ferritin <12µg/L in children <5 
56 
 
years or <15µg/L in children aged ≥5 years (World Health Organization, 2011b)) and compared 
changes in prevalence of iron deficiency using McNemar’s chi-square test of consistency. In 
further models, I additionally corrected ferritin levels for age, sex and underweight. I also 
applied regression-correction for inflammation and malaria to other markers of iron status 
including sTfR, hepcidin, BIS, ferritin index, and zinc protoporphyrin (ZPP). I then tested the 
diagnostic utility of the uncorrected biomarkers in predicting iron deficiency regression-
corrected for inflammation and malaria as the ‘gold standard’. I used receiver operating 
characteristics curves (ROCs) analyses using regression-corrected iron deficiency as a binary 
classifier for identifying the optimal cut-off values of the continuous iron biomarkers. I defined 
the optimal cut-off value as a point on the curve where the Youden index (sensitivity + 
specificity-1) is maximum (Youden, 1950).  
 
3.4 Results 
3.4.1 Characteristics of study participants 
A total of 4,853 children, 1484 Kenyan, 1374 Ugandan, 348 Burkinabe, 894 South African, 
and 753 Gambian children aged between birth and eight years were included in the analyses. 
Table 3.1 shows the characteristics of study participants in the five African cohorts. The 
prevalence of malnutrition (as indicated by stunting, underweight and wasting) was highest in 
Kenya and lowest in Uganda (Table 3.1). Anthropometry data were not available for South 
Africa. The prevalence of malaria parasitaemia was highest in Kenya (21.9%) and Burkina 
Faso (20.6%) and lowest in Uganda (6.8%). Similarly, the prevalence of inflammation was 
high in Burkina Faso (33.9%) and Kenya (27.3%), but lower in South Africa (17.6%) and in 
The Gambia (14.9%).
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Table 3.1. Characteristics of study participants by cohort 
 
Kenya, n=1484  Uganda, n=1374  Burkina Faso, n=348  South Africa, n=894  The Gambia, n=753  Pooled, n=4853 
 n/total %  n/total %  n/total %  n/total %  n/total %  n/total % 
Age in years                  
< 1 321/1484 21.6  26/1374 1.9  21/348 6.0  475/894 53.1  0/753 0.0  843/4853 17.4 
1 - <2 597/1484 40.2  459/1374 33.4  185/348 53.2  418/894 46.8  16/753 2.1  1675/4853 34.5 
2 - <3 170/1484 11.5  622/1374 45.3  142/348 40.8  1/894 0.1  188/753 25.0  1123/4853 23.1 
3 - <4 159/1484 10.7  176/1374 12.8  0 0.0  0 0.0  201/753 26.7  536/4853 11.0 
4 - 8 237/1484 16.0  91/1374 6.6  0 0.0  0 0.0  348/753 46.2  676/4853 13.9 
Sex: Females 726/1484 48.9  678/1374 49.3  173/348 49.7  449/894 50.2  331/753 46.8  2378/4853 49.0 
Nutritional status1                  
     Stunting 117/240 48.8  211/1355 15.6  109/325 33.5  n/a n/a  215/592 36.3  652/2512 26.0 
     Underweight 114/429 26.6  113/1368 8.3  60/327 18.4  n/a n/a  150/593 25.3  437/2717 16.1 
     Wasting 27/237 11.4  67/1353 5.0  22/325 6.8  n/a n/a  51/592 8.6  167/2507 6.7 
Malaria2 262/1199 21.9  92/1353 6.8  66/321 20.6  n/a  n/a   84/751 11.2  504/4518 11.2 
Inflammation3 392/1437 27.3  316/1337 23.6  112/330 33.9  157/894 17.6  112/753 14.9  1089/4751 22.9 
n/a, not available 
Median (IQR) for age in years was as follows: Kenya 1.7 (1.1, 3.1); Uganda 2.0 (2.0, 3.0); Burkina Faso 1.9 (1.6, 2.2); South Africa 1.0 (1.0, 1.0); The Gambia 3.8 (2.9, 
4.9); and Pooled 2.0 (1.0, 3.0) 
1Stunting was defined as height-for-age z-score < -2, underweight as weight for age z-score < -2, and wasting as weight-for-height z-score < -2. These data were not 
available in the South African cohort. 
2Malaria was defined as P. falciparum parasitaemia at any parasite density. 
3Inflammation was defined as C-reactive protein > 5mg/L or α1-antichymotrypsin > 0.6 (in The Gambia). 
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3.4.2 Distribution of iron status and anaemia 
Table 3.2 shows the prevalence of WHO-defined iron deficiency and anaemia, and 
concentrations of the individual iron biomarkers by study cohort. Based on the WHO 
recommended definition, the prevalence of iron deficiency was highest in South African 
children (41.9%), lowest in The Gambia (21.7%) and affected approximately a third of children 
in each of Kenya (35.4%), Uganda (34.6%) and Burkina Faso (35.5%). Anaemia was present 
in 87.0% of children in Burkina Faso, 70.0% in Kenya, 60.1% in The Gambia and 49.7% in 
Uganda, while haemoglobin was not measured in South Africa. Geometric means and 95% 
confidence intervals of the various iron biomarkers are shown in Table 3.2. 
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Table 3.2. Distribution of iron status and anaemia by study cohort 
 Kenya Uganda Burkina Faso South Africa The Gambia Pooled
1 
Category n/total % 95% CI n/total % 95% CI n/total % 95% CI n/total % 95% CI n/total % 95% CI n/total % 95% CI 
Iron deficiency2 499/1408 35.4 32.9, 37.9 438/1267 34.6 31.9, 37.2 115/324 35.5 30.3, 40.7 375/894 41.9 38.7, 45.2 163/752 21.7 18.7, 24.6 1590/4645 34.2 32.9, 35.6 
Anaemia3 609/870 70.0 66.9, 73.1 652/1312 49.7 47.0, 52.4 288/331 87.0 83.4, 90.6 n/a n/a n/a 448/746 60.1 56.5, 63.6 1997/3259 61.3 59.6, 62.9 
Iron deficiency anaemia4 207/833 24.8 21.9, 27.8 255/1209 21.1 18.8, 19.8 96/309 31.1 25.9, 36.3 n/a n/a n/a 123/745 16.5 13.8, 19.2 681/3096 22.0 20.5, 23.5 
Biomarker n Mean 95% CI n Mean 95% CI n Mean 95% CI n Mean 95% CI n Mean 95% CI n Mean 95% CI 
Haemoglobin, g/dL 870 10.2 10.1, 10.3 1312 9.1 9.0, 9.2 331 9.6 9.4, 9.7 n/a n/a n/a 746 10.7 10.6, 10.8 3259 10.5 10.5, 10.6 
Ferritin, µg/L 1408 21.8 20.6, 23.1 1267 20.8 19.6, 22.0 324 22.2 19.7, 24.9 894 14.9 14.0, 15.9 752 25.1 23.6, 26.8 4645 20.5 19.9, 21.1 
sTfR, mg/L 1467 17.9 17.5, 18.3 1343 6.7 6.5, 7.0 342 17.7 16.7, 18.7 893 11.2 10.9, 11.5 661 3.4 3.4, 3.5 4045 11.7 11.4, 11.9 
Hepcidin, µg/L 1373 5.8 5.4, 6.2 1333 6.8 6.4, 7.2 309 5.3 4.6, 6.3 878 7.7 7.1, 8.4 709 6.0 5.3, 6.7 4602 6.4 6.2, 6.6 
BIS, mg/kg5 1393 -0.8 -1.0, -0.5 1241 2.5 2.2, 2.8 322 -0.6 -1.1, -0.1 893 -0.4 -0.7, -0.2 660 5.7 5.4, 6.0 3849 0.4 0.2, 0.5 
Ferritin index6 1389 14.4 13.9, 14.9 1234 5.5 5.3, 5.8 322 13.9 12.8, 15.1 881 10.1 9.7, 10.6 660 2.6 2.5, 2.7 3826 9.7 9.5, 10.0 
Serum iron, µmol/L 1428 6.5 6.3, 6.7 n/a n/a n/a 337 6.0 5.7, 6.4 n/a n/a n/a 737 8.6 8.3, 8.9 1765 6.4 6.2, 6.6 
Transferrin, g/L 1409 2.8 2.7, 2.8 1333 2.8 2.6, 2.7 327 2.7 2.6, 2.8 894 2.7 2.7, 2.8 n/a n/a n/a 3963 2.8 2.7, 2.8  
TSAT, %7 1386 9.4 9.0, 9.8 n/a n/a n/a 325 8.9 8.3, 9.7 n/a n/a n/a 734 12.8 12.3, 13.3 1711 9.3 9.0, 9.6 
ZPP, µmol/mol haem n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 751 85.9 82.4, 89.5 751 85.9 82.4, 89.5 
MCV, fL 499 65.7 65.0, 66.5 1305 71.0 70.6, 71.5 n/a n/a n/a n/a n/a n/a 741 75.6 75.1, 76.1 2545 71.2 70.9, 71.6 
BIS, body iron store; sTfR; n/a, not available; soluble transferrin receptors; TSAT, transferrin saturation; ZPP, Zinc protoporphyrin; MCV, mean corpuscular volume 
The mean values are geometric means except for BIS, transferrin, haemoglobin and MCV which are arithmetic means 
1Pooled for sTfR, BIS, ferritin index, iron, transferrin and TSAT excludes The Gambia since markers were measured using different assays compared to the other cohorts. 
2Iron deficiency was defined by WHO definition as ferritin < 12 µg/L or <30 µg/L in presence of inflammation (C-reactive protein>5mg/L or α1-antichymotrypsin >0.6g/L) in children < 5 years or  <15µg/L in children ³ 5 years (World Health Organization and 
Centers for Disease Control, 2007). 
3Anaemia was defined as haemoglobin<11g/dL in children aged 0 to 5 years or haemoglobin<11.5 g/dL in children above 5 years (World Health Organization, 2001). Missing in South Africa. 
4Iron deficiency anaemia defined as iron deficiency and anaemia (World Health Organization, 2001). Haemoglobin was missing in South Africa. 
5Body iron store was calculated using the ratio of soluble transferrin receptors and ferritin concentrations, -(log10((sTfRx1000)/ferritin)-2.8229)/0.1207 (Cook, Flowers and Skikne, 2003). 
6Ferritin index was defined as sTfR/log10 ferritin (Phiri, Calis, Siyasiya, et al., 2009). 
7TSAT, transferrin saturation was calculated as ((Iron (µmol/L)/Transferrin (g/L) x 25.1) x 100) except in The Gambia where it was calculated using iron and unsaturated iron binding capacity (Yamanishi et al., 2003). Missing in Uganda and South Africa. Transferrin 
missing in The Gambia. Iron available in Kenya, Burkina Faso and The Gambia only. 
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3.4.3 Age and sex differences in iron status 
Concentrations of ferritin, hepcidin, BIS and TSAT decreased during the first year of life and 
increased thereafter, suggesting that iron deficiency is most prevalent at about one year of age 
(Figure 3.1). Male infants were more iron deficient than female infants for each of the different 
measures of iron status. These sex-specific differences were not observed beyond three years 
of age. Haemoglobin concentrations did not differ by sex although there was a trend towards 
higher haemoglobin concentrations in females. 
 
 
Figure 3.1. Geometric means for different iron biomarkers by age in years and sex. 
Orange indicates females and blue males. Error bars indicate 95% confidence intervals. Star 
indicates a Student’s t-test p value < 0.05 for mean differences between sexes. I calculated 
body iron stores (BIS) as proposed by Cook et al as -(log10((sTfR in mg/Lx1000)/ferritin in 
µg/L)-2.8229)/0.1207) (Cook, Flowers and Skikne, 2003) and ferritin index as sTfR in 
mg/L/log10(ferritin in µg/L) (Phiri, Calis, Siyasiya, et al., 2009). sTfR: soluble transferrin 
receptor; TSAT, transferrin saturation. 
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3.4.4 Associations between malnutrition and iron status 
Malnutrition, as indicated by either stunting, underweight or wasting, was associated with 
altered markers of iron status in regression models adjusted for age, sex, and study site. 
Underweight and stunting were associated with lower concentrations of haemoglobin and BIS, 
and higher sTfR and ferritin index indicating increased iron deficiency (Figure 3.2). 
Additionally, underweight was associated with lower serum iron concentrations and stunting 
with higher ZPP concentrations (Figure 3.2). In a multivariable regression model, the effect of 
underweight on iron biomarkers was largely independent of inflammation (Figure 3.3). 
 
3.4.5 Associations between inflammation and malaria and iron status 
Inflammation and malaria were associated with increased concentrations of ferritin, hepcidin, 
sTfR, BIS and ZPP, and decreased haemoglobin and transferrin concentrations in regression 
models adjusted for age, sex and study site (Figure 3.2). Inflammation was associated with a 
small decrease in TSAT (log estimate -0.1; 95% CI: -0.2, 0.001; P = 0.052) while malaria was 
associated with a small increase in TSAT (log estimate = 0.1; 95% CI: 0.02, 0.2; P = 0.015, 
Figure 3.2). Malaria was independently associated with increased ferritin, sTfR and ZPP and 
decreased haemoglobin in multivariable regression models adjusted for inflammation, age, sex, 
and underweight. Inflammation was independently associated with almost all of the iron 
biomarkers, but not sTfR in models adjusted for malaria, age, sex and underweight. TSAT was 
not associated with inflammation or malaria in multivariable regression models (Figure 3.3). 
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Figure 3.2. Predictors of iron biomarkers in regression models adjusted for age, sex and 
study site. 
Effect size represents coefficient from linear regression model with the iron biomarker as the 
outcome variable. Iron biomarkers were ln-transformed except haemoglobin, transferrin and 
BIS. Independent variables were binary variables with exception of age, which was continuous. 
Error bars indicate 95% confidence intervals and values indicate effect size (95% CI). 
Inflammation was defined as C-reactive protein >5mg/L or α1-antichymotrypsin >0.6 (in The 
Gambia). Malaria was defined as P. falciparum parasitaemia. Underweight was defined as 
weight for age z-score < -2, stunting as height-for-age z-score < -2, and wasting as weight-
for-height z-score < -2. BIS, body iron stores; sTfR: soluble transferrin receptor; TSAT, 
transferrin saturation; ZPP, zinc protoporphyrin (measured in The Gambia only). 
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Figure 3.3. Predictors of iron biomarkers in multivariable regression models. 
Iron biomarkers were log transformed except haemoglobin, transferrin and BIS. Error bars 
indicate 95% confidence intervals and values indicate effect size (95% CI). Inflammation was 
defined as C-reactive protein > 5mg/L or α1-antichymotrypsin > 0.6 (in The Gambia). Malaria 
was defined as P. falciparum parasitaemia. Underweight was defined as weight for age z-score 
< -2 and included to adjust for nutritional status. The South Africa cohort was excluded due to 
missing underweight. BIS, body iron stores; sTfR: soluble transferrin receptor; TSAT, 
transferrin saturation; ZPP, zinc protoporphyrin (measured in The Gambia only). 
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3.4.6 Estimating the regression-corrected prevalence of iron deficiency  
I then adjusted ferritin levels for inflammation and malaria parasitaemia using the regression-
correction approach proposed by BRINDA (Namaste, Aaron, et al., 2017; Namaste, Rohner, 
et al., 2017). Figure 3.4 shows the prevalence of iron deficiency mapped on the African malaria 
map for the period 2010-2015 (Snow et al., 2017). Excluding children with inflammation 
resulted in a similar prevalence of iron deficiency as WHO-defined iron deficiency. Adjustment 
of ferritin levels for inflammation alone substantially increased the prevalence of iron 
deficiency compared to adjustment for malaria alone, while adjustment for both malaria and 
inflammation led to a small further increase especially in Kenyan children who had the highest 
prevalence of malaria without inflammation (Figure 3.4). Further adjustments for age, sex and 
underweight did not change the prevalence of iron deficiency as shown in Figure 3.5. The 
pooled prevalence of iron deficiency after adjusting for both inflammation and malaria was 
52.0% and the absolute increase in the prevalence of iron deficiency for each study site was: 
Burkina Faso, 27.0%; Kenya, 21.4%; Uganda, 20.0%; The Gambia, 16.8%; and South Africa, 
8.5% (Figure 3.4). The gap between WHO-defined iron deficiency and regression-correction 
was highest in cohorts that had the highest prevalence of malaria and inflammation (Kenya and 
Burkina Faso) and lowest in malaria-free South Africa. The prevalence of iron deficiency 
defined by other iron biomarkers and by iron deficiency anaemia similarly increased following 
regression-correction for inflammation and malaria (Table 3.3). However, the prevalence of 
iron deficiency based on these other iron biomarkers varied widely underscoring a need for 
standardised assays and cut-offs to define iron deficiency. 
65 
 
 
Figure 3.4. Prevalence of estimated iron deficiency across the study sites. 
The map shows the predicted posterior predictions of age-standardised P. falciparum 
prevalence (PfPR2–10) as previously published by (Snow et al., 2017). Map was reproduced 
with permission. Graph letter ‘a’ indicates prevalence of iron deficiency using WHO definition, 
‘b’ excluding children with inflammation, ‘c’ adjusting for malaria only, ‘d’ adjusting for 
inflammation only, ‘e’ adjusting for both malaria and inflammation, and ‘f’ using transferrin 
saturation cut-off of <11%. Values indicate prevalence. Absolute increase in iron deficiency 
was calculated as the difference between regression-corrected (for both malaria and 
inflammation) prevalence and WHO-defined prevalence. Error bars indicate 95% confidence 
intervals. 
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Figure 3.5. Comparison of prevalence of iron deficiency after additional adjustments for 
age, sex and nutritional status. 
Graph letter ‘a’ indicates prevalence using WHO definition, ‘b’ adjusting for malaria only, 
‘c’ adjusting for inflammation only, ‘d’ adjusting for both malaria and inflammation, and ‘e’ 
adjusting for malaria, inflammation, age, sex and underweight. Error bars indicate 95% 
confidence intervals. No malaria in South Africa. Anthropometry data were unavailable for 
South Africa. 
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Table 3.3. Regression-corrected and uncorrected prevalence of iron deficiency defined by additional iron biomarkers by study site 
  Kenya Uganda Burkina Faso South Africa The Gambia Pooled 
Definition n % 95% CI n % 95% CI n % 95% CI n % 95% CI n % 95% CI n % 95% CI 
ID - sTfR >8.3mg/L                   
Uncorrected 1467 97.9 97.2, 98.6 1343 36.9 34.3, 39.5 342 94.2 91.7, 96.7 893 80.4 77.8, 83.0 661 1.7 0.7, 2.6 4706 63.4 62.0, 64.8 
Inflammation/malaria corrected 1140 96.8 95.8, 97.9 1292 33.1 30.6, 35.7 302 94.4 91.8, 97.0 893 80.9 78.4, 83.5 659 1.5 0.6, 2.5 4286 59.5 58.0, 61.0 
Hepcidin<3.2µg/L                   
Uncorrected 1373 31.7 29.2, 34.1 1333 26.0 23.6, 28.3 309 34.6 29.3, 40.0 878 22.9 20.1, 25.7 709 27.8 24.5, 31.1 4602 27.9 26.6, 29.2 
Inflammation/malaria corrected 1075 51.3 48.3, 54.2 1282 35.2 32.6, 37.8 276 50.0 44.1, 55.9 878 31.4 28.4, 34.5 700 33.6 30.1, 37.1 4211 39.2 37.7, 40.7 
Depleted BIS (<0mg/kg)1                   
Uncorrected 1393 54.1 51.4, 56.7 1241 28.1 25.6, 30.6 322 55.9 50.4, 61.4 893 48.5 45.2, 51.8 660 7.3 5.3, 9.3 4509 39.1 37.7, 40.5 
Inflammation/malaria corrected 1098 77.9 75.4, 80.3 1205 45.2 42.4, 48.0 291 82.5 78.1, 86.9 893 64.2 61.0, 67.3 658 12.8 10.2, 15.3 4145 55.4 53.9, 56.9 
Ferritin index>5.62                   
Uncorrected 1392 96.4 95.4, 97.4 1241 48.9 46.1, 51.7 322 91.6 88.6, 94.7 893 85.1 82.8, 87.4 660 88.9 86.5, 91.3 4508 79.7 78.5, 80.8 
Inflammation/malaria corrected 1098 96.5 95.4, 97.6 1205 57.7 54.9, 60.5 291 95.2 92.7, 97.7 893 90.3 88.3, 92.2 658 91.9 89.9, 94.0 4145 83.1 81.9, 84.2 
Iron deficiency anaemia3                   
Uncorrected 833 24.8 21.9, 27.8 1209 21.1 18.8, 23.4 309 31.1 25.9, 36.3 n/a n/a n/a 745 16.5 13.8, 19.2 3096 22.0 20.5, 23.5 
Inflammation/malaria corrected 731 41.3 37.7, 44.9 1177 30.8 28.1, 33.4 290 55.5 49.8, 61.3 n/a n/a n/a 735 27.6 24.4, 30.9 2933 35.0 33.3, 36.8 
BIS, body iron stores; ZPP, zinc protoporphyrin; n/a, not available. 
Regression-correction for inflammation and malaria were made on individual iron biomarkers and then used to define iron deficiency. 
1Body iron stores were calculated using the ratio of soluble transferrin receptors (sTfR) and ferritin concentrations (Cook, Flowers and Skikne, 2003). 
2Ferritin index defined as sTfR/log10 ferritin (Phiri, Calis, Siyasiya, et al., 2009). 
3Iron deficiency anaemia was defined as iron deficiency and anaemia. 
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3.4.7 Misclassification of iron-deficient children increases with age, inflammation and 
malaria 
The gap between the prevalence of WHO-defined iron deficiency and regression-corrected iron 
deficiency increased with age, increasing prevalence of malaria parasitaemia (Figure 3.6) and 
with increasing CRP levels (Figure 3.7A). Prevalence of regression-corrected iron deficiency 
remained relatively constant over the spectrum of CRP levels, while prevalence of WHO-
defined iron deficiency decreased linearly above the third decile of CRP (0.4 mg/L), before 
adjustment for inflammation (CRP > 5 mg/L) (Figure 3.7A).  
 
Figure 3.6. The hidden burden of iron deficiency by sex and age. 
Error bars indicate 95% confidence intervals for adjusted WHO definition. Darker colours 
indicate the WHO definition of iron deficiency while lighter colours show the hidden burden 
after adjustment for malaria and inflammation. The values in the bars indicate the percentage 
of children with iron deficiency unaccounted for by the WHO definition (a ‘hidden burden’). 
Line plots indicate how the prevalence of inflammation (black), malaria (red) and underweight 
(green) changed with age. 
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Malaria may also contribute to underestimation of prevalence of iron deficiency. Malaria-
endemic countries had a higher percentage of children misclassified as iron-replete (27.0% in 
Burkina Faso compared to 8.5% in South Africa; Fig. 3). Children with malaria also had higher 
ferritin concentrations at every decile of CRP, compared to those without malaria (Figure 
3.7B). Moreover, the gap between WHO-defined and regression-corrected prevalence of iron 
deficiency was larger in children with malaria parasitaemia compared to those without, 
regardless of the presence of inflammation (Figure 3.8). 
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Figure 3.7. Relationship between the estimated prevalence of iron deficiency and 
inflammation / malaria. 
A) shows how the prevalence of various estimates of iron deficiency varied by deciles of C-
reactive protein (CRP). B) shows that ferritin levels were higher in children with malaria 
parasitaemia compared to those without parasitaemia at every CRP decile. Error bars indicate 
95% confidence intervals. Low ferritin was defined as ferritin <12 µg/L in children <5 years 
or <15 µg/L in children ≥5 years. WHO adjustment involved using a higher cut-off (30 µg/L) 
of ferritin for children with CRP ≥5mg/L. Regression adjustment indicates that the effect of 
inflammation and malaria were adjusted for using regression modelling. TSAT, transferrin 
saturation. 
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Figure 3.8. Relationship between the estimated prevalence of iron deficiency and 
inflammation / malaria. 
The graph shows the prevalence of iron deficiency in children with and without inflammation 
and / or malaria. Error bars indicate 95% confidence intervals. Inflammation was defined as 
C-reactive protein > 5mg/L or α1-antichymotrypsin > 0.6g/dL (in The Gambia). Low ferritin 
was defined as ferritin <12 µg/L in children <5 years or <15 µg/L in children ≥5 years. WHO 
adjustment involved using a higher cut-off (30 µg/L) of ferritin for children with inflammation 
according to WHO-defined iron deficiency. Malaria was defined as P. falciparum 
parasitaemia. Regression-correction uses ferritin levels corrected for the effects of 
inflammation and malaria in defining ID. TSAT, transferrin saturation. 
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3.4.8 Diagnostic utility of iron biomarkers in predicting regression-corrected iron 
deficiency 
Finally, I used the regression-corrected iron deficiency (corrected for the effects of 
inflammation and malaria on ferritin levels) as a gold standard to test the diagnostic utility of 
various markers of iron status (Figure 3.9). TSAT outperformed other markers of iron status. 
For TSAT, I observed an area under curve (AUC) of 0.77 and an optimal cut-off of 10.56, 
similar to the overall cut-off (11.11) that was obtained from a meta-analysis of cohort-specific 
optimal cut-offs (Figure 3.10). I then applied a rounded cut-off of TSAT <11% and obtained 
similar prevalence of iron deficiency as that obtained using the regression-corrected definition 
of iron deficiency (green bar in Figure 3.4 above). TSAT <11% also performed well across the 
spectrum of CRP levels with only a modest increase in prevalence of iron deficiency compared 
to regression-corrected iron deficiency during inflammation (shown Figure 3.7A above). Other 
iron biomarkers did not perform as well in predicting regression-corrected iron deficiency. 
Haemoglobin concentrations had an AUC of 0.61 and an optimal cut-off of 11.25 g/dL with a 
sensitivity of 75%, but low specificity of 42%, whilst sTfR concentrations had low sensitivity 
(43%) in predicting iron deficiency corrected for inflammation and malaria (Figure 3.9).  
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Figure 3.9. Receiver operating characteristic curves of the utility of iron markers in 
estimating adjusted prevalence of iron deficiency. 
The ‘gold standard’ was defined using the WHO definition adjusted for malaria and 
inflammation using regression modeling. Green points indicate Youden’s optimal cutoffs for 
each marker. Sensitivity and specificity are for the optimal cutoff. TSAT, Transferrin 
saturation; MCV, mean corpuscular volume; ZPP, zinc protoporphyrin; sTfR, soluble 
transferrin receptor; AUC, area under curve.  
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Figure 3.10. Meta-analysis of optimal cutoffs of transferrin saturation in predicting 
regression adjusted iron deficiency. 
 
3.5 Discussion 
In this chapter, I have described determinants of iron status and estimated the burden of iron 
deficiency in approximately 4,800 children living across the African continent using a wide 
range of iron biomarkers. Iron deficiency increased from birth to around one year, and then 
decreased with increasing age among infants. Iron deficiency was higher in males compared to 
females up to three years of age. Stunting and underweight were associated with increased iron 
deficiency and erythropoietic drive. Inflammation and malaria parasitaemia were associated 
with independent and substantial increases in ferritin concentrations and were associated with 
other biomarkers of iron status. The WHO definition of iron deficiency underestimated the 
burden of iron deficiency in African children compared to regression-correction, which 
predicts ferritin levels in the absence of inflammation and malaria. Of the other iron markers 
that I tested, TSAT was least influenced by inflammation, malaria, or malnutrition and had the 
best diagnostic properties when compared against the gold standard of regression-correction. 
 
Age and sex predicted measures of iron status especially up to three years of age. Iron stores 
decreased rapidly during infancy and then increased during childhood, supporting the argument 
that newborns have higher iron stores that are prenatally accumulated but decrease with the 
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demand for iron during rapid growth (Wu, Lesperance and Bernstein, 2002; Ziegler, Nelson 
and Jeter, 2014; Joo et al., 2016). The prevalence of iron deficiency was highest at around one 
year of age, probably because of rapid child growth at a time when iron supply from breast 
milk and complementary foods is low (Wu, Lesperance and Bernstein, 2002; Ziegler, Nelson 
and Jeter, 2014). Similarly, a recent study in Gambian children showed declining iron status of 
infants monitored from birth up to one year (Armitage et al., 2019). Moreover, weight gain 
was strongly associated with decrease in hepcidin levels suggesting that rapid growth is 
associated with iron depletion (Armitage et al., 2019). Iron status improved during childhood, 
possibly due to diversifying diets and growth rate slowing after infancy (Wu, Lesperance and 
Bernstein, 2002). In agreement with previous studies (Tamura et al., 1999; Domellof et al., 
2002; Jaeggi et al., 2013; Ziegler, Nelson and Jeter, 2014; Armitage et al., 2019), female infants 
were less iron deficient than males. This sex difference might be explained by hormonal 
hepcidin regulation since testosterone is associated with suppression of hepcidin (Bachman et 
al., 2010) and lower ferritin levels (Chao et al., 2015). These results highlight important age 
and sex differences in iron status among infants. 
 
Poor nutrition was associated with iron deficiency. Children with stunting or underweight had 
lower body iron stores, serum iron and haemoglobin concentrations, and higher sTfR, ferritin 
index and ZPP, in keeping with increased iron deficiency. I observed similar associations even 
after controlling for inflammation. These findings suggest that malnourished children are more 
likely to experience iron deficient erythropoiesis (Labbé and Dewanji, 2004). I also found that 
malnourished children were more likely to have malaria parasitaemia, which may in turn lead 
to increased erythropoiesis (Menendez et al., 2001). Furthermore, malaria-associated 
erythropoiesis has been shown to be more common in stunted than in non-stunted children 
(Verhoef, West, Veenemans, et al., 2002). Malnutrition was also associated with decreased 
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haemoglobin concentrations, which may in turn have led to expanded erythropoiesis (Foote et 
al., 2013). Thus, these findings suggest that improving the nutritional status of children may 
also help to address iron deficiency and anaemia. 
 
Inflammation and malaria parasitaemia were substantially associated with measures of iron 
status in agreement with previous studies (Aguilar et al., 2012; Righetti et al., 2013; Namaste, 
Rohner, et al., 2017). Importantly, I found that both inflammation and malaria parasitaemia 
were independently associated with increased levels of ferritin, thus, potentially leading to 
children being misclassified as iron replete. I therefore redefined iron deficiency by correcting 
ferritin levels for the effects of inflammation and malaria parasitaemia using regression-
correction, as previously proposed by BRINDA (Namaste, Rohner, et al., 2017). The strength 
of this approach is that it accounts for continuous measures of inflammation as opposed to the 
arbitrary cut-off points used by WHO (World Health Organization, 2011b). I found that the 
WHO definition substantially underestimated the prevalence of iron deficiency among children 
living in sub-Saharan Africa compared to the inflammation and malaria-corrected definition of 
iron deficiency. The underestimate was particularly higher after adjusting for inflammation 
only and the independent effect of inflammation on ferritin levels was also greater than that of 
malaria parasitaemia. Adjustment for malaria parasitaemia in addition to inflammation resulted 
in a slight increase in the prevalence of iron deficiency. Using a similar approach, Namaste et 
al observed similar absolute percentage increases (of up to 27%) in children misclassified as 
iron-replete using WHO-defined iron deficiency compared to regression-corrected iron 
deficiency (Namaste, Rohner, et al., 2017).  
 
The underestimate of prevalence of iron deficiency by WHO was largest in cohorts that had a 
high burden of malaria parasitaemia. For example, 27.0% of Burkinabe children and 21.4% of 
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Kenyans were misclassified as iron replete compared to 8.5% of South African children. The 
underestimate of the burden of iron deficiency increased with age in line with increasing 
prevalence of parasitaemia. Moreover, ferritin levels were higher among children with malaria 
parasitaemia at every decile of CRP. Malaria parasitaemia also increased ferritin levels 
independently of inflammation in multivariable analyses. In agreement, a study in Burkinabe 
children found that adjustment for asymptomatic malaria, in addition to inflammation, led to 
an increase in the prevalence of iron deficiency by 15.9 percentage points (Wessells and Hess, 
2014). These findings suggest that both inflammation and malaria parasitaemia should be 
accounted for in population estimates of prevalence of iron deficiency in African children.  
 
Finally, I evaluated the diagnostic utility of uncorrected iron biomarkers in predicting iron 
deficiency regression-corrected for inflammation and malaria. I found that TSAT <11% best 
predicted regression-corrected iron deficiency suggesting its potential usefulness in estimating 
the prevalence of iron deficiency in African children. TSAT can be calculated from measured 
serum iron and either transferrin or UIBC, all of which have standard assays that are easy and 
inexpensive to perform. TSAT<11% performed well over a range of CRP concentrations, in 
children with both malaria parasitaemia and inflammation, and across populations. In support 
of my findings, Aguilar et al showed that TSAT had a  high sensitivity (81%) in predicting 
bone marrow iron deficiency in 180 anemic (haemoglobin <11g/dL) children in Mozambique 
although specificity was low (40%) and an optimal cut-off was not derived (Aguilar et al., 
2012). In contrast, another study in Malawian children showed limited value of TSAT in 
diagnosing bone marrow iron stores although children in this study were severely anaemic 
(haemoglobin <5g/dL) (Phiri, Calis, Siyasiya, et al., 2009). Other iron markers did not perform 
as well as TSAT in predicting regression-corrected iron deficiency. Notably, sTfR, which is 
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normally proposed as an alternative indicator of iron deficiency in presence of infections, had 
very low sensitivity (43%).  
 
Anaemia may also be a poor indicator of the burden of iron deficiency. WHO recommends 
iron supplementation in populations where the prevalence of anaemia is ≥40% (World Health 
Organization, 2016). However I found that haemoglobin concentrations had very low 
specificity (42%) for predicting regression-corrected iron deficiency probably because of the 
multifactorial etiology of anaemia in African children (Foote et al., 2013). Based on this 
guideline, all children in my study populations would have received iron, although 
approximately half were iron-replete. Therefore, TSAT may be a better marker than 
haemoglobin for determining the prevalence of iron deficiency in African children although a 
more sensitive and specific marker is needed. 
 
These analyses had a number of important limitations. The cross-sectional nature of the data 
limited analyses of longitudinal effects of inflammation, malaria and nutritional status on iron 
status. Furthermore, I did not have data on α-1-acid glycoprotein (AGP), which has been shown 
to be a better marker for adjusting for inflammation in regression-correction analyses 
(Namaste, Rohner, et al., 2017). Nevertheless, unlike AGP, CRP is more widely measured and 
international reference standards are available. I used iron deficiency regression-corrected for 
inflammation and malaria as the gold standard although this method is yet to be validated, for 
example by either comparing prevalence estimates of regression-correction before, during and 
after infections or with bone marrow iron deficiency. I used a ferritin-based definition of iron 
deficiency since other iron biomarkers have less standardised assays and less well-established 
cut-offs for iron deficiency. Another limitation of my analyses was that TSAT, the best 
performing marker in predicting regression-corrected iron deficiency was not available for 
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Ugandan and South African children. Moreover, although TSAT outperformed all other iron 
markers it had an AUC of only 0.77 which may be lower than is expected of a clinical 
diagnostic test. 
 
3.6 Conclusion 
Using data for more than 4,800 children in five countries across Africa, I determined the drivers 
of iron status and estimated the burden of iron deficiency. I also explored a wide range of iron 
biomarkers to more accurately estimate prevalence of iron deficiency in countries with a high 
burden of childhood infections including malaria. There has been a long-standing concern 
regarding the challenge of using iron biomarkers to accurately estimate prevalence of iron 
deficiency in African populations (Suchdev et al., 2017). In this study, I found that after 
accounting for the effects of inflammation and malaria parasitaemia on ferritin levels, the 
prevalence of iron deficiency was substantially higher in African children than can be estimated 
using the WHO definition. Of the measured iron biomarkers, TSAT was the best predictor of 
iron deficiency regression-corrected for inflammation and malaria parasitaemia Therefore, 
TSAT may be useful in estimating prevalence of iron deficiency to guide planning and 
implementation of nutritional iron interventions, since the regression-correction approach 
would not be practical for programmatic screening of children in routine clinical care. 
However, further research is required to validate the regression-correction approach against a 
gold standard for more accurate interpretation of existing iron biomarkers and / or to identify 
easy to use, more sensitive and specific markers of iron status that are not influenced by 
infection. 
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CHAPTER FOUR: INVESTIGATING WHETHER MALARIA CAUSES IRON 
DEFICIENCY IN AFRICAN CHILDREN 
The material in this chapter forms the basis of a submitted manuscript entitled “Malaria is a 
cause of iron deficiency in African children”, in which I am the first author. 
 
4.1 Abstract  
Introduction: Previous observational studies suggest that malaria may cause iron deficiency in 
African children. The link between malaria and iron deficiency may be explained by the iron 
hormone hepcidin which is upregulated during malaria infection and blocks iron absorption. I 
tested the hypothesis that malaria causes iron deficiency in 7453 African children using sickle 
cell trait (HbAS), a common genetic variant conferring protection against clinical malaria, as 
an instrumental variable in Mendelian randomisation analyses.  
Methods: I used data on measures of iron status, inflammation and sickle cell genotype from 
10 African community-based cohorts of children aged 0-8 years from Malawi, Ghana, Burkina 
Faso, Democratic Republic of Congo (DRC), Kenya (Kilifi and Western Kenya), Tanzania, 
The Gambia, Cameroon and Uganda. I fitted cohort-specific regression models to determine 
the effect of HbAS on iron status then conducted meta-analyses and Mendelian randomisation 
analyses. I tested for pleiotropy (i.e. whether HbAS influences iron deficiency through malaria 
independent pathways) using a malaria-free cohort of 3207 African-Americans from the 
Jackson Heart study. 
Results: In malaria-exposed children, HbAS was associated with a 30% reduction in iron 
deficiency (OR = 0.70; 95% CI 0.58, 0.82; P <0.001). HbAS was not associated with measured 
confounders or with iron deficiency in 3207 non-malaria exposed African-Americans. In 
Mendelian randomisation analysis, genetically influenced malaria risk was associated with a 
2.52 (95% CI 1.60, 3.98; P <0.001) odds of iron deficiency per unit increase in log incidence 
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rate of malaria. This suggests that an intervention that halves the risk of malaria episodes would 
reduce iron deficiency by 47% in African children. 
Conclusion: These findings suggest that malaria might be causing iron deficiency and support 
implementation of malaria control and treatment programs to combat iron deficiency in African 
children. 
 
4.2 Introduction 
Malaria and iron deficiency tend to co-exist in the same geographic and demographic groups. 
Although malaria causes anaemia by the destruction of infected and uninfected RBCs, the iron 
released from the destroyed RBCs is not lost from the body as it is recycled by macrophages. 
The iron hormone, hepcidin, may link malaria and iron deficiency since hepcidin is up-
regulated during clinical and asymptomatic malaria and blocks iron absorption and recycling 
(discussed in Chapter One). I therefore hypothesised that malaria may be causing iron 
deficiency in African children. To determine whether malaria causes iron deficiency, a number 
of epidemiological approaches can be applied although with some limitations (discussed in 
Chapter One Section 1.3.2.1).  
 
In this chapter, I test the hypothesis that malaria may be causing iron deficiency in African 
children by applying a Mendelian randomisation approach (discussed in Chapter One Section 
1.4). I utilised sickle cell trait (HbAS), a genetic variant conferring protection against malaria 
(Taylor, Parobek and Fairhurst, 2012), to proxy malaria exposure. I analysed data for 7453 
African children aged 0-8 years from ten community-based cohorts across Africa. To test 
whether HbAS might influence risk of iron deficiency through a mechanism that is independent 
of its effect on malaria (pleiotropy), I repeated the analyses in 3207 non-malaria exposed 
African Americans from the Jackson Heart Study (JHS) as a no-relevance point sensitivity 
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analysis (Chen et al., 2008). I also assessed the effect of other malaria-protective 
polymorphisms including glucose-6-phosphate dehydrogenase (G6PD) deficiency and α-
thalassaemia.  
 
4.3 Methods 
4.3.1 Study populations 
In this chapter, I used data for iron and inflammatory markers and sickle cell / G6PD / α-
thalassaemia genotypes data from 10 cohorts of malaria-exposed children from the 
iron_vaccgene studies (Kilifi, Kenya; Banfora, Burkina Faso; Entebbe, Uganda; and Soweto, 
South Africa), West Kiang, The Gambia, and from six additional studies that are described 
below. I also included data from a hospital-based study of severe malaria in Kilifi and from a 
malaria-unexposed population of African-Americans from the Jackson Heart Study (JHS).  
 
Malawi: I used data from the 2015-2016 Malawi Micronutrient Survey (MMS) that was 
conducted as part of the Malawi Demographic and Health Survey with an aim of assessing the 
prevalence of anaemia, micronutrient deficiencies, including iron deficiency, infections and 
haemoglobinopathies (McGann et al., 2018). The MMS included all children aged 6-59 months 
from randomly selected clusters and households (McGann et al., 2018). Venipuncture whole 
blood collected in EDTA tubes was used to test for malaria using rapid diagnostic test (RDT) 
(SD BIOLINE Malaria P. falciparum [HRP2], Alere, Inc., Waltham, MA) and to measure 
haemoglobin concentrations using the HemoCue 301 (Hemocue America, Brea, CA). Serum 
ferritin, CRP, and α1-acid glycoprotein (AGP) were measured using sandwich enzyme-linked 
immunoassay (ELISA, VitMin Laboratory, Germany) (Erhardt et al., 2004). Genotyping of 
sickle cell, α-thalassaemia and  G6PD deficiency was performed using TaqMan Polymerase 
Chain Reaction (PCR) as detailed in (McGann et al., 2018). 
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Ghana: This study was part of the 2017 Ghana Micronutrient Survey. Details of the study 
design and ethical approvals are presented in (Wegmüller et al., 2020). Children aged 6 - 59 
months were recruited from three strata (Southern Belt, Middle Belt, and Northern Belt) in 
Ghana and random selection was performed in each stratum. Blood sampling and 
anthropometry were conducted during the survey. Malaria testing was performed using RDT 
(SD BIOLINE Malaria Ag P.f/Pan RDT kit (Standard Diagnostics Inc, Gyeonggi-do, Republic 
of Korea). Haemoglobin concentrations were measured using HemoCue 301 AB, Ängelholm, 
Sweden). Sandwich ELISA (Erhardt et al., 2004) was used to measure serum ferritin and CRP 
concentrations. DNA was extracted from blood pellets and used for typing sickle cell and α-
thalassaemia using PCR at the KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya. 
 
Western Kenya: Children were recruited from the Water, Sanitation, and Handwashing 
(WASH) Benefits Trial, in rural western Kenya (Byrd et al., 2018). Details of the study design 
have been published in (Byrd et al., 2018). I used samples collected from the environmental 
enteropathy endline survey. Venous blood samples were used to test for malaria parasitaemia 
using RDT (SD BIOLINE Malaria P. falciparum [HRP2], Alere, Inc., Waltham, MA) and 
haemoglobin concentrations (Hemocue Hb 301). Serum ferritin and CRP were assayed 
using sandwich ELISA (Erhardt et al., 2004). Genotyping of sickle cell and α-thalassaemia 
was conducted using PCR (Waterfall and Cobb, 2001). 
 
Sud Kivu and Kongo Central, Democratic Republic of Congo: This study used data collected 
during a nutrition survey of mothers and their children aged 6–59 months in rural Sud Kivu 
and Kongo Central provinces in the Democratic Republic of Congo (DRC) as described in 
(Barker et al., 2017). Malaria was tested using RDT (CareStart Malaria Screen, AccessBio, 
Inc.). Serum ferritin, CRP and AGP were assayed using sandwich ELISA (Erhardt et al., 2004). 
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Haemoglobin typing was conducted using Pyrosequencing while PCR was used to detect α-
thalassaemia and G6PD as described in (Barker et al., 2017). 
 
Muheza, Tanzania: Children were recruited from the Mother–Offspring Malaria Studies 
project at Muheza District Hospital in northeastern Tanzania to investigate iron status and risk 
of malaria infection as described in (Gwamaka et al., 2012). Blood samples were collected at 
3, 6, and 12 months of age then once every 6 months in year 2 and 3 (Gwamaka et al., 2012). 
In this thesis, I used data from samples collected at a single timepoint, each child’s oldest 
timepoint, since older children were likely to have experienced more malaria episodes. P. 
falciparum parasitaemia was determined using Giemsa-stained thick blood smears while 
haemoglobin was measured using an impedance-based analyzer (Abbott Cell Dyne 1200). 
Plasma ferritin and CRP were assayed using ELISA and haemoglobin was typed by 
electrophoresis (Helena Laboratories, Beaumont, Texas, USA) (Gwamaka et al., 2012). 
Genotyping for α-thalassaemia was conducted using PCR as detailed in (Chong et al., 2000). 
 
Yaoundé and Douala, Cameroon: Children aged 12-59 months were recruited for a cluster 
study that aimed to determine the prevalence of inherited haemoglobin disorders in Yaoundé 
and Douala, Cameroon as described in (Engle-stone et al., 2017). Malaria testing was done 
using RDT (SD BIOLINE Malaria Ag Pf/Pan, Standard Diagnostics; Gyeonggi-do, Republic 
of Korea) and haemoglobin was measured using a photometer (Hemocue, Ängelholm, 
Sweden). Plasma ferritin, CRP and AGP were assayed using ELISA (Erhardt et al., 
2004). Haemoglobin genotypes were determined by High Performance Liquid 
Chromatography (HPLC) using an Ultra-Resolution Variants Analyzer (Trinity Biotech, Bray, 
Ireland) while α-thalassaemia type was determined by PCR (Engle-stone et al., 2017). 
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Kilifi hospital-based study: Data from this study were used to determine the levels of hepcidin 
in 62 children admitted to Kilifi County Hospital with severe malaria. Hepcidin was measured 
using the Hepcidin-25 [human] Enzyme immunoassay Bachem Kit and harmonised to high 
sensitive DRG hepcidin values (Wray et al., 2017). Severe malaria was diagnosed as P. 
falciparum parasites in the blood film plus clinical features of severe malaria including 
haemoglobin <5g/dL or haematocrit level of <15% (for severe malarial anaemia) or Blantyre 
coma score of <3 (for cerebral malaria). 
 
Jackson Heart Study. This is a population-based cohort study of African-Americans aged ≥21 
years living in Mississippi, USA (Taylor, 2005). This study was designed to evaluate risks of 
cardiovascular disease as described in (Taylor, 2005; Wilson et al., 2005). Serum ferritin 
(Roche immunoturbimetric assay), CRP (ELISA) and haemoglobin (Coulter analyser, 
Beckman Coulter, USA) were measured from blood samples collected at a single clinic visit. 
Iron deficiency was defined as ferritin <30µg/L, anaemia as haemoglobin >12g/dL in females 
or <13g/dL in males, iron deficiency anaemia as presence of iron deficiency and anaemia, and 
inflammation as CRP >5mg/L.  Whole blood was used to extract DNA using Puregene reagents 
(Gentra System, Minneapolis, USA). Genetic studies were conducted as described elsewhere 
(Wilson et al., 2005). α-thalassemia status was determined using ~30X whole genome 
sequencing obtained through the NHLBI TOPMed project (https://www.nhlbiwgs.org/). 
Details of the sequencing, variant calling, and quality control protocols are described at dbGaP 
Study Accession phs000964 (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-
bin/study.cgi?study_id=phs000964.v4.p1). A subset of 3,009 Jackson Heart Study TOPMed 
participants underwent genotyping for the α-globin copy number variation using the Genome 
STRiP multi-sample structural variant calling algorithm (Handsaker et al., 2015). 
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4.3.2. Effect of sickle cell trait on malaria 
I performed a systematic review and meta-analysis of published studies to determine the overall 
effect of HbAS on uncomplicated malaria. I performed the search in Pubmed using search 
terms that included (“malaria” [Title/Abstract] OR “malaria/blood” [MAJR] OR 
“malaria/genetics” [MeSH Terms] OR "Malaria"[Mesh] OR  "Malaria, Falciparum"[Mesh] 
OR  "Plasmodium falciparum"[Mesh] ) AND (“HbAS” [Title/Abstract] OR “sickle cell trait” 
[Title/Abstract] OR “sickle cell trait/genetics” [MeSH Terms] OR “sickle cell trait/blood” 
[MeSH Terms] OR "Haemoglobin, Sickle"[Mesh] OR "Sickle Cell Trait"[Mesh] AND 
"Africa" [MeSH Terms] on 5th December 2019. I retrieved 585 articles and restricted the 
analysis to studies conducted in Africa and reporting incidence rate ratio (IRR). Since clinical 
malaria may occur repeatedly, an IRR provides a better estimate of the true malaria risk 
reduction attributable to HbAS. I found nine studies which I meta-analysed to obtain an overall 
IRR of HbAS on the risk of uncomplicated malaria. I used this estimate to weight the effect of 
HbAS on iron deficiency when calculating the causal estimate in Mendelian randomisation 
analysis. 
 
4.3.3. Statistical analysis 
I conducted all statistical analyses using STATA 13.0 (StataCorp., College Station, TX). I 
performed both cohort-specific and pooled analyses of the effect of HbAS on iron status. Where 
appropriate, I fitted unadjusted linear or logistic regression models to determine the effect of 
HbAS on iron status. Unadjusted analyses are recommended since valid instruments should be 
independent of potential confounders in the exposure-outcome relationship. I meta-analysed 
the cohort-specific odds ratios or estimates assuming fixed-effects since there was little 
evidence of heterogeneity between studies. A P value <0.05 was considered statistically 
significant. All P-values reflect two-tailed tests 
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I used the online http://cnsgenomics.com/shiny/mRnd/ MR power calculator to calculate 
sample size. The sample size of 7453 had power above 80% given the observed odds ratio of 
the outcome variable per standard deviation of the exposure variable of 2.52, 10% variation of 
clinical malaria that is explained by HbAS (Malaria Genomic Epidemiology Network, 2019), 
27% of iron deficiency cases and a type-I error rate of 0.05. 
 
I then conducted a two-sample Mendelian randomisation (Evans and Davey Smith, 2015) to 
investigate whether uncomplicated malaria causes iron deficiency using mrrobust software 
package (Spiller, Davies and Palmer, 2019) in STATA 13.0. This involved two estimates. The 
first sample estimate was from the community-based cohorts where the overall log-odds of 
HbAS on iron deficiency was determined using the meta-analysed cohort-specific estimates. 
The second sample estimate was from the meta-analysed overall log incidence rate of HbAS 
on uncomplicated malaria. A causal log-odds (equation 1), which is the ratio of the first sample 
estimate and the second sample estimate was computed (Evans and Davey Smith, 2015). The 
causal odds ratio was obtained by exponentiating the causal log-odds and interpreted as change 
in iron deficiency per unit increase in log incidence rate of malaria. I further calculated the 
effect of reducing malaria incidence by half on iron deficiency. I obtained this by multiplying 
the causal log-odds by natural-logarithm of 0.5 then exponentiated the result (Burgess and 
Labrecque, 2018). I repeated the analyses in an African-American population with no exposure 
to malaria in ‘no relevance point’ sensitivity analyses (Chen et al., 2008).  
 
Causal log odds = !"#	"%%&	"'	()"*	%+'(,(+*,-	(*	./01!"#	"%%&	"'	2343)(3	(*	./01         (1) 
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4.4 Results 
4.4.1 Characteristics of study populations 
Table 4.1 shows the characteristics of the participants included in these analyses. Studies in 
malaria-endemic sites included children aged 0 - 8 years while the Jackson Heart Study (JHS), 
a malaria-free study included adults aged 21 - 95 years. Figure 4.1A shows the study sites 
mapped against the Africa malaria map of the predicted posterior predictions of age-
standardised P. falciparum prevalence as previously published by (Snow et al., 2017). The 
prevalence of malaria parasitaemia, HbAS and iron deficiency in children from the African 
community-based studies varied across the study sites from 7.26-26.66%, 9.76-16.76% and 
10.27-39.46% respectively as shown in Figure 4.1B. In JHS, HbAS was present in 8.43% and 
iron deficiency in 9.99% of individuals. 
Table 4.1. Characteristics of study participants by site 
 Total  Age (years) mean (sd) 
Sex: females, 
n (%) 
Inflammation1, 
n (%) 
Stunting2, 
n (%) 
Underweight3, 
n (%) 
Malaria-exposed studies        
Malawi 1035 2.75 (1.24) 512 (49.47) 604 (58.36) 319 (31.18) 134 (13.00) 
Ghana 1123 2.67 (1.28) 560 (49.96) 230 (20.48) 248 (22.52) 177 (16.06) 
Banfora, Burkina Faso 314 1.86 (0.46) 153 (48.73) 106 (33.76) 100 (34.01) 57 (19.32) 
Western, Kenya 411 1.85 (0.15) 210 (51.09) 92 (22.38) 95 (23.40) 32 (7.82) 
Sud Kivu and Kongo 
Central, DRC 678 2.41 (1.14) 338 (49.85) 462 (68.14) 329 (53.93) 141 (22.49) 
Kilifi, Kenya 996 2.20 (1.47) 489 (49.10) 261 (26.20) 41 (42.71) 72 (26.67) 
Muheza, Tanzania 652 1.64 (0.79) 313 (48.01) 370 (56.75) 126 (20.59) 49 (8.02) 
West Kiang, The Gambia 723 3.91 (1.16) 333 (46.06) 107 (14.80) 207 (36.51) 145 (25.53) 
Yaoundé and Douala, 
Cameroon 292 2.76 (1.05) 143 (49.48) 62 (21.23) 45 (15.62) 15 (5.21) 
Entebbe, Uganda 1229 2.30 (0.82) 603 (49.06) 291 (23.68) 186 (15.33) 100 (8.16) 
Malaria-free studies        
Soweto, South Africa 648 1.02 (0.94) 317 (48.92) 100 (15.43) n/a n/a 
Jackson Heart Study 3207 55.57 (12.83) 2000 (62.36) 940 (29.31) n/a n/a 
Hospitalised children with 
severe malaria       
Kilifi hospital-based study 62 1.86 (1.06) 28 (45.16) 62 (100.00) 21 (38.18)    26 (41.94) 
DRC, Democratic Republic of Congo; sd, standard deviation; n/a, not available 
1Inflammation was defined as C-reactive protein (CRP) >5mg/L or α1-antichymotrypsin (ACT) >0.6g/L or α1-acid glycoprotein 
(AGP) >1g/L. CRP was measured in all sites except West Kiang, The Gambia where only ACT was measured. In addition to 
CRP, AGP was measured in Malawi, DRC and Cameroon. 
2Stunting was defined as a WHO 2006 reference height-for-age z-score <-2 
3Underweight was defined as a WHO 2006 reference weight-for-age z-score <-2 
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Figure 4.1. Sickle cell trait (HbAS) protects from iron deficiency (ID). 
A) Africa malaria map showing the predicted posterior predictions of age-standardised P. 
falciparum prevalence (PfPR2–10) as previously published by (Snow et al., 2017) and the 
current study sites. Map was reproduced with permission. B) Prevalence of malaria 
parasitaemia, sickle cell trait (HbAS), and iron deficiency (ID) by study site. C) Summary 
results of the effect of HbAS on ID by study site, overall fixed-effects meta-analysis of malaria 
studies, and effect in a non-malaria exposed population, Jackson Heart Study (JHS). The South 
African cohort was excluded since only 6 out of 648 children had HbAS. Overall represents a 
fixed-effect meta-analysis of cohort-specific odds ratios. D) Associations between sickle cell 
trait and age, sex, inflammation, stunting and underweight. In malaria studies, ID was defined 
as plasma ferritin <12µg/L or <30µg/L in the presence of inflammation (CRP >5mg/L or ACT 
>0.6g/L or AGP >1g/L) in children <5 years old or <15µg/L in children ≥5 years old. In the 
JHS, ID was defined as plasma ferritin <30µg/L. HbAA, normal haemoglobin. 
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4.4.2 Sickle cell trait is associated with protection against iron deficiency 
I first evaluated the association between HbAS and iron deficiency. In a meta-analysis of the 
10 community-based study cohorts of malaria-exposed children (n = 7453), HbAS was 
associated with 30% protection against iron deficiency (OR = 0.70; 0.58, 0.82; P <0.001; 
Figure 4.1C) and 31% protection against iron deficiency anaemia (OR = 0.69; 0.53, 0.85; P 
<0.001; Figure 4.2). The protective effect of HbAS against iron deficiency was consistent 
across cohorts (I2 = 0.0%, Figure 4.1C). Since HbAS and α-thalassaemia show 
negative epistatic interaction (Williams, Mwangi, Wambua, Peto, et al., 2005), I further 
adjusted for the effect of α-thalassaemia on iron deficiency. Adjusting for α-thalassaemia did 
not alter the effect of HbAS on risk of iron deficiency (Table 4.2). I also obtained similar results 
in pooled analyses compared to the meta-analysis (OR = 0.79 (0.68, 0.93); P = 0.003). 
Prevalence of iron deficiency and iron deficiency anaemia were similarly lower in malaria-
exposed individuals carrying HbAS compared to those carrying HbAA (Figures 4.3A and 
4.3B). Since poor nutrition could also lead to iron deficiency, I tested whether HbAS might be 
associated with stunting or underweight and found little evidence of an association (Figure 
4.1D). HbAS was similarly not associated with age or sex (P > 0.05; Figure 4.1D). In sensitivity 
analyses, HbAS was not associated with iron deficiency in non-malaria exposed African-
Americans (OR = 0.91; 0.60, 1.40; P = 0.68; Figure 4.1C and Figure 4.3A) suggesting that 
HbAS is protective against iron deficiency only in malaria-exposed populations. 
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Figure 4.2. A meta-analysis of the effect of sickle cell trait on iron deficiency anaemia 
(IDA). 
Overall represents a fixed-effect meta-analysis of cohort-specific odds ratios. n shows the 
number of individuals included in the analysis.  
 
 
 
Table 4.2. Effect of sickle cell trait (HbAS) on iron deficiency before and after adjusting 
for α-thalassaemia. 
Study HbAS  HbAS adjusted for α-thalassaemia  
 n OR (95% CI)  n OR (95% CI) 
Malawi 1035 0.75 (0.45, 1.25)  1030 0.76 (0.45, 1.26) 
Ghana 1123 0.45 (0.26, 0.77)  1045 0.46 (0.26, 0.80) 
Western, Kenya 411 0.73 (0.39, 1.39)  409 0.73 (0.38, 1.38) 
Sud Kivu and Kongo Central, DRC 678 0.91 (0.46, 1.79)  381 0.66 (0.22, 1.98) 
Kilifi, Kenya 996 0.68 (0.47, 0.98)  991 0.68 (0.47, 0.98) 
Muheza, Tanzania 652 0.96 (0.58, 1.59)  616 0.99 (0.59, 1.70) 
Yaoundé and Douala, Cameroon 292 0.99 (0.39, 2.53)  270 0.99 (0.32, 3.08) 
Overall (fixed-effects meta-analysis) 4046 0.76 (0.58, 0.93)  3697 0.74 (0.56, 0.92) 
Summary results of the effect of HbAS on iron deficiency by study site, overall fixed-effects meta-analysis of 
children in malaria-exposed cohorts, and effect of HbAS on iron deficiency after adjusting for α-thalassaemia. 
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Figure 4.3. Malaria may cause iron deficiency through hepcidin-mediated blockade of 
iron absorption and recycling. 
A) Prevalence of iron deficiency is lower in children carrying sickle cell trait (HbAS) than in 
those with normal haemoglobin (HbAA) in malaria studies but not in the Jackson Heart Study 
(JHS), a malaria-free population. B) Lower prevalence of iron deficiency anaemia in children 
carrying HbAS in malaria studies, but not in JHS. C) Higher hepcidin concentrations in 
children with malaria parasitaemia or severe malaria compared to those without. D) The 
prevalence of inflammation is lower in HbAS individuals compared to those carrying normal 
haemoglobin (HbAA) in malaria studies but not in JHS. E) Hepcidin concentrations increase 
with increasing CRP concentrations and remain above the threshold for iron absorption at all 
deciles of CRP in children with malaria parasitaemia. Yellow line shows point at which 
inflammation is clinically diagnosed. Red horizontal line indicates the threshold of hepcidin 
above which iron absorption is inhibited (5.5µg/L). Cp, Ceruloplasmin; DMT1, divalent metal 
transporter 1; FPN, ferroportin; GIT, gastrointestinal tract; Par, malaria parasitaemia; Pf, P. 
falciparum; Tf, transferrin; TfR, transferrin receptor. This diagram is my own illustration. 
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Having shown that HbAS is associated with iron deficiency in African children, but not in 
African Americans, I then estimated the causal effect of uncomplicated malaria on iron 
deficiency using HbAS as an instrumental variable in a two-sample Mendelian randomisation 
analysis (Davey Smith and Hemani, 2014). This requires weighting the effect of HbAS on iron 
deficiency using the effect of HbAS on uncomplicated malaria. The effect of HbAS on severe 
malaria can be obtained from genome-wide association studies (GWAS), however, there are 
no previous GWAS of uncomplicated malaria. I used the effect of HbAS on uncomplicated 
malaria since severe malaria is a rare outcome and thus less likely to be a major cause of iron 
deficiency at the population level. I therefore conducted a systematic review and meta-analysis 
of all published papers that assessed the effect of HbAS on the incidence of uncomplicated 
malaria to obtain an overall incidence rate ratio (Figure 4.4 and Table 4.3). Overall, HbAS was 
associated with 32% (IRR = 0.68; 0.62, 0.73) protection from episodes of uncomplicated 
malaria (Figure 4.4). 
 
 
Figure 4.4. A meta-analysis of the effect of sickle cell trait on uncomplicated malaria. 
Overall represents a fixed-effect meta-analysis of study-specific incidence rate ratio. n shows 
the number of individuals included in the analysis. 
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Table 4.3. A summary of published studies on the incidence rate ratio of sickle cell trait 
on uncomplicated malaria 
Study Country Sample size  Age IRR (95% CI) 
(Parikh, Dorsey and Rosenthal, 2004) Uganda 307 6 months - 5 years 0.72 (0.50, 1.10) 
(Williams, Mwangi, Wambua, Alexander, et al., 2005) Kenya 323 <8 years 0.55 (0.37, 0.81) 
(Clark et al., 2008) Uganda 558 1-10 years 0.68 (0.52, 0.90) 
(Crompton et al., 2008) Mali 176 2-10 years 0.46 (0.27, 0.79) 
(Kreuels et al., 2010) Ghana 852 3 months - 2 years 0.78 (0.66, 0.92) 
(Lopera-Mesa et al., 2015) Mali 1543 6 months - 17 years 0.66 (0.59, 0.75) 
(Lwanira et al., 2015) Uganda 413 3 - 9 years 0.78 (0.76, 1.43) 
(Travassos et al., 2015) Mali 300 0 - 6 years 0.95 (0.51, 1.76) 
(Croke et al., 2017) Tanzania 767 0 - 19 years 0.71 (0.53, 0.96) 
 
 
I then calculated the causal estimate in a two-sample Mendelian randomisation analysis (Davey 
Smith and Hemani, 2014). I estimated the causal log odds estimate as the ratio of the log odds 
of HbAS on iron deficiency (Figure 4.1C) to log incidence rate of HbAS on uncomplicated 
malaria (Figure 4.4). The betas and standard errors are shown in Table 4.4. I exponentiated the 
causal log odds (0.92), to obtain the causal odds ratio. I observed a causal odds ratio of 2.52 
(95% CI 1.60, 3.98; P <0.001) suggesting that genetically predicted risk of uncomplicated 
malaria is associated with 2.5-fold higher odds of iron deficiency per unit increase in log 
incidence rate of malaria. Thus, reducing the incidence of uncomplicated malaria by half would 
reduce iron deficiency by 47% (that is, odds of 0.53 calculated as exponentiate (log 0.5 x 0.92). 
 
Table 4.4. Log estimates used in Mendelian randomisation analyses 
Relation Beta (SE) P Source 
HbAS - ID -0.36 (0.09) <0.001 Meta-analysed African studies (Fig. 4.1C) 
HbAS - uncomplicated malaria -0.39 (0.05) <0.001 Meta-analysis of published studies (Fig. 4.4) 
MR causal estimate 0.92 (0.23) <0.001 Calculated as HbAS-ID/HbAS-malaria 
SE, standard error; HbAS, sickle cell trait; ID, iron deficiency; MR, Mendelian randomisation 
 
I compared the findings for HbAS to other genetic polymorphisms associated with protection 
against malaria by using data for 5021 and 4811 children with G6PD deficiency and α-
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thalassaemia carriage data respectively (Figures 4.5 and 4.6). These polymorphisms are mainly 
associated with protection from severe malaria. However, in previous studies G6PD deficiency 
was associated with 30% protection against uncomplicated malaria in heterozygous females 
(Mbanefo et al., 2017), while α-thalassaemia may protect from uncomplicated malaria in 
heterozygotes (Enevold et al., 2008). Overall, I found that heterozygous G6PD females and 
heterozygous α-thalassaemic children were 39% (OR 0.61; 0.46, 0.76) and 19% (OR 0.81; 
0.68, 0.95) protected from iron deficiency thus supporting the HbAS data. However, findings 
were less consistent across cohorts. These polymorphisms were not associated with iron 
deficiency in non-malaria exposed African-Americans (Figures 4.5 and 4.6). 
 
 
Figure 4.5. A meta-analysis of the effects of glucose-6-phosphate-dehydrogenase 
deficiency (G6PD) heterozygosity on iron deficiency. 
Overall represents a fixed-effect meta-analysis of cohort-specific odds ratios. n shows the 
number of individuals included in the analysis. F Het, female heterozygous; ID, iron deficiency. 
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Figure 4.6. A meta-analysis of the effects of alpha-thalassaemia heterozygosity on iron 
deficiency. 
Overall represents a fixed-effect meta-analysis of cohort-specific odds ratios. n shows the 
number of individuals included in the analysis. Few individuals were homozygous for alpha-
thalassaemia and were excluded from the analysis. Het, heterozygous; ID, iron deficiency. 
 
 
4.4.3 Malaria may cause iron deficiency through a hepcidin-mediated blockade of iron 
absorption and recycling 
I hypothesised that malaria may be causing iron deficiency via a hepcidin-mediated blockade 
of iron absorption and recycling, as illustrated in Figure 4.3 above. I observed that children 
with asymptomatic malaria parasitaemia and severe malaria had increased mean hepcidin 
concentrations compared to those without malaria (Figure 4.3C). Moreover, mean hepcidin 
concentrations in children with either asymptomatic malaria parasitaemia or severe malaria 
were well above the threshold of 5.5µg/L associated with iron blockade (Prentice et al., 2012; 
Pasricha et al., 2014). Since anaemia suppresses hepcidin production (Casals-Pascual et al., 
2012), I further stratified the effects of malaria on hepcidin levels by anaemia status and found 
that hepcidin levels were below a threshold associated with iron blockade only in individuals 
with anaemia and without malaria parasitaemia (Figure 4.7). Children with asymptomatic 
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malaria parasitemia, and severe malaria, had higher geometric mean CRP levels (4.62 mg/L, 
and 100.28 mg/L, respectively) compared to those without malaria (1.15 mg/L).  
 
Figure 4.7. Geometric mean hepcidin concentrations by anaemia status.  
Par, malaria parasitaemia; Severe, severe malaria 
Since inflammation also increases hepcidin levels, I also analysed the interaction between 
malaria and inflammation in influencing hepcidin concentrations. I found that HbAS was 
associated with a 25% reduction in inflammation (OR 0.75; 0.65, 0.87; P <0.001; Figures 4.2D 
and 4.3D) in malaria-exposed African children but not in a non-malaria exposed population of 
African-Americans (OR 0.96; 0.73, 1.26; P = 0.77; Figure 4.3D). I further observed that 
hepcidin concentrations were raised above a threshold shown to block iron absorption, even at 
very low CRP concentrations (1mg/L, Figure 4.3E) long before children would be classified as 
having inflammation (C-reactive protein (CRP) ≥5mg/L). Notably, children with malaria 
parasitaemia had higher hepcidin concentrations at almost every decile of CRP compared to 
children without parasitaemia (Figure 4.3E). However, HbAS itself was not associated with 
hepcidin concentrations (log estimate = 0.07; 95% CI -0.05, 0.20; P = 0.24; n = 3473). 
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4.5 Discussion 
The causal relationship between malaria and iron deficiency is complex and difficult to 
disentangle in observational studies due to confounding bias and reverse causality. Here, I 
applied Mendelian randomisation, an approach that overcomes some of the limitations of 
observational studies by utilising sickle cell trait to proxy malaria exposure. Using large-scale 
data (n = 11,370) from children across the African continent and from African-Americans I 
found that uncomplicated malaria is causally associated with an increased risk of iron 
deficiency in African children. These findings suggest that an intervention that halves the 
incidence of uncomplicated malaria episodes would reduce prevalence of iron deficiency by 
47%. 
 
My findings corroborate reports from previous interventional and observational studies. 
Treatment of afebrile malaria has been shown to reduce hepcidin concentrations by 
approximately half, double iron absorption and reduce iron deficiency by approximately half 
in Ivorian children (Glinz, Hurrell, Righetti, et al., 2015). Similar results have been reported in 
Beninese women treated for afebrile malaria (Cercamondi et al., 2010). A study in Kenyan and 
Gambian children reported significant increase in prevalence of iron deficiency at the end of a 
malaria season compared to the start (from 38.2% to 46.5% in Kenyans and from 18.6% to 
29.5% in Gambians) suggesting that malaria may contribute to iron deficiency (Atkinson et al., 
2014). Similarly, in another study in the Kenyan highlands, interruption of malaria transmission 
using antimalarials and indoor residual spraying reduced prevalence of iron deficiency (from 
35.6% to 24.9%) and more than halved the prevalence of iron deficiency anaemia (from 27.2% 
to 12.2%) (Frosch et al., 2014).  Thus, the predicted benefits from my analyses of reducing iron 
deficiency by approximately half through application of an intervention that halves malaria 
episodes may be translatable to the real world. 
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Malaria control can be achieved by controlling vectors with insecticide-treated bed nets (ITNs) 
and Indoor Residual Spraying (IRS), anti-malarial drugs and larval habitat control. Vaccination 
is a possibility in the future with the RTSS vaccine having an approximately 30% efficacy 
(Bejon et al., 2008; The RTSS Clinical Trials Partnership, 2014).  ITNs, IRS and artemisinin 
combination therapies have been associated with approaching 50% reductions in the burden of 
clinical malaria (Bhatt et al., 2015). Furthermore, seasonal malaria chemoprevention or 
intermittent preventative treatment in children has been associated with protective efficacy of 
up to 75% against clinical malaria, and is safe and cost-effective (Aponte et al., 2009; Wilson, 
2011; Meremikwu et al., 2012). I therefore speculate that a scale-up of these malaria control 
strategies could achieve more than 47% reduction in iron deficiency among African children 
with substantial public health benefits. 
 
Malaria may be causing iron deficiency in African children through chronically up-regulating 
production of hepcidin. In agreement with previous studies, I found that children with 
asymptomatic malaria infection had increased hepcidin concentrations (de Mast et al., 2010; 
Atkinson et al., 2015). Interestingly, I found that hepcidin concentrations in parasitaemic 
children were well above a threshold of 5.5 µg/L beyond which iron absorption has been shown 
to be impaired (Prentice et al., 2012; Pasricha et al., 2014). I then tested whether the effect of 
malaria on hepcidin might be mediated by inflammation since IL-6 strongly up-regulates 
hepcidin production (Nemeth, Rivera, et al., 2004; Atkinson et al., 2014; Prentice et al., 2019). 
I found that sickle cell trait was associated with reduced inflammation in malaria-exposed 
African children but not in a non-malaria exposed population of African-Americans. This 
finding suggests that malaria may be an important cause of inflammation in African children. 
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Malaria raised hepcidin concentrations above a threshold associated with iron blockade 
(Prentice et al., 2012; Pasricha et al., 2014) and at CRP levels below a threshold defining 
inflammation suggesting that malaria may also increase hepcidin concentrations via non-
inflammatory pathways (Spottiswoode et al., 2017). Malaria might also cause hepcidin-
mediated blockade of iron by increasing the prevalence of bacterial infections (Scott et al., 
2011) or by increasing inflammatory cytokines such as TNFa and IFNg (Atkinson et al., 2008). 
Possible pathways mediating the relationship between malaria and iron deficiency are shown 
in Figure 4.8. These findings support previous small radioisotope studies showing that treating 
malaria reduces hepcidin concentrations, increases iron absorption, and reduces prevalence of 
iron deficiency (Cercamondi et al., 2010; Glinz, Hurrell, Righetti, et al., 2015). 
 
Figure 4.8. How sickle cell trait, a proxy for reduced malaria exposure, may be 
protecting from iron deficiency. 
A) Individuals carrying normal beta haemoglobin gene (HbAA) are not protected from 
malaria. Malaria up-regulates production of hepcidin through inflammatory and non-
inflammatory pathways and by increasing the prevalence of other infections. Hepcidin in turn 
blocks iron absorption. B) Sickle cell trait (HbAS) partially protects individuals from malaria 
infection therefore inflammation is reduced leading to lower levels of hepcidin and increased 
iron absorption and recycling. 
 101 
To test for direct effects of sickle cell trait on iron deficiency (through mechanisms independent 
of malaria exposure), I repeated the analyses in a non-malaria population using no-relevance 
point sensitivity analyses (Chen et al., 2008) and also tested effect of sickle cell trait on 
potential confounders. Sickle cell trait was not associated with iron deficiency or inflammation 
in African-Americans, a population that is not exposed to malaria. I also found that sickle cell 
trait was not associated with age, sex, or nutritional status. This suggests that the protective 
effect of sickle cell trait on iron deficiency in malaria-exposed African children is likely to act 
through malaria.  
 
Other polymorphisms have also been shown to protect against malaria. In a meta-analysis, 
heterozygous G6PD deficiency in females conferred 30% protection from uncomplicated 
malaria (Mbanefo et al., 2017). Although there are mixed findings (Taylor, Parobek and 
Fairhurst, 2012), heterozygous α-thalassaemia may protect against uncomplicated malaria 
(Enevold et al., 2008). I found that these polymorphisms were associated with protection from 
iron deficiency. However, G6PD and α-thalassaemia largely protect from severe malaria, a rare 
outcome, rather than uncomplicated malaria which, due to its high incidence, is more likely to 
cause iron deficiency at the population level. Nevertheless, these findings support the results 
obtained using sickle cell trait, which has been shown to consistently and strongly protect from 
uncomplicated malaria (Taylor, Parobek and Fairhurst, 2012). 
 
These analyses had a number of limitations. One limitation was the use of African-American 
adults rather than African children to test whether sickle cell trait might influence iron 
deficiency through a non-malaria related pathway (pleiotropy). I was unable to test for 
pleiotropy in non-malaria-exposed South African children since few carried sickle cell trait (n 
= 6/648), similar to most populations without historical exposure to malaria. However, I 
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obtained similar results using G6PD deficiency and α-thalassaemia, which protect against 
malaria via different mechanisms. Another limitation is that I did not have data on additional 
potential causes of iron deficiency in the various populations, such as differences in diet, risk 
of hookworm infection, or other infections such as human immunodeficiency virus. 
Nevertheless, I obtained a consistent protective effect of sickle cell trait on iron deficiency 
across all cohorts. I would expect sickle cell trait to have a larger protective effect against iron 
deficiency in populations with higher incidence of clinical malaria (Spiller et al., 2019), but I 
did not have data on incidence of clinical malaria for the majority of the cohorts. It is also likely 
that my analyses have underestimated the effect of malaria on iron deficiency since sickle cell 
trait is not known to protect against afebrile malaria parasitaemia (Taylor, Parobek and 
Fairhurst, 2012), prevalent in approximately a quarter of African children (Snow et al., 2017). 
Afebrile parasitaemia has been shown to increase hepcidin concentrations, in agreement with 
my analyses, and thus impair iron absorption (Cercamondi et al., 2010; Glinz, Hurrell, Righetti, 
et al., 2015). 
 
4.6 Conclusion 
Using large-scale data from across the malaria-endemic region of sub-Saharan Africa, I have 
shown that uncomplicated malaria increases risk of iron deficiency in African children. This 
finding has important policy implication and represent an important shift in the paradigm of 
iron and malaria infection. Studies to date have largely focused on iron status as a risk factor 
for malaria, and the difficulties this causes for strategies to treat iron deficiency. These findings 
suggest that malaria itself may be causing iron deficiency in African children. The management 
of iron deficiency has traditionally involved iron supplementation, but there are long-standing 
concerns regarding safety since iron may increase the risk of infections such as malaria 
(Sazawal et al., 2006) and alter the gut microbiome (Paganini and Zimmermann, 2017). 
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Moreover, iron supplementation may be ineffective in malaria-endemic areas due to poor 
absorption in children with chronically raised hepcidin from malaria parasitaemia and other 
infections (Glinz, Hurrell, Righetti, et al., 2015; Prentice et al., 2019), and treatment of malaria 
would allow iron to be more effectively absorbed from the diet. Thus, malaria treatment and 
prevention should be an integral part of programs to control iron deficiency in African children. 
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CHAPTER FIVE: IRON STATUS AND ASSOCIATED MALARIA RISK AMONG 
AFRICAN CHILDREN 
The material in this chapter forms the basis of a published paper in Clinical Infectious Diseases 
entitled “Iron Status and Associated Malaria Risk Among African Children”, in which I was 
the first author. 
 
5.1 Abstract 
Introduction: It remains unclear whether improving iron status increases malaria risk, and few 
studies have looked at the effect of host iron status on subsequent malaria infection. I therefore 
aimed to determine whether a child’s iron status influences their subsequent risk of malaria 
infection in Kenyan and Ugandan children. 
Methods: I used data on iron and inflammatory biomarkers and surveillance of malaria episodes 
from community-based cohorts of 1309 Kenyan and 1374 Ugandan children aged 0 - 7 years. 
I fitted Poisson regression and Cox proportional hazards models to determine the effect of iron 
status on the incidence rate ratio of malaria using longitudinal data covering a period of six 
months. I adjusted for age, sex, malaria parasitaemia, inflammation and study site in the 
models. 
Results: The risk of malaria was 33% and 28% lower in children with iron deficiency (incidence 
rate ratio, IRR = 0.67; 95% CI: 0.55, 0.82; P <0.001) and iron deficiency anaemia (IRR = 0.72; 
95% CI: 0.56, 0.93; P = 0.006), respectively. Low transferrin saturation (<10%) was similarly 
associated with lower risk of malaria (IRR = 0.79; 95% CI: 0.65, 0.96; P = 0.016). However, 
variation in hepcidin, soluble transferrin receptors (sTfRs) and haemoglobin / anaemia was not 
associated with altered malaria risk.  
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Conclusions: Iron deficiency appears to protect against malaria infection in African children 
when defined using ferritin and transferrin saturation, but not when defined by hepcidin, sTfR 
or haemoglobin. Further research is required to confirm causality and determine mechanisms. 
 
5.2 Introduction 
The safety of iron supplementation is a long-standing concern among policy makers and 
clinicians in malaria-endemic areas (Suchdev et al., 2010; Brittenham, 2012). In Chapter One 
Section 1.3.3, I reviewed the literature on iron status and malaria risk.  Clinical trials have 
reported conflicting findings on whether iron supplementation influence risk of malaria 
(Menendez et al., 1997; Sazawal et al., 2006; Veenemans et al., 2011; Esan et al., 2013; Zlotkin 
et al., 2013). Furthermore, previous randomised controlled trials have reported conflicting 
findings on whether baseline iron status of a child determines their risk of malaria infection 
following iron supplementation (Sazawal et al., 2006; Veenemans et al., 2011; Zlotkin et al., 
2013). Thus, it is unclear whether iron supplementation might be unsafe because it improves 
iron status itself thus resulting in a long-term increase in the risk of malaria.  
 
Five observational studies have investigated the effect of a child’s iron status on malaria risk. 
These studies all indicate that iron deficiency is associated with a lower risk of P. falciparum 
malaria in African children (Nyakeriga et al., 2004; Gwamaka et al., 2012; Jonker et al., 2012; 
Barffour et al., 2017; Moya-Alvarez et al., 2017). However, these studies have largely defined 
iron deficiency using ferritin only despite its limitations and the availability of other commonly 
measured iron markers. Thus, little is known about whether other indicators of iron status 
influence malaria risk in humans. These other indicators of iron status include hepcidin, 
haemoglobin, soluble transferrin receptors (sTfR), and transferrin saturation (TSAT). Hepcidin 
has been shown to play a role in preventing superinfection by depriving the Plasmodium liver 
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stage of iron in mice models (Portugal et al., 2011). However, there are mixed findings on 
whether hepcidin protects from malaria risk in children (Atkinson et al., 2015; Brickley et al., 
2016). In Kenyan children, hepcidin concentrations were not associated with malaria risk 
(Atkinson et al., 2015) while high cord blood hepcidin was associated with lower risk of 
uncomplicated malaria in Tanzanian infants (Brickley et al., 2016). Two previous 
observational studies have reported that haemoglobin concentrations do not influence malaria 
risk (Ghosh et al., 1995; Lombardo et al., 2017) while in vitro culture indicates otherwise 
(Goheen et al., 2016). There are no specific reports of the influence of sTfR and TSAT on 
malaria in humans. In this chapter, I report the largest observational study on iron status and 
risk of malaria to date with the most comprehensive range of iron markers in 2683 Kenyan and 
Ugandan children. 
 
5.3 Methods 
5.3.1 Study population 
In this chapter, I report analyses of iron / inflammatory markers and malaria episode data from 
the Kilifi, Kenya and Entebbe, Uganda cohorts described in Chapter Two. I included these two 
studies since they were the only cohorts with available longitudinal data of active malaria 
surveillance. Longitudinal parasitaemia data were obtained from active surveillance during the 
six months following measurement of iron and inflammatory biomarkers (Figure 5.1). In 
Kenya, children were followed up weekly while in Uganda follow-up involved fortnightly 
home visits and quarterly clinic visits. Almost all children were followed up for the full six 
months period (94% in Kenya and 90% in Uganda) and the length of follow-up for the 
remainder ranged from 1-5 months. I chose a follow-up period of not more than six months 
since iron status may change over a longer follow-up period. However, I conducted secondary 
analyses that included a one-year period of follow-up. Clinical malaria data included 
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microscopy confirmed density of asexual P. falciparum parasitaemia and temperature. A 
malaria episode was defined as parasitaemia at any density and temperature above 37.50C. All 
uncomplicated malaria episodes occurring during the follow-up period were included except 
those occurring within 14 days of an initial presentation, which were regarded as 
recrudescence. 
 
Figure 5.1. Study design. 
Iron measurements were taken at baseline. Kenyan children were followed up weekly. In 
Uganda, follow-up involved fortnightly home visits and quarterly clinic visits. 
 
5.3.2 Statistical analysis 
I conducted all analyses using STATA 13.0 (StataCorp., College Station, TX). I ln-transformed 
iron biomarkers (except haemoglobin) to normalise their distributions. I then computed the 
geometric means of iron biomarkers and proportions of iron deficiency and anaemia. I used 
two-tailed Student’s t-tests to test for difference in means between groups. I fitted Poisson 
regression models of counts of malaria episodes as predicted by iron status (iron deficiency / 
anaemia / individual iron biomarkers) adjusting for potential confounders including age, sex, 
malaria parasitaemia, inflammation and study site. I accounted for difference in individual 
length of follow-up by including the length of follow-up as “exposure” in the model. I 
accounted for multiple episodes using robust cluster variance estimation which takes into 
account correlations between multiple events. Secondary analyses involved excluding children 
with parasitaemia or inflammation at baseline to mitigate the effects of concurrent infection on 
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iron status (Aguilar et al., 2012). I used Cox proportional hazards analyses to evaluate the 
temporal effect of iron status on malaria risk. A p-value of <0.05 was considered significant.  
 
I finally searched the databases PubMed and Google Scholar with search terms that included 
“iron deficiency or ferritin or hepcidin or sTfR or TSAT or haemoglobin or anaemia and 
malaria children”. I found five longitudinal studies investigating the effect of iron deficiency 
on malaria risk but only four reported effect sizes. I then performed a meta-analysis of the 
current study and the previous longitudinal studies investigating the relationship between iron 
deficiency and malaria risk using the “metan” command in STATA. 
 
5.4 Results 
5.4.1 Baseline characteristics of study population 
I included a total of 1309 Kenyan and 1374 Ugandan children aged between 0 – 7 years and 1 
- 5 years respectively in the analyses. Table 5.1 shows the characteristics of study participants. 
At baseline, the prevalence of iron deficiency and iron deficiency anaemia were 36.9% and 
23.6% in Kenyan and 34.6% and 17.6% in Ugandan children, respectively. The prevalence of 
iron deficiency based on TSAT (measured in Kenya only) was 52.4%. The prevalence of 
malaria parasitaemia was higher in Kenyan (20.1%) compared to Ugandan children (6.7%). 
During the six-month follow-up, 31.1% of Kenyan and 14.3% of Ugandan children 
experienced at least one episode of malaria infection. Malaria incidence rate per child-year of 
follow-up was 0.6 in Kenya and 0.3 in Uganda.  
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Table 5.1. Baseline characteristics of study participants 
 Kenya, n=1309 Uganda, n=1374 
Mean age in years (range) 2.3 (0.0, 7.1) 2.3 (1.0, 5.1) 
Sex, n/total (%)   
Males 668/1309 (51.0) 696/1374 (51.7) 
Females 641/1309 (49.0) 678/1374 (49.3) 
Malaria parasitaemia, n/total (%) 261/1296 (20.1) 92/1371 (6.7) 
Inflammation, n/total (%)1 334/1264 (26.4) 316/1337 (23.6) 
Iron deficiency, n/total (%)2   
      Low ferritin 457/1237 (36.9) 438/1267 (34.6) 
      TSAT<10% 637/1215 (52.4) n/a 
Anaemia, n/total (%)3 526/765 (68.8) 533/1312 (40.6) 
Iron deficiency anaemia, n/total (%)4 172/729 (23.6) 213/1209 (17.6) 
Sickle cell trait, n (%) 157/1057 (14.9) 224/1355 (16.5) 
Ferritin, n (gmean±sd) in µg/L 1237 (20.8±3.0) 1267 (20.8±2.9) 
Hepcidin, n (gmean±sd) in µg/L 1202 (5.6±3.6) 1333 (6.8±3.3) 
sTfR, n (gmean±sd) in mg/L 1296 (17.8±1.5) 1343 (6.7±2.0) 
Haemoglobin, n (gmean±sd) in g/dL 765 (10.1±1.2) 1312 (11.0±1.1) 
Transferrin saturation, n (gmean±sd) in % 1215 (9.3±2.2) n/a 
gmean, geometric mean; sd, standard deviation; sTfR, soluble transferrin receptors; TSAT, transferrin saturation 
1Inflammation was defined as C-reactive protein > 5mg/L 
2Iron deficiency was defined using two definitions: 1) Low ferritin defined as plasma ferritin < 12µg/L or < 30µg/L in the 
presence of inflammation in children < 5 years or  < 15µg/L in children ³ 5 years; and 2) Transferrin saturation < 10% 
(available in 1215 Kenyan children only and not available (n/a) in Uganda).  
3Anaemia was defined as haemoglobin < 11g/dL in children aged 0 to 4 years or haemoglobin < 11.5 g/dL in children 
above 4 years. The range of haemoglobin was 5.1-14.7 in Kenya and 5.4-18.5 in Uganda while interquartile range (IQR) 
was 9.4-11.3 in Kenya and 10.3-12.1 in Uganda. Only 33 (1.6%) had severe anaemia (Hb<7g/dL in under 5 years or 
<8g/dL in over 5 years old). 
4Iron deficiency anaemia was defined as low ferritin and anaemia. 
Malaria incidence rate per child-year of follow-up was 0.6 in Kenya and 0.3 in Uganda. 
 
 
5.4.2 Higher ferritin concentrations and TSAT are positively associated with malaria 
infection 
Concentrations of ferritin and TSAT, but not other iron markers, were higher in children that 
subsequently developed a malaria episode (Figure 5.2). Similarly, a unit increase in log ferritin 
was associated with an increased incidence rate ratio for malaria overall (IRR = 1.3; 95% CI: 
1.2, 1.4; P < 0.001) and in each cohort individually (Figure 5.3). A unit increase in log TSAT 
was also associated with a 20% increased risk of malaria in Kenyan children (IRR = 1.2; 
95%CI: 1.05, 1.4); P = 0.009; Figure 5.3). However, hepcidin, sTfR and haemoglobin 
concentrations were not associated with subsequent risk of malaria (Figure 5.3).  
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Figure 5.2. Scatter plots of iron biomarkers stratified by no subsequent malaria 
episodes or one or more malaria episodes. 
Horizontal red line indicates mean while vertical line indicates standard deviation. P value 
was derived from Poisson regression model. sTfR, soluble transferrin receptor; TSAT, 
transferrin saturation.  
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Figure 5.3. Adjusted incidence rate ratios for the effect of iron biomarkers on 
subsequent malaria episodes. 
Green indicates overall, red Kenya and blue Uganda. Labels indicate incidence rate ratio and 
95% confidence intervals. Poisson regression models were adjusted for age, sex, parasitaemia, 
inflammation, length of follow-up and study site. sTfR, soluble transferrin receptor; TSAT, 
transferrin saturation.  
 
5.4.3 Iron deficiency defined using ferritin or TSAT is associated with protection 
against malaria risk 
Iron deficiency defined by low ferritin concentrations, and iron deficiency anaemia, were 
associated with 33% and 28% reduction in the incidence of malaria infection (IRR = 0.67; 95% 
CI: 0.55, 0.82; P <0.001 and IRR = 0.72; 95% CI: 0.56, 0.93; P = 0.006, respectively). These 
findings were consistent for the individual cohorts (Table 5.2). Likewise, iron deficiency 
defined by low TSAT was associated with a 21% reduction in the risk of malaria in Kenyan 
children (IRR = 0.79; 95% CI: 0.65, 0.96; P = 0.016). However, anaemia itself was not 
significantly associated with variation in malaria risk (Table 5.2).  
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Table 5.2. Incidence of malaria by iron status and anaemia 
 Kilifi, Kenya Entebbe, Uganda Pooled 
 No. No. of episodes Incidence IRR (95% CI) P No. 
No. of 
episodes Incidence IRR (95% CI) P  No. 
No. of 
episodes Incidence IRR (95% CI) P  
No ID (iron replete) 780 286 0.8 1  829 140 0.3 1  1609 426 0.6 1  
ID (low ferritin)1 457 93 0.4 0.76 (0.59, 0.96) 0.018 438 45 0.2 0.52 (0.36, 0.76) <0.001 895 138 0.3 0.67 (0.55, 0.82) <0.001 
No ID (TSAT ≥10%) 578 224 0.8 1  n/a n/a n/a n/a n/a 578 224 0.8 1  
ID (TSAT <10%)2 637 159 0.5 0.79 (0.65, 0.96) 0.016 n/a n/a n/a n/a n/a 637 159 0.5 0.79 (0.65, 0.96) 0.016 
No anaemia 239 97 0.8 1  779 93 0.2 1  1018 190 0.4 1  
Anaemia3 526 219 0.9 0.99 (0.79, 1.18) 0.774 533 93 0.4 1.21 (0.87, 1.69) 0.156 1059 312 0.6 1.13 (0.93, 1.36) 0.168 
No IDA  557 257 1 1  996 154 0.3 1  1553 411 0.5 1  
IDA4 172 47 0.6 0.84 (0.62, 1.15) 0.269 213 23 0.2 0.47 (0.30, 0.74) <0.001 385 70 0.4 0.72 (0.56, 0.93) 0.006 
ID, iron deficiency; IDA, iron deficiency anaemia; TSAT, transferrin saturation 
1Iron deficiency (low ferritin) was defined as plasma ferritin < 12µg/L or < 30µg/L in the presence of inflammation (CRP > 5mg/L) in children < 5 years or < 15µg/L in children ³ 5 years otherwise iron replete. 
2Transferrin saturation data were available in 1215 Kenyan children. Not available (n/a) for Uganda. 
3Anaemia was defined as haemoglobin < 11g/dL in children aged 0 to 4 years or haemoglobin < 11.5 g/dL in children above 4 years. 
4Iron deficiency anaemia was defined as low ferritin and anaemia.  
Poisson regression models were adjusted for age, sex, parasitaemia, inflammation, length of follow-up, and study site. Maximum length of follow-up was 6 months. IRR=Incidence rate ratio. Incidence defined as 
number of malaria episodes per child-year of follow-up. The number of episodes ranged from 0-5 in Kenya and 0-6 in Uganda. 101 Kenyan and 45 Ugandan children had multiple episodes. 
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In Cox proportional hazards models, iron deficiency defined by low ferritin or by low TSAT, 
and iron deficiency anaemia were associated with 40%, 20% and 30% reduced risk of malaria 
respectively (Figure 5.4A-C) for the six months of follow-up compared to iron replete children. 
However, anaemia was not associated with malaria risk (Figure 5.4D and Table 5.3). 
 
Figure 5.4. Kaplan-Meier curves of time to first malaria episode. 
Categorised by A) iron deficiency (ID) defined by low ferritin, (B) iron deficiency defined by 
transferrin saturation (TSAT < 10%), (C) iron deficiency anaemia (IDA), and (D) anaemia. P 
values were derived from log-rank tests for equality of survivor functions. 
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Table 5.3. Cox proportional hazards regression models for predicting malaria risk 
 Unadjusted 
HR (95% CI) 
P value Adjusted1 
HR (95% CI) 
P value 
ID (low ferritin)2 0.5 (0.4, 0.6) <0.001 0.6 (0.5, 0.7) <0.001 
ID (TSAT<10%) 0.6 (0.5, 0.7) <0.001 0.8 (0.6, 0.9) 0.008 
Anaemia3 0.9 (0.8, 1.1) 0.488 1.2 (0.9, 1.4) 0.085 
Iron deficiency anaemia4 0.5 (0.4, 0.6) <0.001 0.7 (0.6, 0.9) 0.003 
ID, iron deficiency; HR, Hazard ratio; TSAT, transferrin saturation 1Models were adjusted for age, sex, cohort and inflammation. 2ID (low ferritin) was defined as plasma ferritin < 12µg/L or < 30µg/L in the presence of inflammation (CRP > 5mg/L) in children < 5 
years or < 15µg/L in children ³ 5 years. 3Anaemia was defined as haemoglobin < 11g/dL in children aged 0 to 4 years or haemoglobin < 11.5 g/dL in children above 4 years. 4Iron deficiency anaemia was defined as low ferritin and anaemia. 
In secondary analyses, I observed similar results after extending the follow-up period to one 
year (Figure 5.5). Figure 5.5 shows that iron deficiency defined either using low ferritin or 
TSAT was associated with a reduced risk of malaria even after extending the follow up period 
to one year. 
 
Figure 5.5. Effect of iron status on malaria risk over a one-year period. 
Labels indicate incidence rate ratio and 95% confidence intervals. ID is iron deficiency; IDA, 
iron deficiency anaemia; sTfR, soluble transferrin receptor; TSAT, transferrin saturation. ID-
low ferritin was defined as plasma ferritin < 12µg/L or < 30µg/L in the presence of 
inflammation (CRP > 5mg/L) in children < 5 years or < 15µg/L in children ³ 5 years 
otherwise, iron replete. Anaemia was defined as hemoglobin < 11g/dL in children aged 0 to 4 
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years or haemoglobin < 11.5 g/dL in children above 4 years. Iron deficiency anaemia was 
defined as low ferritin and anaemia. Poisson regression models were adjusted for age, sex, 
parasitaemia, inflammation, length of follow-up, and study site.  
 
Further secondary analyses included determining the influence of inflammation, malaria 
parasitaemia and age at baseline on risk of malaria. Exclusion of individuals with inflammation 
or malaria parasitaemia at baseline did not change the results obtained when all groups were 
included (Figure 5.6). Similarly, I observed a trend towards protection in all age groups (Figure 
5.7). 
 
Figure 5.6. Effect of iron status on malaria risk over a six-month period excluding 
children with inflammation and parasitaemia at baseline. 
Labels indicate incidence rate ratio and 95% confidence intervals. Inflammation was defined 
as C-reactive protein > 5mg/L. ID is iron deficiency; IDA, iron deficiency anaemia; sTfR, 
soluble transferrin receptor; TSAT, transferrin saturation. ID-low ferritin iron deficiency was 
defined as plasma ferritin < 12 µg/L in children < 5 years or < 15µg/L in children  ³ 5 years 
otherwise, iron replete. Anaemia was defined as haemoglobin < 11g/dL in children aged 0 to 
4 years or haemoglobin < 11.5 g/dL in children above 4 years. Iron deficiency anaemia was 
defined as low ferritin and anaemia. Poisson regression models were adjusted for age, sex, 
length of follow-up, and study site. Numbers are 660 in Kenya and 969 in Uganda. 
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Figure 5.7. Effect of iron deficiency on malaria risk by age group. 
Labels indicate incidence rate ratio and 95% confidence intervals. TSAT, transferrin 
saturation. ID-low ferritin was defined as plasma ferritin < 12µg/L or < 30µg/L in the presence 
of inflammation (CRP > 5mg/L) in children < 5 years or < 15µg/L in children ³ 5 years. 
 
 
 
Since sickle cell trait protects from the risk of malaria (Taylor, Parobek and Fairhurst, 2012), 
and may also influence iron status (as shown in Chapter Four), I additionally adjusted for its 
effect in Poisson regression models adjusted for age, sex, parasitaemia, inflammation, length 
of follow-up, and study site during the six month maximum follow-up period. I observed that 
additional adjustment for sickle cell trait did not change the results (Figure 5.8).  
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Figure 5.8. Effect of iron status on malaria risk including adjustment for sickle cell 
trait. 
Labels indicate incidence rate ratio and 95% confidence intervals. ID is iron deficiency; IDA, 
iron deficiency anaemia; sTfR, soluble transferrin receptor; TSAT, transferrin saturation. ID-
low ferritin was defined as plasma ferritin < 12µg/L or < 30µg/L in the presence of 
inflammation (CRP > 5mg/L) in children < 5 years or < 15µg/L in children ³ 5 years 
otherwise, iron replete. Anaemia was defined as haemoglobin < 11g/dL in children aged 0 to 
4 years or haemoglobin < 11.5 g/dL in children above 4 years. Iron deficiency anaemia was 
defined as low ferritin and anaemia. Poisson regression models were adjusted for age, sex, 
parasitaemia, inflammation, length of follow-up, sickle cell trait and study site. 
 
 
I finally reviewed all previous observational studies (Table 5.4) and performed meta-analysis 
of the effect of iron deficiency on malaria risk (Figure 5.9). All the studies reported that iron 
deficiency, using a ferritin-based definition, protects against malaria infection, despite 
differences in study site, length of follow-up, and definition of iron deficiency (Table 5.4). The 
overall estimate indicates that iron deficiency is associated with a 34% lower risk of malaria 
infection (Figure 5.9). 
 118 
Table 5.4. A summary of observational studies examining the relationship between iron deficiency and malaria risk 
 
Study  Country Age 
(months) 
Sample 
size 
Length of follow-
up 
ID definition Effect (95% CI) 
(Nyakeriga et al., 2004) Kenya 8 to 96 240 6 months Ferritin<12µg/L plus TSAT<10% 0.70 (0.51, 0.99)1 
(Jonker et al., 2012) Malawi 6 to 60 727 12 months Ferritin<30µg/L 0.49 (0.33, 0.73) 
(Gwamaka et al., 2012) Tanzania 0 to 36 785 3 years Ferritin<30µg/L if CRP<8.2mg/L  
or <70µg/L if CRP>8.2mg/L 
0.77 (0.66, 0.89) 
(Barffour et al., 2017) Zambia 48 to 72 745 6 months Ferritin<12µg/L in children<5 years  
or <15µg/L in children ³5 years 
0.63 (0.35, 1.11)2 
Current study Kenya and 
Uganda 
0 to 84 2504 6 months Ferritin<12µg/L or <30µg/L if CRP>5mg/L in 
children<5 years or <15µg/L in children ³5 
years 
0.67 (0.56, 0.81) 
     
TSAT<10% 0.71 (0.54, 0.95) 
1Children with inflammation and malaria parasitaemia at baseline were excluded. 
2Indicates incidence rate ratio of parasitaemia recalculated as inverse of what was reported (1.60 (0.90, 2.86)). Ferritin concentrations were corrected for baseline 
inflammation (measured using alpha 1-acid glycoprotein) and malaria. 
CRP, C-reactive protein; ID, Iron deficiency; TSAT, transferrin saturation.  
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Figure 5.9. Meta-analysis of observational studies examining the relationship between 
iron deficiency and malaria risk. 
Study-specific estimates and their relative contribution (percentage weight and sample size) to 
overall estimates are shown. Definitions of iron deficiency varied by study as shown in Table 
5.4. 
 
5.5 Discussion 
In this chapter, I report observational analyses of the influence of iron status on subsequent risk 
of malaria in 2683 Kenyan and Ugandan children. I found that iron deficiency, defined using 
either low ferritin or TSAT levels, and iron deficiency anaemia were associated with a lower 
risk of subsequent malaria episodes. However, anaemia (or haemoglobin concentrations), and 
concentrations of hepcidin and sTfR were not significantly associated with variation in risk of 
malaria. 
 
In agreement with these findings, previous observational studies (Table 5.4) have reported that 
iron deficiency based on low ferritin concentrations confers protection against malaria 
infection in African children (Nyakeriga et al., 2004; Gwamaka et al., 2012; Jonker et al., 2012; 
Barffour et al., 2017; Moya-Alvarez et al., 2017). In these studies, the protection ranged from 
23% to 45%. These estimates are similar to my finding of a 30% reduction in malaria risk in 
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iron deficient children aged 0 - 7 years) although length of follow-up differed from that of 
(Jonker et al., 2012) and (Gwamaka et al., 2012). In a meta-analysis of the current analyses 
and previous studies, I observed that iron deficiency based on low ferritin concentrations is 
associated with a 34% reduction in malaria risk. 
 
I further found that iron deficiency defined by TSAT was associated with a 20% reduction in 
the subsequent risk of malaria and TSAT was positively associated with malaria incidence. 
Similarly, (Nyakeriga et al., 2004) reported a 30% reduction in clinical malaria among iron 
deficient Kenyan children using a combination of low TSAT and low ferritin. In support of 
these findings, P. falciparum has been demonstrated to obtain iron from transferrin using in 
vitro parasite culture (Pollack and Fleming, 1984). Furthermore, (Clark et al., 2013) 
demonstrated that parasitised red blood cells utilise serum iron. These in vitro studies suggest 
that increasing bioavailable transferrin-bound iron through iron supplementation may 
predispose an individual to increased risk of malaria. This may explain my finding that higher 
TSAT, which I calculated using serum iron and transferrin, may increase malaria risk in 
children. 
 
There are a number of possible mechanisms through which iron deficiency may protect from 
malaria risk. Iron deficient human erythrocytes are poorly infected by P. falciparum compared 
to those that are iron replete and this protective effect is reversed by iron supplementation in in 
vitro parasite cultures (Clark et al., 2014). In mouse models, (Matsuzaki-moriya et al., 2011) 
showed that during iron deficiency, macrophages cleared parasitised erythrocytes more 
efficiently suggesting that either erythrocytes produced under iron deficient conditions are 
easily phagocytosed by macrophages or that macrophage function may be enhanced during 
iron deficiency. Moreover, iron deficiency has also been shown to up-regulate nitric oxide 
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which has anti-parasitic properties against Plasmodium parasites (Fritsche et al., 2001). 
Another possible explanation is that during iron deficiency, zinc is incorporated in place of 
iron during haem synthesis leading to formation of zinc protoporphyrin that in turn is thought 
to inhibit formation of haemozoin, the parasite survival pigment, in a manner similar to 
quinolines (Iyer et al., 2003). These possible mechanisms may explain how iron deficiency 
might protect against risk of malaria infection. 
 
Anaemia (or haemoglobin concentration) was not associated with subsequent malaria risk in 
my analyses. Similar observations have been reported by two previous studies. Haemoglobin 
concentrations were not associated with subsequent malaria infection in a longitudinal study in 
Papua New Guinean infants aged three months and followed-up for one year (Lombardo et al., 
2017). A similar observation was made by (Ghosh et al., 1995) in Indian children. My findings 
and those from these previous studies show that anaemic children have a non-significant 
increase in malaria risk rather than protection from malaria. Contrary to these findings, 
(Goheen et al., 2016) reported that anaemia was associated with decreased in vitro growth rate 
of P. falciparum. However, it is possible that in vitro parasite growth rate might not mimic 
direct malaria susceptibility for children. Moreover, haemoglobin has low sensitivity and 
specificity in determining body iron status due to the overlap of values in iron deficient and 
replete individuals (Cook and Smith, 1976) and the multiple overlapping causes of anaemia in 
African children (Foote et al., 2013). It also remains unclear whether the malaria parasite 
utilises haem iron in haemoglobin or has other sources and mechanisms of iron acquisition. In 
mice, knock-out of FPN gene caused accumulation of iron within red blood cells and increased 
parasite density (Zhang et al., 2018). There are suggestions that the parasite may utilise storage 
iron since bioavailable iron content increases in parasitised red blood cells as the parasite 
develops from ring stage to schizont (Clark et al., 2013).  
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I hypothesised that raised hepcidin concentrations may reduce malaria risk through 
sequestering iron within macrophages and enterocytes (Nemeth, Tuttle, et al., 2004), thereby 
starving liver-stage Plasmodium (Portugal et al., 2011). Since the parasite requires iron for 
growth, it has been suggested that withholding iron from hepatocytes inhibits the development 
of malaria (Portugal et al., 2011). Furthermore, high cord blood hepcidin has been associated 
with decreased risk of clinical malaria although not parasitaemia or severe malaria in 
Tanzanian infants (Brickley et al., 2016). However, in agreement with my analyses, an 
independent cohort of Kenyan children (Atkinson et al., 2015), found no association between 
hepcidin concentrations and subsequent clinical malaria episodes. Differences in age or 
environmental factors may account for the different findings. Moreover, a possible protective 
role of hepcidin may be countered by the high prevalence of iron deficiency that I observed in 
this population. Iron deficiency is normally associated with decreased hepcidin (Atkinson et 
al., 2014) and is protective against malaria risk. In fact, I observed a trend towards a positive 
association between hepcidin concentrations and malaria risk. Hepcidin may increase malaria 
risk through degradation of erythrocytic ferroportin, which leads to accumulation of iron within 
erythrocytes and thus may favour intraerythrocytic proliferation of malaria parasites (Zhang et 
al., 2018). Moreover, hepcidin may increase spread of the malaria parasites to other red blood 
cells since accumulation of iron leads to increased oxidative stress and haemolysis (Zhang et 
al., 2018). 
 
I found that a child’s erythropoietic drive (as indicated by sTfR) did not influence their 
subsequent risk of malaria infection. The expression of sTfR increases with both iron 
deficiency and expanded erythropoiesis (with the latter being more influential) (Beguin, 2003), 
factors that might have opposing effects on malaria risk. For example, increased erythropoiesis 
may increase malaria risk since Plasmodium parasites preferentially infect young red blood 
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cells  (Pasvol, Weatherall and Wilson, 1980), whereas iron deficiency may be protective. These 
opposing effects could explain why sTfR concentrations were not associated with malaria risk 
in my analyses. Reverse causality is also possible since malaria itself causes increased sTfR 
concentrations (Verhoef et al., 2001; Beguin, 2003) although the effect did not change after 
exclusion of individuals with malaria episodes at baseline. 
There were limitations and strengths in my analyses. A major challenge in these analyses is 
that iron biomarkers are themselves influenced by infections and inflammatory processes 
which may confound the effect of iron status on malaria infection as shown in Chapter Three. 
To mitigate the potential confounding effects of infection on iron biomarkers, I excluded 
children with inflammation or malaria parasitaemia at the time of iron measurement in 
secondary analyses and observed similar results (Figure 5.6). I additionally, adjusted for other 
potential confounders such as age, sex, length of follow-up and study site in regression models. 
Furthermore, the protective effect was consistent across age groups and did not change 
following additional adjustment for sickle cell trait. My analyses were also limited by a lack of 
TSAT concentrations in Ugandan children. Strengths of my analyses included its large size 
(n=2,683 children) across two study populations and that I used multiple iron biomarkers in 
order to determine their individual effects on malaria risk making it the largest and most 
definitive observational study to address the question of iron status and risk of malaria 
infection.  
 
5.6 Conclusion 
These findings, in agreement with other studies, suggest that iron deficiency protects children 
against malaria infection and thus that improving iron status may predispose African children 
to infection. Interestingly, of the iron biomarkers, only higher concentrations of ferritin and 
TSAT were predictive of increased rates of subsequent malaria, perhaps reflecting differences 
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in their relationship to parasite mechanisms of iron acquisition.  Although WHO recommends 
iron supplementation coupled with malaria treatment and prevention strategies in malaria 
endemic areas (World Health Organization, 2016), these strategies remain difficult to 
implement. Thus, it is important to establish whether improved iron status increases malaria 
risk since this would necessitate long-term malaria prevention and treatment programs. 
However, these findings and that of other studies do not necessarily prove causality since 
observational studies may be subject to confounding and reverse causation, for example, prior 
malaria exposure might lead to both iron deficiency and the acquisition of protective immunity 
against malaria, while malaria itself increases ferritin concentrations. Since iron deficiency 
prevents children from reaching their developmental potential it is important to establish 
causality in the iron-malaria relationship. Thus, these data warrant further large-scale studies, 
including Mendelian randomisation studies, which utilise genetic variants associated with iron 
status to infer causality or prospective randomised controlled trials. 
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CHAPTER SIX: FERROPORTIN Q248H IS ASSOCIATED WITH PROTECTION 
AGAINST IRON DEFICIENCY AND ANAEMIA BUT NOT MALARIA 
The material in this chapter forms the basis of a published paper in Science Advances entitled 
“The ferroportin Q248H mutation protects from anemia, but not malaria or bacteremia”, in 
which I was the first author. 
 
6.1 Abstract 
Introduction: Ferroportin is the sole known iron exporter in mammals. Recently, ferroportin 
was shown to export iron from mature red blood cells and deletion of the FPN gene resulted in 
haemolytic anaemia and increased parasite density and deaths in malaria-infected mice. The 
FPN Q248H mutation renders ferroportin partially resistant to hepcidin-induced degradation 
and was associated with protection from malaria in a study of limited size. I therefore aimed to 
determine whether the FPN Q248H mutation influences iron status and malaria infection in 
African children. 
Methods: I used data for 3374 children aged from 3 months to 7 years from community-based 
cohorts in Kenya, Uganda, Burkina Faso, South Africa, and The Gambia, and 11,982 children 
from severe malaria (case-control) studies in The Gambia, Malawi, Kenya, and Ghana.  I fitted 
regression models to determine the effect of the FPN Q248H mutation on iron status, anaemia, 
and malaria infection.  
Results: Overall, the prevalence of the FPN Q248H mutation (homozygotes and heterozygotes) 
was 10.5% but varied by study site ranging from 8.6% in Uganda to 16.5% in South Africa. 
The FPN Q248H mutation was associated with a trend towards improved iron status with a 
23% reduced odds of iron deficiency (OR = 0.77; 95% CI 0.60, 0.99; P = 0.046), and a 25% 
reduced odds of anaemia (OR = 0.75; 0.57, 0.98; P = 0.037). There was little evidence of 
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protection against either uncomplicated malaria (OR = 1.06 (0.68, 1.64; P = 0.79) or severe 
malaria (OR = 0.91; 95% CI 0.81, 1.01; P = 0.08). 
Conclusion: The ferroportin Q248H variant was associated with modest protection against iron 
deficiency and anaemia but there was little evidence of protection against malaria. Moreover, 
the mutation does not seem to have been selected due to malaria exposure as it occurred in 
highest frequency in South Africa, a cohort with no malaria historically. 
 
6.2 Introduction 
Malaria parasites and other infectious pathogens require iron to grow and multiply. The human 
host has therefore evolved mechanisms to withhold iron from pathogens using iron-binding 
and chaperone transport proteins (Barber and Elde, 2014). Ferroportin, the only known iron 
exporter is highly expressed in duodenal enterocytes, hepatocytes, and splenic macrophages to 
allow iron absorption, storage and recycling (Donovan et al., 2000). The iron hormone, 
hepcidin, regulates ferroportin in response to iron status, erythropoiesis, and inflammation. 
Hepcidin occludes and degrades ferroportin thereby reducing cellular iron export (Nemeth, 
Tuttle, et al., 2004; Aschemeyer et al., 2018). A recent study showed that ferroportin is also 
abundantly expressed on mature red blood cells and that knock-out of the FPN gene resulted 
in the accumulation of excess intracellular iron, haemolytic anaemia and increased parasite 
density and death in malaria-infected mice (Zhang et al., 2018). 
 
FPN Q248H, a mutation in the FPN gene in humans, may increase cellular iron export by 
rendering ferroportin partially resistant to hepcidin degradation (Nekhai et al., 2013). However, 
some studies have shown that the Q248H impairs cellular iron export (McGregor et al., 2005) 
or has no functional effect (Drakesmith et al., 2005; Schimanski et al., 2005). Furthermore, 
previous studies with limited sample sizes, have found conflicting associations between Q248H 
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and haemoglobin concentrations (Beutler et al., 2003; Gordeuk et al., 2003; McNamara, 
Gordeuk and MacPhail, 2005; Masaisa et al., 2012; Zhang et al., 2018) or with iron deficiency 
(Beutler et al., 2003; Gordeuk et al., 2003; Kasvosve et al., 2005, 2010, 2015; Rivers et al., 
2007; Nekhai et al., 2013; Cikomola et al., 2017).  
 
The Q248H mutation occurs mainly in African populations and it has been hypothesised that 
the mutation has been positively selected due to protection from malaria (Zhang et al., 2018) 
(reviewed in Chapter One). By increasing cellular iron export, FPN Q248H may deprive P. 
falciparum, an intracellular pathogen, of iron, limiting its survival. In a recent study, (Zhang et 
al., 2018) reported that Q248H mutation is associated with lower P. falciparum parasite density 
compared to the wild type allele in a small sample size of Zambian children and primiparous 
Ghanaian women. Moreover, (Zhang et al., 2018) included only children with uncomplicated 
malaria without matched controls and therefore could not assess malaria risk. In this Chapter, 
I investigated whether the Q248H mutation is associated with protection from iron deficiency, 
anaemia, and malaria infection using large-scale datasets of African children. 
 
6.3. Methods 
6.3.1 Study populations 
To test the effect of FPN Q248H mutation on iron status, anaemia and uncomplicated malaria, 
I used data from community-based cohorts in Kilifi, Kenya; Entebbe, Uganda; Soweto, South 
Africa; Banfora, Burkina Faso; and West Kiang, The Gambia. These studies are described in 
Chapter Two Section 2.1. In this Chapter, I also analysed haptoglobin concentrations that were 
measured in The Gambia only using the Tina Quant Haptoglobin Kit, Roche Diagnostics, 
Cobas Bio centrifugal analyzer. I further tested the effect of the FPN Q248H mutation on the 
risk of severe malaria using case-control data of severe malaria in children from Kenya, 
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Malawi, The Gambia, and Ghana recruited as part of MalariaGEN  
(https://www.malariagen.net/data/genome-wide-study-resistance-severe-malaria-eleven-
populations). Severe malaria was diagnosed as P. falciparum parasites in the blood film plus 
clinical features of severe malaria including haemoglobin <5g/dL / haematocrit level of <15% 
(for severe malarial anaemia) or Blantyre coma score of <3 (for cerebral malaria) (Malaria 
Genomic Epidemiology Network, 2014). With the help of Dr Gavin Band, a member of the 
MalariaGEN consortium and based at the University of Oxford, I retrieved the Q248H mutation 
from the MalariaGEN genome-wide association study datasets and analysed the effect of the 
mutation on severe malaria in the Kenyan dataset. Analyses for Malawi, The Gambia, and 
Ghana severe malaria datasets were performed by Dr Gavin Band and are reproduced in this 
thesis with permission as published in (Muriuki, Mentzer, Band, et al., 2019).  
 
6.3.2 Statistical analysis 
In all community-based cohorts, I conducted all statistical analyses using STATA 13.0 
(StataCorp., College Station, TX). I normalised individual iron markers by ln-transformation. 
I compared proportions between groups by Chi-square or Fisher’s exact test where appropriate, 
and continuous variables by Student´s t-test or Mann Whitney U test. I fitted linear and logistic 
regression models adjusting for age, sex and cohort. I performed meta-analyses using the 
‘metan’ package in STATA. Analyses of MalariaGEN severe malaria data were undertaken 
using logistic regression in R and multinomial regression in SNPTEST (version 2.5) 
respectively. For the malaria case-control analysis undertaken for trios in Ghana, a transmission 
disequilibrium test was undertaken using the ‘trio’ package in R. In all analyses, I assumed a 
dominant model, comparing Q248H heterozygote and homozygote carriers to non-carriers 
since there were very few homozygotes for any meaningful analyses. A p-value of <0.05 was 
considered significant and all p-values reflect a two-tailed test. I also conducted a literature 
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review and meta-analysis of all published papers reporting association between Q248H and 
iron status, anaemia, or inflammation. 
 
6.4 Results  
6.4.1 Characteristics of study participants 
Table 6.1 shows the characteristics of the community-based populations included in this study. 
I tested for associations between the FPN Q248H mutation and anaemia and measures of iron 
status among 3374 children aged from 3 months to 7 years from community-based cohorts in 
Uganda, The Gambia, Burkina Faso, Kenya, and South Africa. Overall, the Q248H mutation 
was observed among 10.5% of children (n = 355 Q248H carriers, 342 heterozygotes and 13 
homozygotes combined assuming a dominant mode of action). In the MalariaGEN severe 
malaria case-control datasets, there were a total of 11,982 children, 5489 hospitalised patients 
with severe malaria (n = 658 Q248H carriers) and 6493 matched controls (n = 1519 Q248H 
carriers) from The Gambia, Malawi, Kenya, and Ghana. 
 
Where appropriate, I used Chi-square, Fisher’s exact or Student´s t tests to explore the 
relationship between iron status / anaemia and Q248H mutation (Table 6.1).  I observed a trend 
towards improved iron status in children carrying the Q248H mutation compared to wild type 
across the study sites (Table 6.1).  
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Table 6.1. Characteristics of participants by study cohort and FPN Q248H mutation 
 Uganda The Gambia South Africa Burkina Faso Kenya 
 Q248H (n=117) 
WT 
(n=1248) 
P Q248H 
(n=71) 
WT 
(n=675) 
P Q248H 
(n=102) 
WT 
(n=518) 
P Q248H 
(n=34) 
WT 
(n=313) 
P Q248H 
(n=31) 
WT 
(n=265) 
P 
Median age in years 
(IQR) 
2.0 (2.0-3.0) 2.0 (2.0-3.0) 0.90 3.8 (2.9-4.5) 3.8 (2.9-4.9) 0.56 1.0 (1.0-1.0) 1.0 (1.0-1.0) 0.35 1.9 (1.6-2.1) 1.9 (1.7-2.2) 0.32 4.2 (2.1-6.1) 4.1 (2.3-6.0) 0.87 
Females, n (%) 49 (41.9) 622 (49.8) 0.10 32 (45.1) 315 (46.7) 0.80 46 (45.1) 253 (48.8) 0.49 18 (52.9) 154 (49.2) 0.68 13 (41.9) 127 (47.9) 0.53 
Iron deficiency, n (%)1 38 (34.2) 397 (34.6) 0.94 11 (15.7) 149 (22.1) 0.22 34 (33.3) 222 (42.9) 0.07 11 (36.7) 104 (35.5) 0.90 4 (33.3) 61 (57.0) 0.12 
Anaemia, n (%)2 36 (33.6) 493 (41.2) 0.13 32 (46.4) 377 (56.3) 0.12 n/a n/a NA 24 (77.4) 263 (88.0) 0.10 19 (63.3) 172 (65.4) 0.82 
IDA, n (%)3 15 (14.7) 197 (17.9) 0.42 8 (11.8) 109 (16.3) 0.33 n/a n/a NA 8 (29.6) 88 (31.3) 0.86 4 (36.4) 41 (39.1) 0.57 
Haemoglobin, g/dL 11.2 (1.1) 11.0 (1.1) 0.26 10.8 (1.1) 10.5 (1.1) 0.12 n/a n/a NA 9.8 (1.1) 9.5 (1.1) 0.10 10.6 (1.1) 10.2 (1.2) 0.34 
MCHC, g/dL 33.0 (1.0) 32.9 (1.0) 0.72 n/a n/a NA n/a n/a NA n/a n/a NA 33.5 (1.1) 32.4 (1.1) 0.001 
MCV, fL 70.6 (1.1) 71.1 (1.1) 0.51 75.3 (1.1) 75.6 (1.1) 0.72 n/a n/a NA n/a n/a NA 76.5 (1.1) 73.5 (1.1) 0.07 
Haptoglobin, µmol/L n/a n/a NA 71.1 (3.5) 69.6 (3.0) 0.04 n/a n/a NA n/a n/a NA n/a n/a NA 
Ferritin, µg/L 20.9 (2.4) 19.6 (2.9) 0.54 29.4 (2.5) 24.8 (2.4) 0.13 17.4 (2.5) 14.5 (2.6) 0.08 22.1 (3.0) 22.0 (2.3) 0.98 19.2 (3.8) 12.2 (3.4) 0.23 
Hepcidin, µg/L 7.2 (3.2) 6.7 (3.3) 0.60 12.2 (4.0) 11.2 (4.7) 0.68 9.4 (2.9) 7.4 (3.6) 0.08 6.0 (4.3) 5.3 (4.2) 0.62 3.7 (4.6) 3.8 (3.9) 0.93 
sTfR, mg/L 6.6 (1.9) 6.8 (2.0) 0.80 3.4 (1.5) 3.4 (1.4) 0.99 10.4 (1.5) 10.8 (1.5) 0.36 16.3 (1.8) 17.9 (1.7) 0.36 16.7 (1.7) 14.9 (1.5) 0.37 
Iron, µmol/L n/a n/a NA 9.0 (1.7) 8.6 (1.6) 0.46 n/a n/a NA 6.4 (1.6) 6.0 (1.8) 0.55 3.5 (2.3) 2.7 (3.1) 0.41 
Transferrin, g/L 2.7 (1.3) 2.7 (1.3) 0.90 n/a n/a NA 2.5 (1.3) 2.7 (1.3) 0.06 2.7 (1.2) 2.7 (1.3) 0.81 2.9 (1.2) 3.0 (1.2) 0.37 
TSAT, % n/a n/a NA 13.3 (1.8) 12.8 (1.7) 0.58 n/a n/a NA 9.5 (1.8) 8.9 (2.0) 0.59 3.7 (2.6) 3.4 (3.4) 0.81 
ZPP, µmol/mol haem n/a n/a NA 97.4 (1.8) 114.6 (1.8) 0.03 n/a n/a NA n/a n/a NA n/a n/a NA 
CRP/ACT, mg/L/g/L 1.1 (4.6) 1.4 (5.2) 0.11 0.5 (1.3) 0.4 (1.3) 0.12 0.8 (5.4) 0.9 (4.9) 0.86 2.2 (5.3) 2.9 (6.2) 0.41 1.2 (4.5) 1.1 (4.8) 0.86 
Values are geometric means (±SD) for the various biomarkers. Proportions were compared between groups by Chi-square or Fisher’s exact test where appropriate, and continuous variables by Student´s t-test or Mann Whitney U test (Age). 
Q248H includes both heterozygotes and homozygotes. 
1Iron deficiency defined as plasma ferritin < 12µg/L or < 30µg/L in the presence of inflammation (C-reactive protein >5mg/L α1-antichymotrypsin >0.6g/L in The Gambia) in children < 5 years or < 15µg/L in children >= 5 years 
2Anaemia defined as hemoglobin < 11g/dL 
3IDA, iron deficiency anaemia defined as iron deficiency and anaemia 
ACT, α1-antichymotrypsin; CRP, C-reactive protein; IQR, interquartile range; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; sTfR, soluble transferrin receptor; TSAT, transferrin saturation; ZPP, zinc 
protoporphyrin; n/a, not available; NA, not applicable; WT, wild type. 
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6.4.2 FPN Q248H is associated with modest protection against anaemia 
In regression analyses, I first evaluated the effect of the mutation on the risk of anaemia in 
2666 children with haemoglobin measurements. In pooled analyses, the prevalence of anaemia 
(Hb < 11g/dl) was lower in Q248H children (46.8%) compared to those carrying the wild type 
(53.7%; OR = 0.75; 0.57, 0.98; P = 0.037; Figure 6.1A, Table 6.2). Mean haemoglobin 
concentrations were 0.22 g/dL higher in Q248H children compared to WT (10.81 g/dl vs. 10.59 
g/dl; P = 0.036) (Figure 6.1B, Table 6.2).  
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Figure 6.1. Association between FPN Q248H mutation and anaemia, red cell haemolysis 
and iron deficiency (ID). 
The Q248H mutation renders ferroportin partially resistant to hepcidin degradation (4) 
increasing iron export through enterocytes, erythrocytes and macrophages. The effects of 
Q248H on (A) anaemia, (B) haemoglobin, (C) mean corpuscular haemoglobin concentrations 
(MCHC), (D) haptoglobin, (E) iron deficiency (ID) (F) transferrin saturation, (G) hepcidin, 
(H) ferritin, (I) soluble transferrin receptors (sTfR), (J) zinc protoporphyrin (ZPP), and (K) 
inflammation indicate reduced haemolysis, limited effect on iron status and no association with 
inflammation. Plotted values are geometric means except anaemia, iron deficiency and 
inflammation, which are percentages. All P values were two-tailed and derived from regression 
models adjusted for age, sex and cohort. I drew this diagram and it is reproduced from 
(Muriuki, Mentzer, Band, et al., 2019). 
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Table 6.2. Association between FPN Q248H mutation and anaemia, haemolysis, and 
iron deficiency in community-based children  
 Q248H1  WT   
Category All, n Q248H, n n (%) 
 WT, 
n n (%) OR (95% CI) P value 
Anaemia2 2666 237 111 (46.8)  2429 1305 (53.7) 0.75 (0.57, 0.98) 0.037 
Iron deficiency3 3065 325 98 (30.2)  2740 933 (34.1) 0.77 (0.60, 0.99) 0.046 
Iron deficiency 
anaemia4 2363 208 35 (16.8) 
 2155 435 (20.2) 0.77 (0.52, 1.14) 0.19 
Inflammation5 3149 334 66 (19.8)  2815 587 (20.9) 0.94 (0.70, 1.25) 0.65 
Biomarkers All, n Q248H, n 
Geometric  
mean (SD) 
 WT, 
n 
Geometric  
mean (SD) 
Estimate  
(95% CI) P value 
Haemoglobin, g/dL 2666 237 10.81 (1.15)  2429 10.59 (1.16) 0.21 (0.01, 0.40) 0.036 
MCHC, g/dL 1537 131 33.10 (1.04)  1406 32.87 (1.04) 0.27 (0.05, 0.50) 0.017 
MCV, fL 2324 205 72.98 (1.12)  2119 72.76 (1.12) 0.16 (-0.87, 1.19) 0.76 
Haptoglobin, µmol/L 587 50 133.22 (1.98)  537 109.32 (1.87) 0.20 (0.02, 0.38) 0.030 
Ferritin, µg/L 3065 325 20.80 (2.53)  2740 20.03 (2.84) 0.08 (-0.03, 0.20) 0.16 
Hepcidin, µg/L 3080 319 8.31 (3.48)  2761 7.33 (3.87) 0.14 (-0.02, 0.30) 0.089 
sTfR, mg/L 3091 325 11.98 (1.66)  2766 13.30 (1.67) -0.07 (-0.16, 0.01) 0.088 
Iron, µmol/L 459 45 5.45 (1.91)  414 4.83 (2.35) 0.14 (-0.10, 0.37) 0.25 
Transferrin, g/L 2380 258 2.62 (1.28)  2122 2.70 (1.27) -0.06 (-0.14, 0.02) 0.14 
TSAT, % 430 40 7.89 (2.13)  390 6.95 (2.62) 0.09 (-0.18, 0.36) 0.52 
ZPP, µmol/mol haem 684 66 97.43 (1.80)  618 114.63 (1.77) -0.17 (-0.31, -0.03) 0.018 
CRP, mg/L 2403 263 1.08 (5.07)  2140 1.35 (5.44) -0.19 (-0.41, 0.02) 0.079 
ACT, g/L 737 68 0.47 (1.34)  669 0.44 (1.30) 0.05 (-0.01, 0.12) 0.12 
1Heterozygotes and homozygotes 2Anaemia was defined as haemoglobin < 11g/dL. 3Iron deficiency was defined as plasma ferritin < 12µg/L or < 30µg/L in the presence of inflammation in children < 5 years or < 15µg/L 
in children >= 5 years. 4Iron deficiency anaemia was defined as iron deficiency with anaemia. 5Inflammation was defined as C-reactive protein >5mg/L or α1-antichymotrypsin >0.6g/L in The Gambia. 
Analyses were adjusted for age, sex and country.  
ACT, α1-antichymotrypsin; CRP, C-reactive protein; MCHC, mean corpuscular haemoglobin concentration; MCV, mean corpuscular 
volume; sTfR, soluble transferrin receptor; TSAT, transferrin saturation; ZPP, zinc protoporphyrin 
 
Since pooling datasets from different populations or assays may be influenced by 
heterogeneity, I then performed a meta-analysis of cohort-specific associations between the 
Q248H mutation and anaemia and haemglobin concentrations. FPN Q248H mutation 
consistently increased haemoglobin concentrations and was protective against anaemia across 
the study populations (Figures 6.2; I2 = 0.0%). I also meta-analysed the pooled estimate of the 
current study and previous published studies (Table 6.3 and Figure 6.3). Overall, the mutation 
was associated with higher haemoglobin concentrations compared to wild type (Figure 6.3). I 
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similarly observed higher mean corpuscular haemoglobin concentrations (MCHC) in children 
carrying Q248H compared to WT (P = 0.017, Figure 6.1C), but no evidence of a difference in 
mean corpuscular volume (MCV) (Table 6.2). I hypothesised that the modestly increased 
haemoglobin concentrations and MCHC observed in Q248H carriers could be due to reduced 
haemolysis and / or improved iron status. 
 
Figure 6.2. Meta-analysis of associations of the FPN Q248H mutation with anaemia and 
haemoglobin across the study populations. 
Labels indicate odds ratios or estimates and 95% confidence intervals. Haemoglobin 
measurements were not available for the South African cohort. Regression models were 
adjusted for age and sex. OR, Odds Ratio; ES, Effect Size.
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Table 6.3. Summary of studies examining the relationship between the FPN Q248H mutation and haemoglobin, ferritin, and C-reactive protein 
Study Country Age Sample size Q248H, n WT, n Summary statistic Q248H Wild Type (WT) 
Haemoglobin, g/dl         
(Gordeuk et al., 2003)1 South Africa and Swaziland Adults 51 7 44 Mean (±SD) 12.5 (±1.3) 13.7 (±1.3) 
(Beutler et al., 2003)2, males  USA - African Americans Adults 276 25 251 Mean (±SD) 14.2 (±1.5) 14.5 (±1.6) 
(Beutler et al., 2003), females  USA - African Americans Adults 293 40 253 Mean (±SD) 12.5 (±1.3) 12.6 (±1.6) 
(McNamara, Gordeuk and MacPhail, 2005)2  South Africa Adults 217 53 164 Mean (±SD) 13.6 (±1.5) 13.5 (±1.3) 
(Masaisa et al., 2012)3 Rwanda Women 200 12 188 Mean (±SD) 13.1 (±3.4) 12.4 (±2.9) 
(Zhang et al., 2018) Zambia Children 66 13 53 Mean (±SD) 9.2 (±2.5) 9.5 (±2.2) 
(Zhang et al., 2018) Ghana Women 290 25 265 Mean (±SD) 11.5 (±1.5) 11.2 (±1.9) 
(Kasvosve et al., 2010) Zimbabwe Children 59 13 46 Median (IQR) 11.2 (10.6, 12.0) 10.9 (10.3, 11.5) 
Current study4 Across Africa Children 2666 237 2429 Mean (±SD) 10.8 (±1.1) 10.6 (±1.2) 
Ferritin, ng/ml or µg/L       
 
 
(Gordeuk et al., 2003) South Africa and Swaziland Adults 51 7 44 Geometric mean (95% CI) 63.0 (40.0, 100.0) 35.0 (29.0, 42.0) 
(Beutler et al., 2003), males  USA - African Americans Adults 276 25 251 Geometric mean (95% CI) 141.8 (93.9, 214.4) 158.4 (141.3, 177.5) 
(Beutler et al., 2003), females  USA - African Americans Adults 293 40 253 Geometric mean (95% CI) 62.9 (40.5, 97.9) 51.2 (44.4, 59.0) 
(Kasvosve et al., 2005) Zimbabwe Children 195 38 157 Geometric mean (95% CI) 32.0 (27.0, 39.0) 21.0 (19.0, 23.0) 
(McNamara, Gordeuk and MacPhail, 2005) South Africa Adults 217 53 164 Geometric mean (95% CI) 163.0 (138.0, 193.0) 131.0 (119.0, 144.0) 
(Katchunga et al., 2013), controls  DRC Adults 86 7 79 Geometric mean (95% CI) 105.3 (92.3, 186.7) 128.3 (65.1, 228.7) 
(Katchunga et al., 2013), diabetic  DRC Adults 179 25 154 Geometric mean (95% CI) 214.4 (121.2, 309.1) 183.6 (97.1, 292.6) 
(Nekhai et al., 2013)5 USA Adults 78 9 69 Geometric mean (95% CI) 88.0 (29.0, 273.0) 211.0 (74.0, 602.0) 
(Kasvosve et al., 2010) Zimbabwe Children 64 14 50 Median (IQR) 17.0 (11.0, 29.0) 20.0 (10.0, 33.0) 
(Masaisa et al., 2012) Rwanda Women 200 12 188 Median (IQR) 295.0 (179.0, 363.0) 74.9 (47.2, 118.0) 
(Kasvosve et al., 2015)6, males  Botswana Adults 84 14 70 Median (IQR) 127.4 (97.2, 192.5) 79.7 (50.6, 137.0) 
(Kasvosve et al., 2015), females  Botswana Adults 74 12 62 Median (IQR) 47.4 (22.2, 83.8) 38.5 (24.1, 68.1) 
(Cikomola et al., 2017) DRC Adults 42 15 27 Median (IQR) 211.0 (142.0, 476.0) 228.0 (115.0, 540.0) 
Current study Across Africa Children 3065 325 2740 Geometric mean (95% CI) 20.8 (18.8, 23.0) 20.0 (19.3, 20.8) 
C-reactive protein, mg/L 
        
(Masaisa et al., 2012) Rwanda Women 200 12 188 Mean (±SD) 5.2 (±2.0) 4.8 (±1.2) 
(McNamara, Gordeuk and MacPhail, 2005) South Africa Adults 217 53 164 Geometric mean (95% CI) 4.5 (4.0, 5.1) 2.7 (2.5, 2.9) 
(Kasvosve et al., 2005) Zimbabwe Children 195 38 157 Median (IQR) 0.8 (0.3, 2.8) 0.6 (0.1, 2.5) 
(Kasvosve et al., 2010) Zimbabwe Children 64 14 50 Median (IQR) 1.0 (0.3, 2.0) 0.5 (0.1, 2.0) 
Current study Across Africa Children 2403 263 2140 Geometric mean (95% CI) 1.1 (0.9, 1.3) 1.4 (1.3, 1.5) 
1I used community controls. I calculated standard deviation from the provided standard error. 2Participants had iron overload. I calculated standard deviation from the provided standard error. 3HIV positive women. 4The current study included data from Kenya, Uganda, South Africa, Burkina Faso and The Gambia. 5The study included patients with sickle cell anaemia and transfused <5 units of blood. 6The study analysed data for those with serum ferritin ≥10ng/mL and ≤200ng/mL. 
CI, confidence interval; DRC, Democratic Republic of Congo; IQR, interquartile range; SD, standard deviation; USA, United States of America. 
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Figure 6.3. A meta-analysis of studies investigating the relationship between the FPN 
Q248H mutation and haemoglobin levels. 
The current study included Ugandan, Gambian, Burkinabe, and Kenyan children. Table 1 gives 
more details of the studies included in the meta-analysis. The grey boxes indicate sample size. 
SA, South Africa; AA, African-American; SMD, standardised mean difference. 
 
To test the hypothesis that higher haemoglobin concentrations among Q248H children may be 
due to reduced haemolysis, I used data for haptoglobin concentrations in 587 Gambian children 
aged 2 to 6 years. I observed that Q248H carriers (n = 50) had higher geometric mean 
haptoglobin concentrations compared with wild type (133.22 µmol/L vs. 109.32 µmol/L; β = 
0.20; 0.02, 0.38; P = 0.03) consistent with reduced haemolysis in Q248H children (Figure 6.1D, 
Table 6.2 above). These findings support the hypothesis that reduced haemolysis may 
contribute to the higher haemoglobin concentrations observed in Q248H children. 
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6.4.3 FPN Q248H is associated with protection against iron deficiency 
I further hypothesised that higher haemoglobin concentrations could be due to enhanced 
absorption and recycling of iron among Q248H carriers leading to improved iron status as 
previously observed in smaller studies (Table 6.3). Among 3065 children, 1031 (33.6%) were 
iron deficient. In pooled analyses, the Q248H variant (n = 325) was associated with a 23% 
reduction in the odds of iron deficiency (P = 0.046; comparing Q248H heterozygotes and 
homozygotes to non-carriers) and iron deficiency anaemia (P = 0.19, Table 6.2). I observed a 
trend towards improved iron status for individual measures of iron status among Q248H 
children, however with the exception of ZPP, a sensitive indicator of iron deficiency (P = 
0.018), none of the associations reached conventional statistical significance (Figure 6.1, Table 
6.2). In a meta-analyses of cohort specific associations of Q248H mutation and iron deficiency 
and ferritin, I observed a 30% protection from iron deficiency and higher ferritin concentrations 
in individuals carrying the mutation compared to the wild type (Figure 6.4). 
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Figure 6.4. Meta-analysis of associations of the FPN Q248H mutation with iron status 
across the study populations. 
Labels indicate odds ratios or estimates and 95% confidence intervals. Ferritin was 
normalised by ln-transformation. Regression models were adjusted for age and sex. OR, Odds 
Ratio; ES, Effect Size. 
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Since increased hepcidin expression is a major factor in the alteration of iron stores during 
inflammation, and Q248H ferroportin may be partially resistant to hepcidin (Nekhai et al., 
2013), I stratified analyses by inflammation (Figure 6.5A).  The prevalence of inflammation 
did not differ between Q248H and WT children (P = 0.65; Figure 6.1K, Table 6.2). After 
excluding children with inflammation, I observed a 30% reduction in the odds of iron 
deficiency and anaemia among Q248H carriers (n = 2409, adjusted OR = 0.7; 95% CI 0.5, 0.9; 
Figure 6.5A). Similarly, the mutation was associated with a significant increase in ferritin 
concentrations in individuals without inflammation (β = 0.1; 0.01, 0.2; P = 0.037) but not in 
individuals with inflammation (β = 0.02; -0.2, 0.3; P = 0.91). However, I found no significant 
interaction between the Q248H mutation and inflammation in predicting iron deficiency and 
anaemia. I further stratified by low and high hepcidin (using the absorption threshold of 5.5 
µg/L (Pasricha et al., 2014)) but found no evidence of an interaction or any effect after 
stratification (Figure 6.5B). Taken together these findings suggest, in agreement with some 
previous studies (Table 6.3), that the Q248H mutation is associated with modestly improved 
iron status in African children. 
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Figure 6.5. Effect of the FPN Q248H mutation on anaemia and iron deficiency stratified 
by inflammation and hepcidin concentrations. 
Solid circles indicate no inflammation; hollow circle, those with inflammation; solid diamond, 
hepcidin ≤5.5 µg/L; and hollow diamond, hepcidin >5.5 µg/L. Markers indicate the odds ratios 
while error bars indicate 95% confidence intervals and are labelled respectively. Regression 
models were adjusted for age, sex, and study site. 
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6.4.4 Little evidence that FPN Q248H is associated with protection from malaria 
It has been proposed that the FPN Q248H variant protects individuals from malaria (Zhang et 
al., 2018). The Q248H mutation was not significantly associated with severe malaria overall 
(OR = 0.91; 0.81, 1.01; for an effect of one or two copies of Q248H relative to wild type; P = 
0.08) or in individual cohorts (Table 6.4). Moreover, in subgroup analyses the Q248H mutation 
was not significantly associated with cerebral malaria (OR = 0.90; 0.77, 1.06; P = 0.21; 
estimated across cohorts), severe malarial anaemia (OR = 0.90; 0.71, 1.16; P = 0.42) or 
mortality (OR = 1.00; 0.78, 1.29; P = 0.99, Table 6.4). Inclusion of genotypes at the sickle-cell 
causing variant rs334, which is strongly associated with malaria susceptibility in these 
populations (Taylor, Parobek and Fairhurst, 2012), did not affect these results. The prevalence 
of uncomplicated malaria among community-based children also did not differ by Q248H (OR 
= 1.06; 95% CI 0.68, 1.64; P = 0.79; Table 6.4). Moreover, parasite density in children with 
either uncomplicated or severe malaria did not differ by the Q248H mutation (Figure 6.6). 
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Table 6.4. Association between FPN Q248H and uncomplicated or severe malaria 
Outcome All Q248H1 WT RR / OR (95% CI) P value 
Malaria susceptibility2      
Uncomplicated malaria 260/2550 (10.2%) 25/232 (10.8%) 235/2318 (10.1%) 1.06 (0.68, 1.64) 0.79 
Severe malaria3 5489/11982 (45.8%) 658/1519 (43.3%) 4831/10463(46.1%) 0.91 (0.81, 1.01) 0.08 
     (The Gambia4) 2419/4910 (49.3%) 225/479 (47.0%) 2194/4431 (49.5%) 0.88 (0.73, 1.07) 0.21 
     (Malawi4) 1023/2345 (43.6%) 174/419 (41.5%) 849/1926 (44.1%) 0.89 (0.72, 1.10) 0.28 
     (Kenya4) 1446/2924 (49.5%) 191/405 (47.2%) 1255/2519 (49.8%) 0.98 (0.79, 1.22) 0.87 
     (Ghana5) 601/1803 (33.3%) 68/216 (31.5%) 533/1587 (33.6%) 0.83 (0.59, 1.17) 0.29 
      
Cerebral malaria3 1948/7971 (24.4%) 249/1043 (23.9%) 1699/6928 (24.5%) 0.90 (0.77, 1.06) 0.21 
     (The Gambia4) 758/3676 (20.6%) 60/356 (16.9%) 698/3320 (21.0%) 0.73 (0.55, 0.99) 0.04 
     (Malawi4) 644/2057 (31.3%) 116/373 (31.1%) 528/1684 (31.4%) 0.95 (0.75, 1.22) 0.71 
     (Kenya4) 546/2238 (24.4%) 73/314 (23.2%) 473/1924 (24.6%) 1.00 (0.75, 1.34) 0.99 
      
Severe malarial anaemia3 735/7971 (9.2%) 82/1043 (7.9%) 653/6928 (9.4%) 0.90 (0.71, 1.16) 0.42 
     (The Gambia4) 428/3676 (11.6%) 43/356 (12.1%) 385/3320 (11.6%) 0.96 (0.68, 1.35) 0.82 
     (Malawi4) 91/2057 (4.4%) 12/373 (3.2%) 79/1684 (4.7%) 0.69 (0.37, 1.29) 0.24 
     (Kenya4) 216/2238 (9.7%) 27/314 (8.6%) 189/1924 (9.8%) 0.93 (0.60, 1.43) 0.74 
      
Malaria-related death3 677/4669 (14.5%) 86/571 (15.1%) 591/4098 (14.4%) 1.00 (0.78, 1.29) 0.99 
     (The Gambia4) 309/2335 (13.2%) 27/219 (12.3%) 282/2116 (13.3%) 0.91 (0.59, 1.39) 0.65 
     (Malawi4) 200/1018 (19.6%) 37/173 (21.4%) 163/845 (19.3%) 1.14 (0.76, 1.71) 0.51 
     (Kenya4) 168/1316 (12.8%) 22/179 (12.3%) 146/1137 (12.8%) 0.94 (0.58, 1.52) 0.80 
1Heterozygotes and homozygotes 
2Uncomplicated malaria was defined as P. falciparum positive slide measured in community-based cohorts in Uganda, The Gambia, 
Burkina Faso, and Kenya. Severe malaria was defined as positive for P. falciparum parasites plus clinical features of severe malaria (8), 
including diagnosis of cerebral malaria, severe malarial anaemia, and other clinical symptoms.  
3Relative risk, confidence interval, and P value are computed by fixed-effect meta-analysis of estimates from the three case-control 
cohorts and (where applicable) the Ghanaian trios. 
4Association analysis estimated by logistic regression adjusted for the first five principal components.  For severe malaria and malaria-
related death, results reflect binomial logistic regression of the phenotype compared to controls.  For severe malaria sub-phenotypes, 
results reflect multinomial logistic regression of cerebral malaria, severe malarial anaemia, and other severe malaria cases compared to 
controls. A dominant mode of effect is assumed. 
5Counts reflect numbers of probands (affected children) and parents in 608 Ghanaian trios.  Relative risk, confidence interval and P-
value are computed using a transmission disequilibrium test.  A dominant mode of effect is assumed. 
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Figure 6.6. Effect of FPN Q248H variant on P. falciparum parasite density. 
P. falciparum parasite densities in all community-based children with uncomplicated malaria 
and in hospitalised Kenyan children with severe malaria stratified by carriage of Q248H. 
Parasite densities are geometric means from log-transformed data. N = malaria cases. P 
values were derived from regression models adjusted for age and sex. *Q248H heterozygotes 
and homozygotes combined.
6.5 Discussion 
The FPN Q248H variant is prevalent in African populations, and is thought to have been 
naturally selected to confer protection against malaria by increasing iron export from red blood 
cells (Zhang et al., 2018). In this Chapter, I evaluated the effect of the Q248H mutation on 
anaemia, iron status, and malaria infection. I found that the mutation was associated with 
modest protection against anaemia and iron deficiency but little evidence that it protects against 
malaria infection. 
 
The Q248H mutation was associated with a modest reduction in the risk of anaemia and 
modestly improved haemoglobin concentrations. The Q248H variant has previously been 
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associated with trends towards both lower and higher haemoglobin concentrations in studies 
of small sample size (Figure 6.3 and Table 6.3). A meta-analysis of the current and previous 
studies indicates an overall increase in haemoglobin concentrations in Q248H carriers (Figure 
6.3). Higher haemoglobin concentrations might be due to higher iron efflux from Q248H 
erythrocytes protecting the cell from haemolysis (Zhang et al., 2018). Indeed, I observed higher 
concentrations of haptoglobin among Q248H carriers, suggesting reduced haemolysis. These 
findings are consistent with a previous report in a mouse model, which demonstrated that 
ferroportin, by reducing intracellular accumulation of iron and oxidant species, prevents 
haemolytic anaemia and maintains integrity of red blood cells (Zhang et al., 2018). 
 
I further hypothesised that reduced hepcidin-induced degradation of ferroportin among Q248H 
carriers might lead to improved iron absorption by duodenal enterocytes and iron recycling by 
macrophages. Consistent with this hypothesis, I observed a trend towards improved iron status 
among children carrying the mutation corroborating findings from other studies (Gordeuk et 
al., 2003; Kasvosve et al., 2005, 2015; Rivers et al., 2007). ZPP concentrations were also 
significantly lower among Q248H individuals suggesting no evidence for iron deficient 
erythropoiesis, as previously suggested (Zhang et al., 2018). These findings suggest that the 
Q248H mutation is associated with lower risk of iron deficiency. 
 
It has been proposed that FPN Q248H protects from malaria by depriving the parasite of iron 
within the red blood cell (Zhang et al., 2018). However, I did not find a significant association 
between the mutation and malaria susceptibility. These data indicate that any protection 
afforded by the Q248H mutation in African populations is weak, with previous estimates of 
effect size (Zhang et al., 2018) not generalising to the phenotypes and populations considered 
here. Additionally, the current study included 658 Q248H children with severe malaria, in 
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contrast to a previous report with a limited sample size of 13 Q248H children with 
uncomplicated malaria and 11 Q248H women with placental malaria (Zhang et al., 2018). A 
possible explanation for a lack of protection may be due to the opposing effects of Q248H 
mutation on erythrocyte iron levels versus serum iron levels. This is because by increasing 
erythrocytic iron export the mutation may deny the parasite of iron (Zhang et al., 2018). 
Conversely, by increasing iron export by duodenal enterocytes (Nekhai et al., 2013), the 
mutation may increase serum iron levels and increase parasite growth.  
 
Finally, I found that the frequency of Q248H was highest in South African children, a 
population which has historically experienced low malaria transmission. Moreover, further 
investigation of the relationship between historical rates of P. falciparum transmission (1900 - 
2015) and the minor allele frequency of Q248H mutation showed a lack of correlation 
(Muriuki, Mentzer, Band, et al., 2019). This suggests that P. falciparum prevalence in the 
population is not associated with the mutation and arguing against selective pressure due to 
malaria. 
 
6.6 Conclusion 
Using large-scale genomic datasets from African populations, I found that the Q248H mutation 
was associated with modest reductions in the risk of anaemia and iron deficiency, putatively 
due to reduced haemolysis and modestly improved iron status in Q248H carriers. These 
findings in large epidemiological studies build support for proposed biological pathways 
observed in mouse models (Zhang et al., 2018), although the observed effect sizes are small, 
and may not be clinically significant at an individual level. Finally, I found little evidence that 
the Q248H mutation protects against malaria and possibly no evidence of positive selection of 
the variant attributable to malaria exposure. 
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CHAPTER SEVEN: CONCLUDING REMARKS AND RECOMMENDATIONS 
Through this thesis, I investigated the complex relationship between iron deficiency and 
malaria. First, my findings show that iron deficiency is likely to be more common than can be 
estimated using the WHO definition since malaria and inflammation obscure the true burden 
of iron deficiency. I have also shown that transferrin saturation <11% may be a good indicator 
of the prevalence of iron deficiency in African children. Transferrin saturation best predicted 
the adjusted prevalence of iron deficiency and was also least influenced by malaria and 
inflammation. Accurate and reliable measurements of iron deficiency are necessary for the 
planning and monitoring of interventions to prevent and treat iron deficiency. Anaemia is used 
as a proxy for iron deficiency. However, I have shown that haemoglobin concentrations 
perform poorly in predicting a more accurate estimate of the prevalence of iron deficiency 
possibly because there are multiple overlapping factors that influence haemoglobin 
concentrations (Foote et al., 2013). My findings also suggest that improved control of malaria 
and other infections would also improve assessment of the prevalence of iron deficiency.  
 
Second, my findings suggest that malaria is an important cause of iron deficiency. Although 
iron supplements are the mainstay for treating iron deficiency (World Health Organization, 
2016), there is a long-standing concern regarding their safety since iron may increase the risk 
of infections such as malaria (Sazawal et al., 2006). Furthermore, since prolonged exposure to 
malaria leads to chronically raised hepcidin concentrations and blockade of iron absorption 
(Cercamondi et al., 2010; Glinz, Hurrell, Righetti, et al., 2015), oral iron supplements may not 
benefit iron-deficient children. Unabsorbed iron is also likely to disturb gut microbiota causing 
gastrointestinal disorders (Paganini and Zimmermann, 2017). Thus, my findings suggest a 
paradigm shift in the management of iron deficiency. That is, by improving control of malaria 
(and other infections) we can also address iron deficiency. Specifically, my findings suggest 
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that an intervention that halves the incidence of uncomplicated malaria would reduce 47% of 
the burden of iron deficiency.  
 
Third, my findings suggest that iron deficiency may be protective against malaria risk in 
agreement with previous longitudinal studies (Nyakeriga et al., 2004; Gwamaka et al., 2012; 
Jonker et al., 2012; Barffour et al., 2017). In other words, children who are iron replete may 
be at an increased risk of malaria infection. Previous longitudinal studies largely reported the 
effect of a ferritin-based definition of iron deficiency on malaria risk. In this thesis, I analysed 
the effect of a wide range of iron biomarkers on subsequent risk of malaria infection. I found 
that concentrations of ferritin and transferrin saturation were positively associated with 
increased malaria risk but variation in hepcidin, sTfR, and haemoglobin or anaemia was not 
associated with altered malaria risk. This might reflect differences in the relationship between 
the iron biomarkers and the mechanisms of iron acquisition by malaria parasites. However, 
since my analyses and those of others (Nyakeriga et al., 2004; Gwamaka et al., 2012; Jonker 
et al., 2012; Barffour et al., 2017) are observational, the observed association does not prove 
causality. 
 
I finally used FPN Q248H mutation that is associated with iron overload in previous studies 
(Gordeuk et al., 2003; Kasvosve et al., 2005; McNamara, Gordeuk and MacPhail, 2005; 
Masaisa et al., 2012) to determine whether the mutation is also associated with increased 
malaria risk. Moreover, the FPN Q248H mutation predominantly occurs in African populations 
and is thought to be selected due to malaria exposure (Zhang et al., 2018). My findings show 
that the Q248H mutation is associated with modestly improved iron status but that did not 
translate to increased malaria risk. Furthermore, the mutation occurred at highest prevalence in 
South African children, a cohort without historical malaria transmission thus arguing against a 
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possible selective pressure of the mutation in Africans to protect from malaria infection. It is 
possible that this mutation is preserved in Africans to protect against anaemia due to historical 
consumption of poor dietary iron. However, further research is required to understand the 
evolutionary benefits of the Q248H mutation in African populations.  
 
Taken together, my findings echo the fact that there are complex interactions between iron 
deficiency and malaria. I found that malaria may be an important cause of iron deficiency. 
Conversely, (although inconclusive) iron deficiency may protect from malaria infection 
although anaemia or low haemoglobin concentrations are not protective. So far, these findings 
suggest a focus on malaria control to address both public health problems. However, future 
studies should investigate whether the casual relationship between iron deficiency and malaria 
is bidirectional. 
 
7.1 Limitations and future directions 
There are several limitations to the work presented in this thesis that warrant future research. 
Although the regression-correction method that I applied to estimate the ‘true’ burden of iron 
deficiency performs better than other methods (Namaste, Rohner, et al., 2017), it is important 
to validate this approach. Future work should compare the prevalence estimates from the 
regression-correction approach and estimates obtained using the gold standard method of 
staining bone marrow aspirate for iron. Furthermore, the regression-correction approach could 
be validated by comparing prevalence estimates of regression modelling before and during / 
after infections. Although transferrin saturation <11% best predicted the regression-corrected 
estimate of iron deficiency, it had an area under the curve of only 0.77. There is therefore a 
need to identify easy to use, more sensitive and specific markers of iron status that are not 
influenced by infection. 
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In Chapter Four, I applied Mendelian randomisation to infer whether malaria causes iron 
deficiency. This method has strengths in that it avoids many of the biases that influence 
observational studies and provides causal effects, similar to randomised controlled trials. I used 
sickle cell trait as an instrumental variable to proxy malaria exposure and found that African 
children carrying sickle cell trait were protected from iron deficiency. I did not find a 
statistically significant effect of sickle cell trait in non-malaria-exposed African-American 
adults suggesting that the protective effect of sickle cell trait may be through malaria. However, 
there is a need to test whether sickle cell trait might influence iron deficiency among non-
malaria-exposed African children. In addition, data comparing the degree of protection 
afforded by sickle cell trait against iron deficiency in populations with varying incidence of 
clinical malaria would be important. I would expect sickle cell trait to have a large protective 
effect in populations where the incidence of malaria is high. This proof of concept should also 
be extended to other causes of chronic infection, which may contribute to the burden of iron 
deficiency through inflammation-induced up-regulation of hepcidin. This would provide 
evidence for an integrated approach in which control of malaria and other infections could be 
utilised as an additional strategy to improve the iron status of children. Future research should 
also confirm my findings through conducting intermittent preventative treatment trials of 
malaria to evaluate the effect of malaria treatment on iron status. 
 
Finally, although iron deficiency is consistently associated with protection from malaria risk 
(Nyakeriga et al., 2004; Gwamaka et al., 2012; Jonker et al., 2012; Barffour et al., 2017; 
Muriuki, Mentzer, Kimita, et al., 2019), reverse causality is a possibility whereby the observed 
effect may be due to malaria-induced acute response of iron markers (Aguilar et al., 2012; 
Righetti et al., 2013). Future studies should infer causality using approaches such as Mendelian 
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randomisation and randomised controlled trials. In Mendelian randomisation analyses, a 
prerequisite step would be to conduct a genome-wide association study (GWAS) of iron status 
in African children to identify genetic variants that reliably influence iron status in this 
population. This is because the common genetic variants from European GWAS of iron status 
(Benyamin et al., 2009, 2014; McLaren et al., 2011) do not appear to replicate in African 
populations (Gichohi-Wainaina et al., 2016). This limits the transferability of the European 
iron GWAS to populations of African ancestry. The next step would be to validate the 
identified genetic variants for use as instrumental variables in Mendelian randomisation 
analyses involving malaria case-controls in the same population. If genetic variants that are 
associated with improved iron status are also associated with malaria risk, then this would 
suggest that a child’s iron status influences their risk of malaria infection. To assess how 
improving baseline iron status through iron supplementation would influence malaria infection, 
a randomised controlled trial would be necessary. Lastly, to disentangle the causal direction 
between iron deficiency and malaria, a bidirectional or network Mendelian randomisation 
study would be necessary (Davey Smith and Hemani, 2014). 
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